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General introduction:
The leucocyte common antigen 
(LCA or CD45)
PROTEIN STRUCTURE AND GENOMIC ORGANISATION
CD45 (or B220, T200 or Ly-5) is a high molecular weight transmembrane 
glycoprotein, which is expressed exclusively on hematopoietic cells except 
for erythrocytes. The molecule occupies more than 10% of the cell 
surface, with more than 106 molecules per cell. See for reviews 
[9,67,162,170].
CD45 was identified as a transmembrane tyrosine phosphatase after a 
database comparison was done with the peptide sequence of PTP1B, an 
intracellular tyrosine phosphatase [36,166]. Then it turned out that 
CD45’s large cytoplasmic domain of 705 amino acids comprises in fact 
two tyrosine phosphatase (PTPase) regions of which the first, the 
membrane proximal domain, contains the catalytic activity. It is now 
known that the CD45 molecule is the major PTPase in immune cells 
and plays an essential role in signalling cascades, not only in B and T 
lymphocytes but also in monocytes/macrophages, granulocytes and NK 
cells.
As depicted in Figure 1 the molecule consists of a large extracellular 
domain of 391 to 552 amino acids, depending on the isoform, a single 
transmembrane segment of 22 amino acids and a cytoplasmic domain 
of 705 amino acids [51,162,169]. The extracellular domain is highly 
glycosylated and contains three structural regions that are conserved 
among vertebrates: (a) a region containing O-linked carbohydrate sites, 
partly encoded by exons 3-8, which is also rich in Ser, Thr and Pro; (b) a 
cysteine-rich region with, in human, five cysteine residues; and (c) a
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General Introduction: The leucocyte common antigen •
region containing three fibronectin type III domains, also enriched in cysteine residues. The 
extracellular domain of CD45 contains also several sites (11-16) for N-linked glycosylation 
and sulfation. The overall domain structure of CD45 is conserved between vertebrates, 
however the actual sequence identity of the extracellular region is very low between the 
species. The isoform variation provided by the differential splicing, glycosylation and sulfation 
of the extracellular CD45 domain may allow interaction with a variety of ligands on other 
cells to potentiate selective intercellular communication [4,109].
The CD45 gene is located on chromosome 1 in both mouse and man (1q31-q32) [49,126] 
and is spanning 120 kilobases comprising 33 exons (Figure 1). The exons 3-15 encode the 
extracellular domain, exon 16 the transmembrane domain and exons 17 through 33 the 
intracellular domain whereby exons 17 to 24 encode the first PTPase domain and 25 to 32 
encode the second PTPase domain. These two PTPase domains are highly homologous and 
probably originate from gene duplication of several exons [49,56] early in evolution. The 
potential promoter of CD45 has been located upstream of two adjacent transcription 
initiation sites present in exon 1 [56,165]. Exon 2 contains the initiation ATG codon and the 
signal peptide sequence. The last exon, 33, contains the code for the carboxy terminal amino 
acids and the entire 3' untranslated region of the mRNA. Together the 33 exons encode an 
mRNA of 3832 to 4315 bases in size, depending on the alternative splicing of exons 4, 5 and
6 [133,153].
Structure and function relationship
As stated above, a 300 nucleotide duplication in the cytoplasmic domain of CD45 exhibits 
sequence homology with the catalytic domain of PTPase 1B, the first cloned PTPase [36]. 
This provided the first hint that CD45 possesses intrinsic phosphatase activity [166] and 
belongs to the type I receptor type PTPases. Later, in vitro studies provided evidence that 
only the membrane proximal phosphatase domain (I) contains catalytic activity. Mutation 
of the key cysteine in domain I, Cys-828 in human, caused a complete loss of phosphatase 
activity in vitro [66,154]. In contrast deletion of the catalytic cysteine of domain I did not
Figure 1
Protein structure and genomic organisation o f the human CD45 molecule.
The genomic organisation is shown on the left, w ith the corresponding protein structure next to the 
coding exons. The symbols used are explained in the boxed area o f the figure.
The high molecular weight isoform o f CD45 is depicted, with exon A, B and C as coloured circles in the 
N -term inal p a r t o f the extracellular domain. The CD45 molecule is a transmembrane molecule w ith  
two intracellular tyrosine phosphatase dom ains (PTPase). The extracellular dom ain contains three- 
fibronectin type III modules (F3) and a cysteine region (C), followed by the variable region comprising 
exon 4, 5 and 6.
13
•  Chapter 1
abrogate the phosphatase activity of the protein, when tested on myelin basic protein as a 
substrate [159]. In vivo evidence showed convincingly, however, that only the catalytic activity 
of domain I is necessary and sufficient for TCR mediated signal transduction and for ligand 
mediated regulation of CD45 function [45].
Different experimental approaches have demonstrated the relative importance of the 
extracellular domain and the transmembrane region of CD45 for functional reconstitution 
of signal transduction. Chimeric molecules containing the cytoplasmic domain of CD45 
coupled to the extracellular domain of EGF [44], MHC class 1 [63], or a small amino terminal 
sequence of p60c-src [181] were all able to reconstitute TCR mediated signal transduction. 
Mutational analysis of the p60c-src-CD45 chimeric protein confirmed that the membrane 
proximal domain is essential for signal transduction and established that CD45 has to be 
localised in close proximity of the membrane [106] in order to fulfil its biological role.
CD45 ISOFORM VARIATION
The heterogeneity of CD45 proteins is caused by alternative splicing of three variable exons 
(4, 5 and 6 or A, B and C) in the N-terminal part of the molecule giving rise to a maximum 
of eight different isoforms [126,152,163]. The expression of CD45 isoforms differs among 
species. In human five isoforms have been identified and cloned as cDNAs. In mice all eight 
isoforms are being expressed. Besides molecules with alternative exon 4, 5 and 6 segments, 
alternative spliced isoforms lacking exon 7 and 8 have been reported for murine cells [35]. 
Recently, also in- and exclusion of exon 10 has been demonstrated by RT-PCR, further 
increasing the potential number of isoforms [178]. However, in most cases these splicing 
events are rather rare and corresponding protein products have not yet been identified. Some 
of the products may therefore have no biological significance.
In addition, the variability of CD45 proteins is further enlarged by differential glycosylation 
patterns. Glycosylation is required for cell surface expression and stability of the CD45 protein 
along with phosphatase activity [124]. The pattern of glycosylation undergoes changes upon 
cellular differentiation and proliferation [79,83,100,122,123].
The CD45 isoform profile is species specific, highly regulated and dependent on cell type, 
stage of development and activation. For example, corresponding (sub)populations of cells 
in man and rodents express CD45 isoforms that slightly differ in the number and composition 
of exons. Naive T cells are identified as CD45RA cells in human, CD45RC in rats and CD45RB 
or Rhi in mice. Memory T-cells, on the other hand, are identified as CD45RO in humans, 
CD45Blow in rats and CD45R'° in mice [170].
To study the distinct CD45 isoforms, monoclonal antibodies have been raised that are 
classified as anti-CD45 (reacting with determinants present on all isoforms) or anti-CD45R
14
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(specific for restricted determinants). Anti-CD45R antibodies are further categorised by the 
specific exon that is recognised: CD45RA, RB, RC or RO. When applied to the situation for 
human CD45 isoforms it means that anti-RA antibodies recognise exon A epitopes present 
in the CD45AB isoform (205 kDa) and CD45ABC isoform (220 kDa). Anti-RB antibodies 
recognise exon B epitopes in isoforms CD45B (190 kDa), CD45BC (205 kDa) and CD45ABC 
(220 kDa). Exon C epitopes are recognised by anti-RC antibodies which detect protein 
isoforms CD45BC (205 kDa) and CD45ABC (220 kDa). The low molecular weight isoform 
CD45 Null (180 kDa) is recognised by anti-RO antibodies. In addition, cells may express 
more than one CD45 isoform. The UCHL-1 antibody is isoform specific and recognises the 
human CD45 Null isoform [1,147]. This antibody is directed against a glycosylation- 
dependent epitope formed by junction of exon 3 - exon 7. The last amino acid of exon 3, a 
threonine, which is a putative O-linked glycosylation attachment site, as well as the presence 
of sialic acid is essential for recognition by UCHL-1 [125]. Since this threonine is not conserved 
in mouse and rat, the UCHL-1 antibody does not detect the exon-3-7 junctional epitope in 
these species.
Other than by using CD45R antibodies also the RT-PCR technique can be applied to study 
CD45 isoform expression patterns. The advantage of this technique is that the individual 
exon composition of the expressed isoforms can be established more easily and the detection 
of minor expressed isoforms is facilitated by the high sensitivity of the approach.
Non-specific immune cells
The so-called non-specific immune cells (i.e. non-T and non-B cells), share quite similar 
CD45 expression patterns with few exceptions. The main isoforms expressed in these cells 
are the CD45 Null and B isoforms. Most non-specific immune cells are derived from myeloid 
precursor cells except for the NK cells, which are derived from a lymphoid precursor stem 
cell.
Human neutrophils express mainly the lowest molecular weight isoform (CD45R0) on the 
cell membrane as detected with the UCHL-1 antibody [160]. However, they possess an 
intracytoplasmic pool of CD45RA isoforms, which can be translocated to the membrane 
after stimulation [33]. This translocation process requires phosphorylation of tyrosine 
residues in the CD45 molecule, a step known to modulate phosphatase activity [40]. In 
patients with systemic acute infections cell surface expression of CD45RA is highly increased 
indicating CD45RA translocation upon activation and subsequent degranulation of 
neutrophils [116]. Chemokine receptors CXCR1 (Il8Ra) and CXCR2 (Il82B), expressed by 
human neutrophils, are downregulated upon treatment with anti-CD45RB antibodies (Bra11) 
indicating that CD45 regulates chemokine induced signalling in neutrophils [98].
Murine basophils and mast cells express the CD45 Null and B isoforms [55,179] which are 
required for IgE-mediated mast cell degranulation [16].
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Human peripheral blood eosinophils express the CD45RB and CD45RO epitopes but not 
CD45RA. Stimulation with anti-CD45 antibodies induces activation of eosinophils indicating 
that CD45 might be involved in modulating eosinophil function and participate in allergic 
inflammation [93].
The CD45 Null isoform is also the main isoform expressed in monocytes and derived 
macrophages. However, monocytes also express minor quantities of the isoform lacking exon
7 [179]. Under certain circumstances they express the CD45RA epitope which increases after 
stimulation [26].
Dendritic cells and antigen presenting cells like Langerhans cells (LC) also express the low 
molecular weight isoforms of CD45 [19,55]. However, CD45RO expression on LC can be 
discriminated from the RO isoform of memory T cells based on differences in the terminal 
sialic acid moiety of the oligosaccharide portion. [191].
Resting NK cells predominantly express CD45RA, whereas activation converts expression 
completely to CD45RO. Stimulation via CD45RO specific antibodies in these cells induces 
INF-gamma production but not NK-cytotoxicity [25,144]. The non-involvement of CD45 
in cytotoxicity reactions of NK cells was confirmed in exon-6 deficient knockout mice [193]. 
In NK cells CD45 is associated with accessory adhesion molecules like LFA-1 and CD16 and 
with signal transduction molecules like pLck56, thereby regulating the activation state and 
the function of these molecules [3,38,121].
Specific immune cells
The main CD45 isoform in B cells is the high molecular weight isoform CD45ABC. This 
isoform is already expressed during early B-cell development. Upon activation or malignant 
transformation B cells will express other CD45 isoforms.
LPS- and Il-5 stimulated B cells reduce the expression levels of the ABC isoform and expression 
levels of low molecular weight isoforms are increased [59]. Stimulation with PMA plus 
ionomycin switches the CD45 expression in murine splenic B cells dramatically towards the 
production of the smallest isoform, while the use of anti-IgM antibodies induces only a 
partial shift to CD45-Null. In B-cell lymphoma’s and also in Crohn’s disease expression of 
the CD45RO isoform on B cells is found. In Crohn’s disease the level of CD45RO expression 
is correlated to the severeness of the disease [192,197].
On T cells the pattern of CD45 isoform expression varies with the subpopulation of cells 
[60,143], their stage of development [35,52,70,82] and the nature of the antigenic stimulation 
[22,89,108,120,188]. Individual T cells express more than one isoform and all known isoforms 
are expressed by T cells.
During T-cell development in the thymus, thymocytes mature into fully competent T cells. 
They gain expression of CD3/TCR, CD4 or CD8 molecules and are educated to recognise
16
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self-peptide-M HC complexes. The m ajor isoform expressed by a large population of 
thymocytes is the CD45RO isoform. However, subpopulations of thymocytes may express 
distinct CD45 isoforms depending on the maturation status. Modulation of CD45 isoform 
expression is involved in thymic selection events. Immature cortical thymocytes (CD3-, CD4- 
and CD8-, 5% of the thymocytes) express relatively high levels of RA or ABC isoform (20%) 
and upon differentiation to double positive CD4+CD8+ cells (85% of the total thymocytes) 
they upregulate RO and RB expression and downregulate RA and RC (ABC) expression to 
almost zero. When they are positively selected and migrate to the medulla they start to 
upregulate RC and downregulate RO, thereby coexpressing both epitopes. These double 
positive thymocytes (CD4+CD8+) are still RA negative. After maturation into single positive 
thymocytes (CD4+ or CD8+) they further downregulate RO and start to express RA and 
become RA/RB/RC positive. These mature thymocytes which are ready to be exported to 
the periphery bear the same CD45 profile as naive T-cells [52,127,183,194].
Early studies have shown that mature but naive T cells (either CD4+ or CD8+) predominantly 
express CD45RA whereas memory T cells express higher levels of CD45RO, suggesting that 
CD45RA and CD45ROmark virgin and memory T cells, respectively in both CD4+ and CD8+ 
T-cell populations [134]. By stimulation with a mitogen or antigen a switch from CD45RA 
to CD45RO is achieved (reviewed in [10,13]). The suitability of the CD45RO marker for T- 
cell memory was questioned some years ago when it was shown that rat CD4+T cells 
expressing the memory phenotype (RO) could switch back and re-express the high molecular 
weight isoform (RA) [11,97]. Furthermore, in vivo experiments show that CD4+T cells can 
switch isoforms in both directions and that CD45RO T cells can revert to the double positive 
CD45RA/RO phenotype [130,135,188]. In addition, the CD45 isoform expression pattern 
of the CD45Rhi (RA) revertants derived from CD45RO T cells can not be distinguished at the 
RT-PCR level from truly naive T cells (CD45RA) [58]. Surprisingly, not the supposed memory 
pool of CD45RO T cells, but the CD45Rhi (RA) T cells appear to be the slow cycling and long 
lived cells [97,148,168]. Another indication that the CD45RO T cells are not the true or 
exclusive memory T cells came from experiments that showed that Fas is upregulated and 
Bcl-2 is reduced upon re-exposure of CD45RO T cells to antigen. These stimulated cells are 
turned on to undergo apoptosis and for evident reasons can not be considered as the guardians 
of long-termed immunological memory. On the basis of these findings a new model of 
immunological memory has been proposed [12]. This model (depicted in Figure 2) is based 
on the existence of two distinct subsets of CD4 memory T cells, the antigen-primed CD45R'° 
T cells and the derived revertant CD45Rhi T cells [30]. When naive CD45Rhi (RA) T cells 
proliferate in response to a first contact with an antigen they become blast cells and express 
the CD45R'° (RO) phenotype. These blasts cells can respond rapidly to antigen: they become 
effector cells which are in fact terminally differentiated, release cytokines to mediate T-cell 
help and subsequently undergo apoptosis. Blasts cells can also revert to memory (i.e. primed)
17
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MEMORY T-CELL
Figure 2
Immunological memory: a model which is based on the existence of distinct types of CD4 memory 
cells expressing high and low molecular weight isoforms of CD45.
Naive T  cells (RA+, CD4+) proliferate upon antigenic stim ulation, undergo blast transformation and  
express CD45RO+. A t this stage they are memory cells, can respond rapidly to antigen and can terminally 
differentiate into effector cells. This CD45RO+ T-cell population is unstable and dependent on antigen. 
W ithout antigen they revert to CD45RA+ expression and become quiescent. These cells are memory cells 
but resemble naive cells. Dashed lines indicate alternative or uncertain pathways.
CD45R'° (RO) T cells which are unstable and depend on the presence of antigen. Without 
antigen, however, they revert to CD45Rhi (RA) T-cells and become quiescent. The revertant 
T cells are slow responders, show primary kinetics, are long lived and resemble in all respects 
naive T cells, except that they are amplified to form an increased pool of antigen-specific 
precursors. The memory primed CD45R'° T cells are rapid responders, show secondary 
kinetics but are short lived. Upon contact with residual antigen they can recycle through the 
CD45R'° stage directly or via the formation of blasts cells. This relatedness model explains 
the existence of revertant CD45Rhi (RA) T cells as memory cells. The scheme is further 
substantiated by data of Thiel et al. [161] who illustrated that within the pool of RA+ T cells 
the “real” naive unprimed T cells are identified by CD31+ expression, while the revertant, 
primed but quiescent memory T cells are recognised by the absence of CD31.
18
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The dynamics of CD45 isoform expression of T cells is reflected in the tissue distribution 
pattern. In cord blood CD4+ or CD8+ T-cells express up to 90% the RA epitope and less than 
10% of the cells express the RO epitope while in the peripheral blood, CD4+ or CD8+ T cells 
highly upregulate RO and RB expression and downregulate RA.
T cells in tum our tissues also called tum our-infiltrating T cells dominantly express the 
CD45RO isoform compared to high expression levels of CD45RA in freshly isolated peripheral 
blood lymphocytes. This memory phenotype (CD45RO) might be induced by specific tumour 
antigenic stimulation [105].
THE ROLE OF CD45 IN LYMPHOCYTE ACTIVATION AND DEVELOPMENT
Once CD45 was identified as a Protein Tyrosine Phosphatase (PTPase) involved in signal 
transduction three approaches have been used to elucidate its role in lymphocyte activation 
and the development of an immunocompetent system, namely by (a) the use of mAbs, as 
surrogate ligands, against CD45 which causes cross-linking of CD45 on lymphocytes resulting 
in potentiation or attenuation of an immune response; (b) the use of CD45 deficient cell 
lines to pinpoint the precise role of CD45 in the cellular activation cascade; (c) the use of 
transgenic mice in which CD45 has been impaired or knocked out. Although not all data are 
yet entirely congruent they do consistently show that CD45 acts as a tyrosine phosphatase 
that associates with more than one type of receptor-like molecule or signal transduction 
molecule and modulates the activation process of lymphoid cells.
Analysis of CD45 function using monoclonal antibodies
Antibodies directed against CD45 were in fact used long before CD45 was identified as a 
PTPase to study its involvement in the regulation of lymphocyte activation, differentiation 
and lymphocyte aggregation (reviews on CD45 [162,170]). However, the outcome and the 
interpretation of studies that involved the use of antibodies to cross link or block CD45 
molecules on the cell surface is complicated due to the fact that most antibodies used are 
directed against different epitopes on CD45. This implies that a given antibody may not 
recognise all cells within a population or may not bind all CD45 molecules on the cell, 
potentially leading to selective effects on subpopulations of cells. Besides being dependent 
on the specificity of the anti-CD45 antibody used, the interpretation of the obtained data is 
also depending on the experimental approach and the cell population proper.
Briefly summarised, anti-CD45 antibodies are able to potentiate or attenuate T-cell activation 
in response to a number of different mitogenic stimuli. Anti-CD45 antibodies against the 
high molecular weight isoform evoke increased Il-2 production and proliferation in response 
to PHA [81,91]. In contrast, anti-CD45 antibodies com m on to all isoforms inhibit 
proliferation and IL-2 production after stimulation with PHA [17].
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Other reports show that simultaneous cross-linking of CD2 and CD45 resulted in a greater 
proliferative response in CD45RA positive cells than in CD45RO cells [137], and the outcome 
is therefore dependent on the cell population used.
Most extensively studied is the effect of anti-CD45 antibodies on T-cell receptor or CD3 
mediated activation although the outcome of these studies vary to some extent. The general 
consensus is that binding of anti-CD45 antibodies inhibits signal transduction events and 
suppresses lymphocyte proliferation.
The inhibitory effects induced by anti-CD45 antibodies as observed in CD2 or CD3 mediated 
T-cell activation involve in all cases changes in tyrosine phosphorylation, activation of 
phospholipase C and mobilisation of intracellular calcium (reviewed in [67]).
Anti-CD45 antibodies also induce apoptosis in T-cells [73,111] and promote either homotypic 
adhesion in immature T cells or inhibit adhesion and homotypic aggregation in resting 
human peripheral blood T cells [6,39,149,151,182]. These modulating effects of anti-CD45 
antibodies are thought to be associated with integrin dependent aggregation via engagement 
of LFA-1 with ICAM [18,87].
CD45 deficient cell lines
CD45 deficient cell lines, either selected as spontaneous m utants or derived by forced 
mutagenesis or homologous recombination, have proven useful to unravel the function of 
the CD45 molecule further.
Early studies with CD45 deficient murine T-cell lines indicated that CD45 is required to 
couple T-cell receptor signalling to intracellular signal transduction pathways. The response 
of these murine CD45 deficient T-cell lines (CD4+ or CD8+) was drastically impaired upon 
stimulation with antigen, anti-Thy-1, or anti-CD3 antibodies, i.e. cells failed to proliferate, 
or to produce Il-2 or IFNg, or failed to lyse target cells. Supplementation of IL-2 restored the 
proliferation indicating that IL-2 receptor signalling was not depending on CD45 expression. 
Spontaneous re-expression of CD45 restored normal signalling function of these cell lines 
[119,189]. The response to Con-A and PHA in these CD45 deficient cell lines was not affected, 
probably by bypassing the block in the antigen-receptor signalling complex, since both 
mitogens did not induce tyrosine phosphorylation or p56lck activation which normally 
observed after T-cell activation via TCR-CD3/CD4/CD8 [118]. Similar results were obtained 
with human CD45 deficient lymphoma (Yac-1) or leukaemic (Jurkat, HPB-ALL) cell lines 
[43,77,78]. The block in signal transduction could be restored by transfection with cDNAs 
of the CD45 Null or AB isoforms [20,76,145]. These experiments indicate that the block in 
Ag-receptor signalling is proximal to the receptor complex itself and involves regulation of 
protein kinases. Downstream activation by PMA or ionomycin restores production of 
cytokines and proliferation indicating that these events are not regulated by CD45. Therefore 
it was suggested that CD45 regulates the function of the tyrosine kinases p56lck and p59Fyn.
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Indirect evidence indeed showed that the loss of CD45 expression leads to impaired activation 
of these Src kinases and causes a subsequent block in TCR signalling [20,43,94,145]. TCR- 
signalling is also restored in a CD45 negative Jurkat cell line that is transfected with a chimeric 
molecule of EGFR fused to a constitutively active form of p56lck. Inadequate, inefficient 
dephosphorylation of p56lck-Tyr505 accounts for the unresponsiveness of CD45 negative 
cells, which can be restored by the presence of an active pool of p56lck [48]. Similar experiments 
in CD45 negative YAC-1 cells shows that the absence of CD45 causes hyperphosphorylation 
of bo th  the PTK pZAP-70 and the Z chain o f the CD3 com plex [103], bo th  being 
hyperphosphorylated in the absence of Ag stimulation.
In B-cell lines, the requirement for CD45 in Ag-receptor signalling is not as strict as is 
demonstrated for T cells. In the CD45 deficient B-cell line, J558mm3, abnormal BCR-mediated 
signalling, evidenced by the absence of calcium mobilisation, could be restored by transfection 
with the CD45 ABC cDNA [68]. However, upon stimulation via the Ag-receptor these cells 
were able to phosphorylate numerous substrates [113,114]. This suggested that not all protein 
tyrosine kinases involved in BCR mediated signalling require CD45 expression. Therefore, 
CD45 may regulate the activity of the Src kinases, like p53/56Lyn, p59Fyn, and p55Blk, but 
other PTKs, like p72Syk, are not regulated by CD45 [37,113,114].
Studies with CD45 deficient cell lines have led to the opinion that whereas CD45 is absolutely 
required for signalling through the TCR complex, CD45 expression in B cells is not an absolute 
prerequisite to trigger early activation events during BCR signalling. Still, CD45 is important 
for regulating signal transduction via the B-cell antigen receptor.
Not only are CD45 deficient T- and B-cells impaired in their signalling ability, also CD45 
negative rat NK cells do fail to kill tum our cells. Activation through CD2, CD53 and NKR-p1 
is impaired in these cells but again activation with mitogens is not altered. These results 
suggest that CD45 expression is required for signal transduction via CD2, CD3, CD53 and 
NKR-p1 in NK cells [14].
CD45 knockout mice
The generation of CD45-deficient mice has not only confirmed the important role of CD45 
in T- and B-cell activation but also has shed light on CD45’s significance in the development 
and selection of properly programmed immunocompetent lymphocytes. Two CD45-deficient 
mouse models have now been developed, (a) an exon 6 -/- mouse model [71], and (b) an exon 
9-/- mouse model [32].
CD45 exon 6 deficiënt mice
In mice homozygous for the CD45 exon-6 mutation, B cells and most T cells did not express 
CD45, however low levels of CD45 are detected since, exon 6 can be excluded from the pre-
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mRNA. Thymic T-cell development is severely impaired in exon 6-/- mice which was arrested 
at the CD4+CD8+ double positive stage before positive and negative selection occurs. A minor 
block is observed at the transition from double negative (CD4-CD8-) to double positive 
(CD4+CD8+) thymocytes as indicated by a slight increase in double negative thymocytes. 
Another major block in m aturation is observed at the transitional stage from immature 
CD4+CD8+ (double positives) to mature CD4+ or CD8+ cells (single positives). As a result, 
only a few mature T cells can be detected in peripheral lymphoid organs [71]. This major 
block in T-cell developm ent is probably due to the inability of these thymocytes to 
dephosphorylate the inhibitory phosphorylation site (Y505) in p56lck. This site is normally 
dephosphorylated by CD45 to maintain the active state of p56lck in order to phosphorylate a 
number cellular signalling proteins. CD45 exon 6-/- carrying also the transgene for the Lck 
Y505F mutation, which results in a constitutively active kinase, demonstrated that thymocyte 
development was rescued and T cells accumulated in the periphery [142].
The serious impairment of T cell functioning in CD45 exon 6-/- also appeared from the inability 
to m ount a cytotoxic T cell response upon infection with lymphocytic choriomeningitis 
virus (LCMV). The peripheral T cells that were detected in exon 6-/- mice are unable to respond 
when stimulated with anti-CD3, anti-TCR, Con-A or PMA probably due to inactivation of 
the Src-kinases p56lck and p59fyn by hyperphosphorylation.
Positive selection of ab-TCR transgenic thymocytes is completely blocked in CD45 exon 
6-/- mice expressing P14-TCR molecules specific for LCMV, but not completely in the 
heterozygous exon6+/- mice, suggesting that the actual expression levels of CD45 influence 
thymic selection [184]. The development of gd-TCR T cells in the thymus is also affected in 
CD45 exon 6-/- mice as assayed from the low number of these cells in epidermal tissues [69]. 
However, clonal deletion of T cells expressing superantigen reactive T-cell receptors occurred 
normally in exon 6 deficient mice. This can be explained by the fact that negative selection 
of superantigen reactive cells does not require CD45 expression [71,117].
B-cell development appeared normal in exon 6-/- mice as analysed by the number of pre-B 
cells, B cells and myeloid cells from the bone marrow, spleen, or foetal liver. However, the 
animals displayed a decline in the number of IgDhi, IgMlo splenic B cells suggesting that B- 
cell development was affected at the transition from immature to mature B cells [15]. In 
contrast with B-cell development, B-cell receptor mediated signalling in mature B cells is 
severely impaired in exon 6-/- mice. CD45 negative B cells are unable to respond upon IgM 
cross-linking, but their response to LPS was not affected [15,71]. Basal phosphorylation 
levels are normal but the calcium mobilisation response was abnormal suggesting a role for 
CD45 in this process [15].
CD45 regulates the level of antigen-receptor signalling in B cells, which determines whether 
a B cell with a BCR for self-antigens undergoes positive or negative selection. This outcome
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was elegantly demonstrated in the hen egg lysozyme (HEL) model. CD45 exon 6-/- deficient 
mice were crossed with transgenic mice that express in all B cells Ig specific for hen egg 
lysozyme (HEL) [41]. Soluble HEL autoantigen normally mediates in CD45+/+ mice negative 
selection of newly produced HEL-binding B cells by blocking their migration and subsequent 
amplification in lymphoid follicles. This prevents a survival beyond three days and results in 
low numbers of autoreactive HEL-B cells. Strikingly, rather than being decreased, the number 
of CD45-/- Ig-transgenic B cells was increased in blood and lymphoid organs in the presence 
of circulating HEL autoantigen, reaching numbers equivalent to those of CD45+/- Ig-transgenic 
B cells in the absence of HEL antigen. These findings are consistent with a signal-threshold 
model for B-cell selection and demonstrate that changes in antigen receptor signalling can 
cause high-affinity self-reactive B cells to be actively retained instead of eliminated, thus 
revealing a potential mechanism for inherited susceptibility to autoimmune disease. We may 
thus conclude that CD45 plays an important role in regulating the intensity of that B-cell 
response and affects the outcome of B-cell selection processes.
Taken together, the data show that CD45 is differentially required for the development and 
function of T and B lymphocytes and suggest that both the level of CD45 expression and the 
variation in CD45 isoforms may have specific functions and affect the T-cell selection process 
in the thymus as well as the B cell selection process in other lymphoid organs [74,184].
CD45 exon 9 deficiënt mice
The second CD45 knock out model is based on the targeted disruption of CD45 exon 9 [32]. 
These transgenic mice lack expression of all isoforms of CD45 and are arbitrarily called 
CD45-Null mice (not synonymous with CD45RO). This model shows an even more reduced 
number of T cells in thymus and spleen than the exon 6 model. Similar as in the exon 6 
deficient model the transition of “double negative” thymocytes to “double positive” cells was 
strongly reduced, resulting in further four- to fivefold reduced output to “single positive” 
cells, while also a severely impaired apoptotic response upon cross-linking signals via T cell 
receptor (TCR) in thymus was reported. The exon 9 model confirmed the important role of 
CD45 in the development of T cells via the TCR-signalling system. At the same time, detailed 
analysis revealed that the number of B cells is increased, confirming that CD45 is not really 
required in B lymphocyte development. Although, the molecule is absolutely required to 
induce proliferation upon Ag-receptor cross linking, in 9-/- mice transmission of mitogenic 
signals via IgM or IgD were not observed whereas the response to anti-CD40 Ab was not 
affected. CD38 is also not functional in 9-/- mice as it requires the expression of a functional 
B-cell receptor complex [32].
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INTERACTION OF CD45 WITH OTHER MOLECULES
In order to understand the way in which CD45 regulates lymphocyte activation and 
development it is essential to elucidate the signalling pathways which activate the CD45 
molecule as well as transduce the signals to effector molecules.
In the following section, we will discuss the regulatory mechanism of CD45 phosphatase 
activity.
Potential ligands
The observation of the flexible nature of the extracellular domain where structural variation 
is introduced by alternative splicing and different O-linked glycosylation patterns raised the 
possibility that CD45 function is differentially regulated by interaction with multiple ligands. 
Ligand binding could either induce phosphatase activity directly or change the accessibility 
of CD45 for specific substrates. Consistent with this model is that antibodies binding to the 
CD45 extracellular domain can modulate Ag-receptor signalling as described in the previous 
section. The rather unpredictable effect of antibodies are in fact strongly dependent on the 
type of antibody used, the recognised CD45-epitope, and whether the antibody acts as a 
surrogate ligand or as a cross-linking agent.
The first potential ligand described was provided by studies that showed that CD45 expressed 
by m urine thymocyte binds to heparan sulphates, indicating that CD45 promotes cell 
adhesion by interaction with glycosaminoglycan-containing molecules present on the surface 
of stromal cells [39,115]. Subsequently, CD45 was shown to interact with the B-cell restricted 
transmembrane glycoprotein CD22S. Binding of B cell to T cells is promoted by the specific 
interaction between CD22S and the CD45RO isoform [150]. Additional studies revealed 
that CD22 also interacts with other CD45 isoforms and binding of CD22 inhibits TCR 
signalling [7,150]. The fact that CD22 binds to a2-6 sialic acids displayed by multiple cell 
surface molecules questioned the specificity of the interaction with CD45. This observation 
demonstrated that the interaction between CD22 and CD45 is not a classical receptor-ligand 
interaction but mediates homotypic aggregation between B cells and heterotypic aggregation 
between B- and T-cells.
An unique glycosylated form of CD45 (a hybrid type high in mannose and containing N- 
linked oligosaccharides) expressed by immature murine thymocytes was found to carry 
binding sites for the serum mannan-binding protein [173]. The specific interaction of this 
third candidate ligand with (immature) thymocytes and not with mature T cells suggests 
involvement in thymocyte maturation.
The function of CD45 may in fact also be regulated by ligand binding to CD45 via allosteric 
mechanisms involving dimerization and functional inactivation of the CD45 phosphatase 
activity.
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Evidence for this possibility came from studies using CD45 chimeric constructs composed 
of the extracellular domain of the EGF receptor fused to the intracellular phosphatase domains 
of CD45. The (transfected) chimeric EGFR-CD45 molecule restores TCR-mediated signal 
transduction in a CD45 deficient cell line. However, binding of the ligand EGF inhibits TCR 
mediated signalling suggesting that ligand binding downregulates CD45 function by ligand 
induced dimerization of the EGF-CD45 chimera’s [44]. This model for negative regulation 
was supported by crystal structure analysis of the membrane proximal catalytic domain of 
RPTPa which revealed that each monomer forms a wedge that fits in the catalytic site of the 
opposing monomer [21]. By mutating a glutamate (position 624, analogous to the highly 
homologous aspartate present in the wedge of RPTPa), in EGFR-CD45 chimeric molecules 
it was revealed that the inhibition of signal transduction induced by dimerization of the 
chimeric molecules was made less effective [90]. Thus one may assume that in cells expressing 
the wild type CD45, the catalytic site of each molecule will be blocked by the wedge. This 
will inhibit CD45 phosphatase activity and keep Lck phosphorylated and inactive, thereby 
blocking TCR signals. In the CD45-624-mutant the wedge is altered so that the catalytic 
sites are not occluded after ligand induced dimerization. Phosphatase activity is retained 
and Lck is maintained in its active conformation [90]. These results strongly suggest that 
CD45 activity is regulated by ligand induced dim erization thereby inactivating the 
phosphatase activity.
Regulation of activity by expression of specific isoforms
Different isoforms of CD45 have been demonstrated to exhibit different modulatory activities 
concerning TCR signalling. T cells expressing the low molecular weight isoform, CD45 Null, 
in association with CD4 were more efficient in promoting T-cell activation compared to T 
cell expressing the high molecular weight isoform, CD45 ABC [107]. This finding was in 
agreement with previous observations indicating that increased expression of the CD45 Null 
isoform in CD4+ m em ory cells correlates with increased responsiveness to antigenic 
stimulation [62]. Other studies demonstrate that the increases in cytosolic calcium and protein 
kinase C activity are higher in CD45RO than in RA T-cells stimulated with anti-CD3 [128]. 
Purified populations of “naive” CD45RA+ and “memory” CD45RO+ hum an CD4+ T cells 
stimulated with anti-CD3 antibodies demonstrated also different patterns of intracellular 
signalling, as measured by greater IP3 and (intracellular) Ca++ levels, in naive cells and 
hyperphosphorylation levels (TCR Z and ZAP-70) [57]
CD45 deficient Jurkat cell lines reconstituted either with the CD45 ABC or Null isoform 
confirmed the higher responsiveness of the CD45 Null transfected Jurkat cells after CD3 
stimulation. These Jurkat cells also secreted higher amounts of IL-2 and IFN-g [50,140]. 
Interestingly, after CD3 stimulation Jurkat cell lines expressing the ABC isoform induced 
greater phosphorylation levels of Vav and SLP-76 compared to Jurkat CD45 Null cells [96,112].
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These results are consistent with the view that different isoforms support different TCR 
downstream signalling events as illustrated by isoform specific association of CD45 with 
LFA-1 (CD45RA), CD2 (CD45RO) and CD4/8 (presumably to CD45RC) [47,107].
Association of CD45 with (transmembrane) proteins in T- and B-cells
Next to binding to putative ligand molecules CD45 can also engage in interactions with 
neighbouring transmembrane molecules. This latter kind of physical association could be 
helpful to target (phosphorylated) substrates to the CD45 phosphatase. It is also possible 
that some associated proteins utilise the transmembrane signalling ability of CD45 to mediate 
their effects. Co-immunoprecipitation and co-capping experiments have demonstrated that 
CD45 associates to Thy-1 [88,180], CD2 [2,138], TCR/CD3 [53], CD4 and CD8 [23,85,99], 
CD7 [80], CD16 [3], CD26 [167], CD28 [196], LFA-1 (CD58) [47], CD100 [61] and membrane 
immunoglobuline (mIg) [27,68].
Many of the transmembrane proteins, which associate with CD45 also associate with the 
Ag-receptor complexes. The composition of the transmembrane protein complexes thus 
formed is depending on the specific isoforms and components expressed and differs between 
cell types.
In T cells, CD45 forms a large signalling complex with the TCR/CD3 receptor complex and 
CD4 or CD8, depending on the cell type (illustrated in Figure 3). The TCR-complex consists 
of the aS  heterodimer non-covalently associated with the CD3 complex comprising the g,d, 
and e chains and a disulfide linked ZZ or h h  chain homodimer or Zh heterodimer. The TCR- 
aS  heterodimer determines antigen recognition while the CD3 complex couples the TCR to 
intracellular signalling mechanisms. In this complex CD45 is physically associated with the 
phosphorylated CD3 Z chain [53]. This interaction is specific since the LAR (Leukocyte 
common antigen related) protein or CD45-LAR hybrids were not able to interact with the 
CD3 Zchain. Moreover, the CD3 Z chain is also preferentially dephosphorylated by CD45. 
This indicates that the Z chain is a specific and high-affinity substrate for the CD45 PTPase. 
The other molecule in this large complex, CD4, consists of four domains of which domain 
D1 and D2 interact with the MHC class II molecules expressed by antigen presenting cells 
(APCs) and domain D3 and D4 interact with the CD3/TCR complex [177]. The equivalent 
CD8 co-receptor on cytotoxic T cells, is a hetero- or homodimer of an a  and a b  chain,
Figure 3
The Ag-receptor complex in T cells.
Signal transduction by the TCR-CD3 complex and the role o f CD45. Interaction, in naive versus m em ory/ 
effector T  cells, between the TCR-CD3 complex and other membrane bound proteins or intracellular 
substrates. Binding o f antigen to the TCR leads to phosphorylation o f Z chain and other components o f 
the CD3 complex.
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which is covalently associated by a disulfide bond, and interacts with the MHC class I 
molecules on target cells.
Studies with naive and memory T cells indicated that the CD45RA isoform expressed by 
naive cells did not co-migrate with CD4, whereas in memory cells expressing the CD45RO 
isoform co-migration was induced with CD4 and TCR [46]. It is therefore clear that 
interaction between CD4 and CD45 is mediated by the nature of the extracellular domain, 
CD45RO being the isoform with the highest avidity. In the same experim ent it was 
demonstrated that CD4 and the TCR also preferentially associate with the low molecular 
weight isoform [85]. Leitenberg et al. recently demonstrated a basal biochemical association 
of CD45 with the TCR complex, which is independent of CD4 and is regulated by the 
ectodomain of CD45 [84]. The efficiency of this association is regulated by the ectodomain, 
i.e. the high molecular weight isoform does not associate as well as the low molecular weight 
isoform, probably due to steric and static hindrances. M aintenance of the CD45-TCR 
association is differentially regulated by TCR ligation by peptide. Partial agonist peptide 
induce dissociation whereas agonist peptide promotes association in a CD4 dependent 
manner. Thus CD45 association with the TCR complex may be a regulatory mechanism for 
T cell activation. The basal association is also detected in resting, primary T cells.
In B cells it is less clear what molecules are part of the large signalling complex. The BCR 
consists of membrane immunoglobuline (mIg) non-covalently associated with heterodimeric 
signal transduction molecules Iga and IgS (CD79) (illustrated in Figure 4). The mIg (mIgM 
or mIgD) binds antigen and the Iga/S heterodimer transduces the signals intracellularly. 
CD45 has been shown to interact with the mIgM and mIgD molecules [27]. In addition, the 
Iga/S heterodimer co-immunoprecipitated with CD45 in lysates from B cells. The close 
physical interaction of CD45 and the BCR indicates that phosphorylation of the Iga/S  
heterodimer might be regulated by CD45 like in TCR signalling (illustrated in Figure 3).
CD45 also associates with a 116 kDa tyrosine phosphorylated transmembrane protein that 
is expressed in all hematopoietic cells [5]. The function of this protein, however, is still 
unknown.
Furtherm ore, another transm em brane protein referred to as lymphocyte phosphatase 
associated protein (LPAP) in human and CD45-AP in mouse interacts specifically with CD45 
[139,158]. This 30 kDa phosphorylated protein is uniquely expressed in the lymphoid lineage 
(but not in monocytes) and it associates to CD45 via the transmembrane regions [28,95]. 
Both LPAP and CD45-AP were found to consist of a short (7-10) amino acid) extracellular 
domain, a single transmembrane pass of 21-23 amino acids and a larger (158-174 amino 
acids) cytoplasmic domain. The molecule undergoes (variable) (hyper)phosphorylation on 
serine and tyrosine residues regulated by p56lck and CD45 [139].The state of phosphorylation
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Figure 4
The Ag-receptor complex in B cells.
Signal transduction after cross-linking o f the BCR upon Ag-binding. Interactions between the BCR and 
associated molecules are illustrated in resting versus activated B cells.
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changes with T cell activation [29,158]. CD45-AP might be considered as an adaptor molecule 
that targets substrates or regulatory molecules to CD45 [72]. The antigen-receptor signalling 
function in both T- and B-cells was reduced in CD45-AP-null mice, due to a diminished 
interaction between CD45 and Lck in T cells indicating that CD45-AP may indeed mediate 
this interaction [92]. The interaction between CD45 and LPAP/CD45-AP is apparently 
required for stabilisation of this protein because expression of LPAP/CD45-AP is not detected 
in CD45-deficient T- or B-cells due to rapid turnover as a result of proteolytic degradation. 
It appears that CD45-AP is part of a multi-molecular complex comprising CD45, TCR, CD4/
8 and p56lck. It is associated with the TCR and CD4/8 through and directly with p56lck and 
this suggest that CD45-AP orchestrates the interactions in the TCR-complex and functions 
by recognising activated Lck and by bringing it into the vicinity of CD45 [176].
CD45 is also reported to associate with the cytoskeletal proteins fodrin and spectrin [24,156], 
and upon binding to these molecules CD45 phosphatase activity is increased [86]. The fodrin 
binding domain in CD45 is mapped to amino acid 930-939 that also mediates the induction 
of the phosphatase activity [64]. This suggests that the interaction of CD45 with components 
of the cytoskeleton could contribute to the regulation of its phosphatase activity. The 
physiological significance of some of the associations of CD45 with these and other molecules, 
i.e. adhesion molecules such as LFA1 (CD58) remains to be elucidated.
Association of CD45 with intracellular substrates
In the previous sections it was pointed out that CD45’s role as a signal effector is exerted via 
the regulation of the activity of several intracellular tyrosine kinases involved in TCR and 
BCR signalling. In this section only the major substrates of CD45 and the kinases involved 
in signalling are described and illustrated in Figure 3 (T-cell signalling) and Figure 4 (B-cell 
signalling).
The TCR/CD3 complex itself does not have intrinsic kinase activity, but upon Ag-binding it 
mediates its effect by interacting with various intracellular substrates. Ag-binding induces 
specific and essential activation of the tyrosine kinases p56lck and p59Fyn of the Src family 
and Syk and ZAP-70 of the Syk-family [65,101]. In resting T cells the CD3 complex is 
associated with p59Fyn which interacts with the e chain and ZAP-70 which interacts with 
the constitutively phosphorylated Z chain [174,185,190]. P56lck associates with CD4 (or CD8) 
[172,175] and upon TCR stimulation it phosphorylates and activates ZAP-70 [34]. This 
activity is promoted by the recruitment of p56lck to the TCR as a result of CD4 or CD8 
binding to the MHC molecule [186]. The next step is that ZAP-70 activates it’s substrate 
SLP-76 which in turn interacts with Vav and Grb2 (components of the Ras pathway) and 
phospholipase Cg1, thereby phosphorylating and activating PLCg1 [54,187]. Activated PLCg1 
generates IP3 (inositol 1,4,5-triphosphate) and DAG (diacylglycerol), second messengers
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which increase the intracellular calcium levels and activate protein kinase C, both of which 
are necessary and sufficient to induce T-cell activation [157].
What is the role of CD45 in this signalling cascade? First, CD45 regulates the family of Src 
kinases. CD45 is able to associate w ith p56lck and p59Fyn [75,102,104,136] and to 
dephosphorylate these kinases in order to maintain them in an active state. In turn, p56lck 
and p59Fyn are required for tyrosine phosphorylation of a num ber of cellular proteins 
including phospholipase Cg1, upon stimulation of the TCR. Tyrosine phosphorylation of 
the carboxy terminal Tyr-505 and Tyr-531 of p56lck and p59fyn, respectively, provides a 
negative regulatory mechanism, which suppresses the activity, of their kinase domains. It is 
now well established that phosphorylation of these tyrosine residues facilitates the formation 
of an intramolecular association (bridge) of the phosphorylated residue with the internal 
SH2 dom ain of the kinases. This intram olecular bond causes the kinase to assume a 
catalytically inactive conformation in which the interaction between substrate and the 
catalytic dom ain is sterically inhibited. D ephosphorylation of the tyrosine by CD45 
phosphatase opens the bridge and reconfigures the kinase to the active conformational state. 
CD45 is thus required for maintenance of Src family kinases in a pre-active state [131,146]. 
Examination of the phosphorylation status of tyrosine residues in p56lck and p59Fyn in CD45- 
deficient T cell lines revealed that, despite the fact that these kinases were spontaneously 
hyperphosphorylated, their catalytic activity was increased when compared to that of kinases 
from CD45-positive cells [31], and exposure of these hyperphosphorylated kinases to CD45 
in vitro decreased their activity to basal levels. The hyperphosphorylation appeared to be 
extended to a second stimulatory autophosphorylation site, Tyr-394, in addition to the 
inhibitory Tyr505 in p56lck. Increased phosphorylation of Tyr-394, in the absence of CD45, 
potentiates kinase function despite the hyperphosphorylation at the inhibitory Tyr-505 
residue [42]. Taken together, the evidence suggests that CD45 is required for keeping a balance 
between the amount of phosphorylated and dephosphorylated kinases, p56lck, p59Fyn, ZAP- 
70, SLP-76 and other components of the TCR-CD3 complex. Thus, CD45 modulates the 
responsive state of lymphoid cells.
The activity of CD45 phosphatase itself is probably subject to similar regulation mechanisms 
as outlined for the PTKs, as CD45 has also a num ber of potential serine and tyrosine 
phosphorylation sites. A protein tyrosine kinase p50csk has been shown to phosphorylate 
specific tyrosines in CD45 causing enhanced CD45 phosphatase activity, and providing a 
binding site or docking station for p56lck [8,110,170]. The importance of such a regulatory 
mechanism for the activity of CD45 is currently under study in many laboratories.
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REGULATION OF ALTERNATIVE SPLICING OF CD45
The pattern of CD45 isoform expression is highly regulated indicating that alternative exon 
usage must be controlled by cell-type specific factors. Both cis-acting sequence elements 
and trans-acting protein factors may be involved. By careful analysis of the behaviour CD45 
reporter constructs cis-acting sequence elements were identified [155,171]. Human CD45 
minigenes with one alternative exon (exon 4 or 6) and various deletion and linker -canning 
mutants were transfected into a B-cell line and a thymocyte cell line and specific sequences 
necessary for tissue specific alternative splicing were delineated in exons 4 and 6 and the 
immediate flanking intron sequences of exon 4. In exon 4 three short elements of 3, 52 and 
11 nucleotides and in exon 6 a large segment of 120 nucleotides (out of 144) were identified 
as essential (Figure 5). Furtherm ore, trans-acting splicing factors were identified by 
heterokaryon formation of cells having different CD45 splicing patterns. Human B cells, 
normally expressing the high molecular weight isoforms, could splice out the alternative 
exons after fusion with mouse thymocytes. In contrast, fusion of hum an T cells with mouse 
B cells did not alter the hum an splicing pattern. This suggest that cells, like T cells and 
thymocytes, expressing the low molecular weight isoforms of CD45 contain negatively acting 
trans-acting splicing factors. B cells on the other hand, expressing the high molecular weight 
isoforms, do not contain the negatively acting trans-acting splicing factors [129]. A similar 
observation was made after transfecting a yeast artificial chromosome containing the entire 
human CD45 gene in mouse myeloma cells that express the low molecular weight isoform. 
This resulted in expression of hum an low molecular weight isoforms [49]. Noteworthy are 
cell fusion experiments with mouse cell lines. Stable synkaryon formation of T- and B-cells 
resulted in a B-cell specific CD45 splicing pattern in the hybrid cells [132]. This apparent 
discrepancy between the synkaryon and heterokaryon experiments can be ascribed to loss 
of genetic material upon nuclear fusion in the synkaryon [129].
Furtherm ore, Rothstein and colleagues showed that fusion of the B-cell line with 3T3 
fibroblast results in the same shift to the smallest CD45 isoform. Thus, non-hematopoietic 
cells contain splicing factors capable of splicing out all alternative CD45 exons. This indicates 
that the default pattern of CD45 splicing excludes exon 4, 5 and 6 and promotes direct joining 
of exon 3 to exon 7 because non-hematopoietic cells are not expected to regulate CD45 
splicing.
A splicing defect is found in healthy individuals showing a genetically determined variant 
pattern in CD45 splicing. The T cells of these individuals remain CD45RA+ during in vitro 
stimulation [141]. A point mutation in exon 4 (A), position 77 leading to a C -> G transition, 
is responsible for this phenomena [164]. Normally, T cells switch from CD45RA+ to CD45RO+ 
during stimulation meaning that exon 4, 5 and 6 are spliced out. This indicates that the 
mutation blocks splicing of exon 4 probably because it is at a position interfering with binding
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CD45 genomic structure
V ........\ /  A/
EXON 4
0 8-10 40 91 127 - 137 198
EXON 6
0 16
57-67 T  78-8990-100
1 3 3 1 4 4
-19 24-35 79-89
3 5 7
j j Sequences essential for tissue specific alternative splicing
□ ✓ Exon 4: A GAA AGA GAA AAPurine rich sequences:^
Exon 6: GGA GAG AGG AG
^  Nucleotide essential for exon A splicing 
77
■ Homology area between exon 4 and 6 (12 mer)Exon 4: (78) GCA AGC ACC TTT (89)
Exon 6: (24) GCC AGC ACC TTT (35)
□ Homology area between exon 4 and 6 (11 mer)Exon 4: (57) CAC ACC ACT GC (67)
Exon 6: (79) CAC ACC ACA GC (89)
Figure 5
CD45 regulatory sequences in exon 4 en 6.
Regulatory sequences involved in alternative splicing o f CD45 are depicted fo r  exon 4 and 6. Numbers 
above and below the exon are corresponding to the nucleotide position in the exon. Regulatory sequences 
are depicted as grey boxes and explained in the boxed area o f the figure.
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of a trans-acting splicing factor. Recently, this contention was confirmed by showing an 
association between the presence of the mutation and abnormal splicing. CD45 minigenes 
with and with out mutation were compared and the minigene with the mutation showed a 
more than tenfold increase in retention of exon A compared to the normal minigene [195].
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THE PROCESS OF pre-mRNA SPLICING 
Introduction
During the last two decades, after the discovery of intron interruptions 
in genes in 1977 [12,32], the basic principles of splicing of pre-mRNA 
were established [69,104,169]). It is now known that intervening 
sequences are removed from individual nuclear pre-mRNAs in a multi­
step pathway. Moreover, cis-acting sequence elements and trans-acting 
protein factors involved in intron removal have been identified. The 
essential steps in this process are carried out in the spliceosome, a large 
ribonucleoprotein complex. The best characterised components of the 
spliceosome are the snRNPs (small nuclear ribonucleoproteins) U1, U2, 
U4/U6 and U5 which contain RNA moieties that align with the pre- 
mRNA splice sites and guide the cleavage-religation events. O ther 
components of the splicing machinery are the hnRNP proteins (associate 
with the heterogeneous nuclear RNA) and the non-snRNP splicing 
factors, including the SR-proteins which will be discussed in detail in 
this chapter. Together, these factors participate in the complex cascade 
of reactions that lead to recognition, selection and juxtaposition of the 
splice sites and drive the conformational changes during spliceosome 
assembly and catalytic cleavage.
All these steps are carried out with great fidelity, thus preventing the 
formation of aberrant gene products (i.e. proteins). Conspicuously, the 
elucidation of one particular form of pre-mRNA splicing, alternative 
splicing, by which multiple functional products can be formed from one
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gene, is lagging behind in our knowledge of the splicing process (see for review [129,159]). 
Here two key questions are at the focus of attention: (1) By what kind of signals are 
alternatively spliced genes regulated in a tissue and cell type specific manner? and (2) What 
are the cellular factors involved in this process? Pertinent knowledge concerning these issues 
will be dealt with in the following sections.
Pre-mRNA SPLICING
During the process of RNA splicing intervening sequences or intron sequences are excised 
from the primary transcript, which results in the joining of exon sequences and ultimately 
in the formation of a mature transcript. This reaction takes place in the nucleus and can 
occur co- or post-transcriptionally. Ultimately, the mature RNA is exported to the cytoplasm 
and translated into protein. Most mammalian genes contain significantly more intron 
sequences than exon sequences. Whereas exon sequences are relatively short (typically 10­
400 nucleotides in length), intron sequences can comprise more than 200,000 nucleotides. 
This means that RNA splicing accounts for the conversion of very long nuclear hnRNA 
molecules or primary transcripts (comprising up to more than 500,000 nucleotides) into 
m uch shorter cytoplasmic mRNA molecules (average length ranging form 500-3000 
nucleotides) [104].
Intron sequences are not translated and their nucleotide sequence seems not to be of biological 
importance. When retained in the mature transcript they often introduce in-frame stop 
codons generating truncated proteins. Furthermore, most intron sequences appear to be 
dispensable and not essential for mature mRNA production [212,213]. The only highly














Sequence elements essential for pre-mRNA splicing.
Consensus sequences o f the 5'- and 3' splice site, branchpoint and poly pyrim idine track are shown in 
bold. In  capitals are indicated exon sequences and the branchpoint (A), sm all characters are intron  
sequences. Exons are hereby shown as boxes, introns as lines. The exonic enhancer elements that influence 
splicing are depicted as dark boxes in the exon boxes. Size o f the intron and exon sequences are depicted 




General Introduction: Alternative pre-mRNA splicing •
conserved sequences in introns are found at either end of the intron and these sequences are 
crucially relevant for intron removal. Alteration of these homologous intron sequences af­
fect the splicing process considerably [181]. Yet, these sequences do not contain all necessary 
information to distinguish bona fide splice sites from cryptic splice sites present in intron 
and exon sequences. The precise details on how splice sites are initially recognised, how 
cryptic splice sites are ignored and how exons are contiguously joined without nucleotide or 
exon skipping is largely unknown. However the importance of “enhancer” elements present 
in alternative and constitutive exons is becoming more and more clear [17] (Figure 1).
Two catalytic steps occur during the splicing reaction. The first is the cleavage of the 
phosphoribose chain next to the guanosine residue at the 5' splice site and covalent binding 
by phosphodiesterification to the adenosine at the branchsite. This is also called lariat 
formation. The second step involves an attack and cleavage of the bond at the 3' splice site 
resulting in displacement of the lariat intron and ligation of the exons. These catalytic steps 
are carried out in the spliceosome. The complex formation of the spliceosome with the two 
catalytic steps are shown in detail in Figure 2.
Generally, after binding of the U1 snRNP to the 5' splice site and the U2AF65/35 complex to 
the polypyrimidine track near the 3' splice site, both splice sites are brought together via an 
interaction between U1-70K protein and U2AF65 which is mediated by SR-proteins (E- 
complex). Next, U2 snRNP basepairs with the branchpoint (A-complex), and U1 snRNP 
and U2AF65 become less tightly bound to the splice sites. The tri-snRNP particle U4/U6 
and U5 is recruited to the 5' splice site (B-complex). After the dissociation of U4 and U6, U1 
snRNP is replaced by U6, which now interacts with the 5' splice site. U6 is now able to 
basepair with U2 bringing the 5' splice site in close proximity to the branchpoint. This is the 
time-point of the first catalytic step. The products, exon 1 and the lariat with exon 2, are 
present in complex C. The last step is the rapid conversion into the splice products (second 
catalytic step), i.e. the ligated exons and the lariat intron (i-complex and D-complex).
E-complex formation can occur across introns or exons. For mammalian pre-mRNAs 
containing short introns, often used in invitro splicing studies, or yeast mRNAs with short 
introns and highly conserved splice sites it was demonstrated that in the first step of E- 
complex formation the 5' and 3' splice site of an intron are brought together by interaction 
between U1 snRNP and U2AF. This step is depending on RNA-protein and protein-protein 
interactions involving U2AF, U1 snRNP and SR-proteins (as depicted in Figure 2). It is notable 
that most mammalian pre-mRNAs contain very large introns (103 - 105 nucleotides) with 
relative small exons (average 300 bp) which contain also less conserved splice sites. More­
over, the long intron sequences contain almost obligatory ‘cryptic’ splice sites. Therefore, 
there must be mechanisms to distinguish true splice sites and cryptic sites and to ensure that
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Figure 2 (opposite page)
Model for spliceosome assembly on pre-mRNAs containing short introns.
The spliceosomal complexes E, A, B, C, i and D are shown. The complexes E, A  and B contain unspliced 
pre-m RNA, the C complex contains the products o f the firs t catalytic steps o f splicing (exon 1 and the 
lariat-exon interdiate). Complexes i and D  contain the excised intron and the joined exons (catalytic 
step II). Formation o f complex A, B, C, i and D are all ATP dependent except fo r E-complex form ation as 
indicated by the arrow. Exons are depicted as open boxes (1 and 2) and the intron as a line. Only the best 
characterised splicing factors are depicted in this model. Components, splicing factors and snRNPs, 
interacting with the R N A  are shown in grey, components less tightly bound are shown w ith dashes. The 
specific spliceosomal complexes are indicated on the left or above the figures.
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a given 5' splice site is joined to the correct 3' partner splice site. The discovery of exon 
bridging interactions and the formulation of the exon-definition model has simplified these 
problems [11,142,160]. It was demonstrated that a 5' splice site on the downstream end of 
an exon is able to promote splicing of the intron immediately upstream. More specifically, 
binding of U1 to the downstream 5' splice site will stabilise U2AF binding across the exon at 
the upstream 3' splice site [80,107]. The E-complex formation across the exon is depicted in 
Figure 3. The exon definition model is supported, among others, by the fact that single
E






The exon definition model: Splicing across an exon.
Early steps in spliceosome assembly on pre-m RN As containing long introns. E-complex form ation across 
exon 2 is shown. U1 snRNP, bound to the 5 ' splice site is linked across the exon to the U2AF complex, 
bound to the 3' splice site, via SR-protein interactions. Transition from  the E-complex to the A-complex 
requires ATP. In  the A-complex U2 snRNP is bound the branchpoint. Symbols are the same as in figure 2. 
Size o f the exon and intron are depicted above the figure.
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splice site m utations lead to skipping o f the entire exon, even though the splice site of the 
opposite side o f the exon rem ains unaltered [106]. The exon, in this m odel, acts as the 
recognition unit for assembly of the spliceosome. Each splice site serves as a buddy to prevent 
that the splice site on the opposite side o f the exon is becom ing lost in the wilderness. M ore­
over, exonic enhancer elements recruit splicing factors like SR-proteins m aking the exon 
m ore attractive for recognition by the splicing m achinery (for review see [17]).
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Patterns of alternative splicing.
D ifferent alternative splicing events are indicated on the right o f the figure. Constitutive exons are depicted 
as open boxes, alternative exons as solid boxes and introns as lines. Dashed lines represent splicing events. 
In  F the arrow indicates the alternative transcription initiation sites, in G the arrow indicates the alternative 
polyadenylation sites.
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ALTERNATIVE mRNA SPLICING
One way to regulate gene expression is alternative splicing of the primary RNA transcript 
leading to the production of multiple protein isoforms originated from single genes (for 
review see [69,117,129,159]). Alternative splicing can also regulate the production of
Figure 5
Alternative splicing pathways of vertebrate pre-mRNAs.
The pre-m RN As are indicated on the left. Exons are indicated as boxes, the grey coloured boxes are the 
alternative spliced exons. Introns are lines, dashes indicate the splicing events. The arrows indicate 
alternative polyadenylation sites. CGRP, calcitonin gene-related peptide.
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functional and non-functional protein isoforms and is therefore important for the on/off 
control of gene expression. Alternative splicing is observed in a variety of organisms including 
Drosophila, C. elegans, vertebrates and also in viruses. In many cases, alternative splicing is 
developmentally, or tissue/cell type specifically regulated. There are different patterns of 
alternative splicing, which are summarised in Figure 4.
The best-studied case of alternative splicing is probably the sex determination pathway in 
Drosophila, which will be discussed in detail in this section. In vertebrates, genes like 
tropomyosins, troponin, mIgM-heavy chain, fibronectin, calcitonin/Calcitonin Gene-Related 
Peptide, CD45 and many others are studied intensively. The splicing events of the pre-mRNAs 
of these genes are depicted in Figure 5.
SEX DETERMINATION IN DROSOPHILA
Sex determination in Drosophila melanogaster involves the action of three genes, namely Sex 
lethal (Sxl), transformer (Tra) and doublesex (dsx) which are all controlled by alternative 
splicing and demonstrate examples of negative and positive control of splice site choices 
(Figure 6). The female specific splice patterns are the regulated splicing events while the 
male patterns are the default pattern, requiring only the general splicing machinery. The 5' 
and 3' splice site used in males are more optimal than the regulated, female specific, splice 
sites and as a result these splice sites will be favoured by the general splicing machinery.
The first gene in this deterministic cascade is the Sxl gene. The Sxl gene is activated early in 
development via a female-embryo specific promotor, in animals were the X-chromosome to 
autochromosome ratio is 1 [5]. The Sxl protein (two RRM domains, no RS domain; domain 
structure of SR-proteins is explained in section 4.2) promotes its own synthesis by directing 
female specific splicing of its pre-mRNA. It blocks splicing of exon 3 leading to exclusion of 
this exon and to the production of a functional protein [8,81,82,96]. Beside regulating splicing 
of its own pre-mRNA, Sxl also regulates splicing of the Tra gene.
Figure 6
Alternative splicing involved in the sex determination cascade in Drosophila.
Regulation o f the three regulatory genes, Sex lethal (Sxl), transformer (Tra) and doublesex (dsx) is depicted 
in (A). Influences o f the specific protein products on the other genes or via auto-regulation is denoted by 
interaction o f the products with the specific exons. Protein products, male and female, are indicated on 
the right. Splicing events and bindings sites o f the proteins are depicted on the left. Exons are boxes, 
introns are lines, proteins are grey coloured circles. Regulated, fem ale splicing is shown above the exon 
boxes and the males splicing events are shown below the exon boxes.
In  (B) exon 4 o f double sex (dsx) is enlarged showing the dsx repeat elem ent which consists o f 6 13- 
nucleotide repeat sequences (grey) and a purine rich elem ent (PRE, black). Specific protein factors binding  
to these elements are indicated. The situation for Drosophila is depicted. See text fo r  details.
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Inclusion of exon 2 of the Tra gene is inhibited by Sxl by blocking the 3' splice site of exon 2. 
Binding of Sxl to the strong polypyrimidine track of this site, blocks binding of U2AF thereby 
promoting the binding of U2AF to the weaker female specific 3' splice site. Exclusion of exon 
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differentiation [87,202].
In male flies no functional Slx and Tra proteins are produced. However the next gene in the 
cascade, double sex (dsx), produces in male and female flies functional proteins which are 
required for sexual differentiation. Intron 3 of dsx contains a non-consensus 3' splice site 
that is not recognised by the splicing machinery in males. Thus in males exon 3 is directly 
joined to exon 5. In females this 3' splice site is recognised leading to inclusion of exon 4. For 
activation of this weak 3' splice site the proteins Tra, Tra-2 and other SR-proteins are required 
as is the dsx repeat element [75,83,130,140,141]. The dsx repeat element (illustrated in Figure 
6) consists of six 13-nucleotide repeats and a purine rich element both of which are required 
for exon 4 splicing [118]. Tra-2 is expressed in both male and female flies and contains a 
RRM domain and two RS domains whereas Tra only contains one RS domain. Moreover, 
Tra-2 can interact with itself, Tra and SF2/ASF [3]. The Tra, Tra-2 and SR-proteins form 
multiprotein complexes, which are associated with the dsx repeat element [197,198]. The 
Drosophila SR-protein RBP-1 participates in the activation of the female specific 3' splice 
site by recognising RBP-1 target sequences in the repeat element [76]. The dsx repeat elements 
recognised by Tra-2/Tra are close to or overlap with the RBP-1 target sequence, and RBP-1 
can in co-operation with Tra-2/Tra be cross-linked to the repeat (depicted in Figure 6) [119]. 
Tra appears not to bind to RBP-1 in this complex as was demonstrated with the yeast two 
hybrid system, RBP-1 binds only to itself and to Tra-2 [77]. In HeLa cells (human), the SR- 
protein 9G8 is recruited to the dsx repeat together with Tra-2/Ttra and appears to be the 
functional homologue of RBP-1. Tra-2/Tra also interacts with the purine rich element and 
recruits in Drosophila the dSRp30 protein and in human SF2/ASF [119].
CIS-ACTING SEQUENCE ELEMENTS
Studies as in the case of sex determination in flies, but in many other systems as well, have 
been instrumental for the identification of different cis-elements in the pre-mRNA which 
can contribute to (alternative) splice site selection. First, the strength of the 5' splice site, the 
poly-pyrimidine track of the 3' splice site and the branchpoints are important for splice site 
selection [54,59,144,146,157]. Strength is defined by the match to the consensus sequences 
of the splice sites (section 2.1), by the complementarity of the 5' splice site and the branchpoint 
to the corresponding regions in the U1 and U2 RNAs, and by the content and length of the 
polypyrim idine track. Alternative 5' and 3' splice sites including branchpoints and 
polypyrimidine track sequences are often weak binders. This enables regulation of alternative 
splicing through competition between sites of different strength. When splice sites including 
polypyrimidine tracks are modified in more optimal sites or tracks, splicing of the particular 
exon is promoted. The polypyrimidine track is the binding site for U2AF, which is necessary 
for stable binding of U2 snRNP. U2AF binds with different preferences to polypyrimidine 
tracks and poly-U rich sequences are better binders than poly-C or purine rich sequences
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[171]. The size of the intron can also be a regulatory factor. Variation in the overall intron 
length has profound effects on the splice site choice since shorter introns generally lead to 
the inclusion of the following exon [9,150]. The secondary RNA structure around the splice 
sites can also affect the splice site choices [50,173] but the most im portant and best studied 
cis-acting elements are the enhancer sequences which can be intronic or exonic (ERE: exon 
recognition element or ESE: exon splicing enhancer).
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Table 1a: Exonic splicing enhancers
Purine rich Sequence element References
Cooper, 1992 [35]
cT N T  e x o n  5 +1 AAGAGGAAGAATGGCTTGAGGAAGACGACGXu et al., 1993 [218]
(c a rd ia c  t r o p o n in  T ) +30 Ramchatesingh et al., 1995
[155]
+694-900 repeast h  t 1 1995 [86]
C a ld e sm o n  e x o n  5 GAGGAAGAGAAAAGGGCAGCAGAGGAGAGGC-Mum prey f  ’’ [ ] 
A Elrick et al., 1998 [48]
h F b A o n e i ”  ^  tg g tg a a g a a g a c a c t  M ardon et al., 1987  [123](E IIIA  o r  E D A  ex o n ) M uro et al., 1999 [137]
bGH exon 5 +117 TCTCCTGCTTCCGGAAGGACCTG +132 Ham pson et al., 1989 [72]
h-hprt exon 3 +18 GAGATGTGATGAAGGAGATGGGAGG +42 Steingnm iidott^ et a1., I 992
[180]
mIgM exon M2 +20 GGAAGGACAGCAGAGACCAAGAG +42 W atakabe et al., 1993 [211] 
+42
ASLV env 3' exon TCCAAGAAGCCGCCAGCAACAAGCAAGAAGGAKatz and Skalka, 1990 [94] 
+77
+ GACAG AGGAGAGC 
HIV-tat exon 1 AAGAAATGGAGCCATGGCA GGAAGAAG Fu, 1993 [52] 
CGGAGACAGCGA CGAAGACC
+ CGAAGGAA T AGAAGAAG AAGGTGGAG 
HIV-tat exon 2 AGAGAGAC AGAT Fu, 1993 [52]
Legend:
Indicated are purine  rich, non-purine rich enhancer elements and splicing silencer elements. 
Nucleotide sequences involved in regulated splicing are shown.
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Table 1b: Exonic splicing enhancers and silencer elements
Non-purine rich Sequence element References
CT/CGRP exon 4 ACTTCAACAAGTT van Oers et al., [203]
cTNT exon 16 CCACCAGAAGGT Wang et al., 1994 [206]
dsx repeats exon 4 ( CAA) CCATCAACA(A) Nagoshi and Baker, 1990 [140]
HSV thymidine kinase TCGCGAACATCTACACCACACAACA-CCGCCTCGA Lui and Mertz, 1995 [116]
MVM NS2 specific exon CA- and Purine rich element Gersappe and Pintel, 1999 [65]
Splicing Silencer 
elements
hFibronectin EIIIA CAAGG Muro et al., 1999 [137]
hHIV-tat exon 2 and 3 AGATCC Amendt et al., 1995 [1]Staffa and Cochrane, 1995 [177]
FGFR-2 K-SAM exon TAGGGCAGGC Del Gatto and Breathnach, 1995 [41]
bGH exon 5 CAGACCT Sun et al., 1993 [183]
Legend:
Indicated are purine rich, non-purine rich enhancer elements and splicing silencer elements. 
Nucleotide sequences involved in regulated splicing are shown.
Splicing enhancers
An important role for exon sequences in splicing was revealed in studies showing that nor­
mal 5' and 3' splice sites are often not used when the exon sequence is substituted by random 
sequences [60,156] or when splice sites are inserted into different locations in the pre-mRNA 
[143]. Exon sequences (cis-acting sequences) are also essential for alternative splice site 
selection as demonstrated for a number of pre-mRNAs [36,37,72,78,113,123,182,201]. It is 
now known that these sequences can effect splice site recognition by binding of SR-proteins 
(see section 4.6.3) which stabilise or inhibit binding of the spliceosomal components U1 
snRNP, U2 snRNP and U2AF. In this way ESEs are essential to promote activation or splicing 
of the normally weak splice sites of the resident exon [86,154,190,219]. It is of note, that 
these exonic enhancers are often purine rich. However, non-purine rich enhancers have also 
been described (data and references can be found in table 1 where the exonic enhancer 
sequences are summarised).
Most purine rich enhancer sequences contain the generic core sequence (GAR)n (R=G or A). 
Short purine rich sequences are already effective. The longer the purine stretch, the stronger 
the effect on splicing and multiple ESEs within a single exon can exert an additive effect.
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Synthetic strings of alternating purine sequences can activate splicing but poly (A) or poly 
(G) can not [190,218]. Most purine rich enhancers are interchangeable in their ability to 
activate weak 3' splice sites [38,45,86,190,218,219]. Although most enhancer sequences 
stimulate splicing of the upstream intron, there are exceptions such as in the case of exon 5 
of the caldesmon gene. Here splicing of the downstream intron is promoted by a long purine 
rich enhancer present in this exon. The enhancer consists of 4 repeats of 32 nucleotides of 
which one repeat is already able to promote exon inclusion [48,86].
Coulter and colleagues developed an assay, which specifically selects the enhancer sequences. 
Besides selecting purine rich motifs, they identified A/C rich splicing enhancers (ACEs) and 
also non-ACE, non-purine rich sequences. The last sequence were as strong or even stronger 
in promoting exon inclusion than the ACE or purine-rich sequences [38]. The existence of 
other splicing enhancers, without a sequence motif was also demonstrated by Tian and Kole 
[196]. ACEs are for example found and probably active as enhancer sequences in cTNT exon 
16, calcitonin/CGRP exon 16 and the dsx exon 4 repeat enhancer [38]. Other non-purine 
rich enhancers have been described and are summarised in table 1.
Besides exonic enhancers, intronic enhancers other than those specifying splice site signals, 
have also been found to affect splice site recognition. Neuron-specific splicing of the c-src 
exon N1 is depending on a intronic sequence element of 123 nucleotides downstream of the 
N1 exon [15,16]. In addition, specific intronic TGCATG repeats present in the intron 
downstream of the EIIIB exon of the fibronectin gene affect splicing of this exon. The repeats 
are evolutionary highly conserved and point mutations in the repeats greatly reduced EIIIB 
inclusion [114].
D ifferent enhancers dem onstra te  b ind ing  preferences for ind iv idual SR-proteins 
[111,154,178,184,198]. The interaction of SR-proteins with specific enhancer sequences is 
described in section 4.6.3. The general picture is that this binding leads to assembly of an 
array of factors on purine rich and non-purine rich enhancer sequences during pre- 
spliceosomal E-complex formation. Thus exonic enhancers function by prom oting the 
assembly of a complex on pre-mRNAs containing weak 5' and 3' splice sites. This resembles 
the process of E-complex assembly on pre-mRNAs containing strong splice sites. Ultimately, 
the assembly of SR-proteins and U1 snRNP is able to recruit U2AF65/35 to the 3' weak splice 
site [178].
MAMMALIAN PRE-mRNA SPLICING FACTORS
Considerable advances in our understanding of the splicing process were made when factors 
were discovered that are either essential for the general pre-mRNA processing steps or involved
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in the regulation of alternative splicing. The best-characterised group of metazoan splicing 
factors are the family of SR-proteins.
THE SR-PROTEIN FAMILY
Members of this group of proteins share a characteristic C-terminal serine-arginine rich 
(RS) domain (where they were named after) and an N-terminal RNA recognition m otif 
(RRM). As will be outlined below similar domains have also been found in other splicing 
factors for example the U1-70K polypeptide, the 65 and 35 kDa sub-units of U2AF and the 
Drosophila proteins Tra and Tra2 and SWAP [14]. The prototypes of the SR-protein family, 
SF2/ASF and SC35, were identified as (essential) splicing factors and are representatives of 
the two subgroups of this family. SF2/ASF, with two RRM domains, belongs to the type I SR- 
proteins and SC35, with one RRM domain, belongs to the type II class of SR-proteins. The 
discovery of these two proteins led to the disclosure of a whole new family of splicing factors 
which also play an important role in the regulation of alternative splicing (Figure 7).
One characteristic of the SR-protein family is that they are all reactive with the mAb 104 
[163,222]. This antibody recognises a conserved phospho-epitope in the RS domain shared 
by all SR-proteins. MAb 104 immuno-reactive proteins with molecular masses of 75, 55, 40, 
30 (panel) and 20 kDa were detected in several tissues, and also in HeLa cell nuclear extracts. 
Most of the cDNAs encoding these abundantly expressed proteins have been isolated 
independently, but one of these SRp, namely SRp55, was identified using the mAb 104 by 
affinity-purification and cloning from Drosophila cells [164]. What follows is a description 
of the discovery and characterisation of each member of this family starting with the two 
prototypes.
The splicing factor SF2/ASF
The first SR-protein was identified as a factor possessing complementing activity to induce 
splicing by an otherwise inactive HeLa S100 extract. This factor was termed SF2, Splicing 
Factor 2 [102]. Later SF2 was purified form HeLa nuclear extracts and shown to modulate in 
vitro alternative splicing of the a-thalassemia and b-globin pre-mRNA in a concentration 
dependent m anner [100,101]. Independently another factor was isolated term ed ASF 
(Alternative Splicing Factor) which was purified form 293 cells [62]. ASF was able, in an 
alternative splicing assay with HeLa nuclear extracts, to modulate 5' splice site selection of 
the SV40 early pre-mRNA. Subsequently, both factors were cloned and sequence analysis 
revealed that SF2 and ASF were identical [63,103]. They coded for a 248 amino acid protein 
with two copies of the RNA-recognition m otif (RRM), separated by a glycine hinge and a C- 
terminal RS domain. Additional analysis of cDNA clones revealed that SF2/ASF itself is also 
alternatively spliced by using different 3' splice sites [63]. Two alternatively spliced isoforms,
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called ASF2 and ASF3, lack the RS domain. Remarkable is that both are highly conserved 
between mice and hum an [187].
SC35
A monoclonal antibody raised against size fractionated mammalian spliceosomes identified 
another splicing factor, known as SC35 (Spliceosomal Component 35) [55]. This factor was 
required for spliceosome assembly and was localised in speckles in the nucleoplasm. Cloning 
of the SC35 cDNA (designated PR264) revealed that the sequence was complementary to 
the sequence of the trans-spliced c-myb exon. Recently, it was demonstrated that this locus 
in human and mouse is bidirectionally transcribed. The function of the ET RNAs encoded 
by the opposite strand is still unknown however, the ET gene is differentially expressed in 
several mouse tissues [186]. A retropseudogene of PR264/SC35 was identified, which encodes 
a new human SR-protein: SRp46. This protein differs significantly from SC35 at the protein 
level, mainly in the RS domain, is active in splicing assays but does not display the same 
activities as SC35 [174]. SC35 has one N-terminal RNA binding domain and a C-terminal 
RS domain and is extremely well conserved in human and chicken, [56,205]. Despite the fact 
that SC35 displays only 31% overall amino acid sequence identity with SF2/ASF, they 
demonstrate similar functions in vitro. Both proteins can reconstitute the splicing activity 
of S100 and SC35 depleted extracts. They also promote the selection of the most proximal 5' 
splice site, and can be antagonised by A1 hnRNP [58]. Furthermore, SF2/ASF and SC35 are 
both able to interact specifically with U1 snRNP and U2AF35, the two components of the 
spliceosomal complex which bind to the 5' and 3' splice site respectively [215]. Finally, it was 
demonstrated that SC35 can reconstitute U2AF depleted nuclear extracts by restoring splicing 
which was substrate specific and U1 snRNP dependent [120].
SRp20 and 9G8
Like SC35, SRp20 and 9G8 both have one RNA binding domain and an RS domain. They are 
the three members of the type II subfamily of SR-proteins characterised by one RRM domain 
of the canonical type. SRp20 is the smallest SR-protein yet described (20 kDa) and 9G8 
belongs to the group of 30kDa SR-proteins. The RRM domain in both proteins has 79% 
similarity, which is unusual among the SR-proteins [25].
SRp20 was initially cloned as a mouse cDNA (X16) by subtraction hybridisation. X16 is 
more strongly expressed in pre-B cell lines than in mature B-cell lines. However, its expression 
is not limited to lymphoid tissue only. The strongest expression was found in adult mouse 
thymus but mRNA was also demonstrated in testis, brain and spleen [4]. In contrast, the 
mRNA level was low or not detectable in liver, lung and kidney. The Drosophila RNA-bin- 
ding protein RBP-1 was found to be identical to X16 [97], this protein was shown to have
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SF2/ASF like splicing activities. The human SRp20 was cloned via PCR amplification from 
HeLa cells [198]. The SRp20 gene in mouse is alternatively spliced, like the RBP1 gene in 
Drosophila [97], and its expression is regulated during the cell cycle [91]. The gene consists 
of 7 exons of which exon 4 is alternatively used. Inclusion of exon 4 leads to a premature 
stop, which results in truncated proteins without RS domain. SRp20 regulates splicing of its 
own mRNA by activating the weak splice acceptor site of exon 4. Overexpression of SRp20 
results in a higher production of the ‘exon 4 included’ form. SF2/ASF antagonises this effect 
by suppressing the inclusion exon 4 [92].
The SR-protein 9G8 was identified by a monoclonal antibody raised against purified hnRNPs 
[25]. Its RRM domain and the RS domain are separated by a Zinc knuckle (CCHC motif), 
and another remarkable feature is the presence of a consensus sequence RRSRSXSX which 
is repeated six times in the RS domain. 9G8 plays a role in splicing which is similar to that of 
SC35. The 9G8 gene consists of 8 exons and is alternatively spliced. Complete or partial 
retention of intron 3 introduces stop codons downstream of exon 3 leading to truncated 
proteins without RS domain. Also two polyadenylation signals are used [151]. W hether the 
truncation process modulates the function of 9G8, like in SRp20, remains subject for further 
study.
SRp30c
SRp30c is a SR-protein with an unusually short RS domain, of only 36 amino acids. It is 
differentially expressed and the highest expression is found in liver and small intestine, 
remarkable is the upregulation of SRp30c in activated T-cells [168].
SRp40 or HRS
The splicing factor HRS was initially cloned as an immediately early gene expressed in an 
insulin treated rat hepatoma cell line [44]. After cloning of the human homologue of HRS, 
SRp40, it was demonstrated that the protein possessed in-vivo and in-vitro splicing activities 
and that it is alternatively spliced raising at least two more isoforms [168,172]. SRp40 mediates 
for example, the inclusion of the fibronectin EIIIB exon which is largely dependent on the 
presence of a purine rich region within this exon [46]. It is of note that, SRp40 is upregulated 
in the proliferative phase of liver development, which correlates with expression of the EIIIB 
exon. Also the presence of TGCATG repeats in the intron downstream of the EIIIB exon 
may have a role in EIIIB exon retention as may SRp40 therein, but this has not been 
established unequivocally up to now [114].
SRp55 or B52
The human SRp55 is nearly identical to B52, which was independently cloned from Drosophila
60
General Introduction: Alternative pre-mRNA splicing •
embryos using an antibody that recognises transcriptionally active sites on Drosophila 
polytene chromosomes [28,168]. The protein contains two RRM domains and one RS domain. 
SRp55 as well as B52 are both able to complement splicing-deficient S100 extract and the 
human SRp55 promotes the use of the distal alternative 5' splice site of SV40 large T RNA 
via enhancing the binding of U1 to this distal splice site [225]. B52 is an abundant protein 
and critical for Drosophila development, deletion mutants are lethal and overexpression 
causes severe developmental defects [105,158]. RNAs that specifically bind to B52 share a 
consensus m otif that forms the core of a secondary structural element. The binding site of 
B52 on these RNAs was defined to a hairpin loop structure covering 20 nucleotides which 
specifically associate with the RRM domain [170].
P54 or SRp54
P54 was identified by its reactivity with an autoantiserum [30]. This member of the SR- 
protein family contains one RRM domain and a RS domain and its is active in constitutive 
splicing and alternative splicing. It can interact with U2AF65 and the SR-proteins SF2/ASF 
and SC35 but not with U1-70K and U2AF35. Moreover, p54 is differentially expressed [228]. 
The Drosophila p54 protein, SRp54, is highly homologous with the human protein, they
Figure 7
Domain organisation of the human SR-proteins.
The eight well-known hum an SR-proteins are drawn to scale in decreasing order o f molecular mass. The 
grey boxes denote the RN A recognition motifs and the vertical black lines or boxes indicate the location o f  
RS or SR di-peptides, w ith the thickness being proportional to the num ber o f di-peptides.
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exhibit a similarity of 84% across their RRM domains which is strikingly high. In addition, 
the Drosophila SRp54 protein contains a putative second RRM domain which is also found 
in the C. elegans sequence but this domain is absent in the hum an sequence. Studies in 
Drosophila demonstrated that SRp54 can act as an intron bridging factor of a small intron 
containing pyrimidine tracts which are located upstream of the branchpoint [95]. This int­
ron of 59 nucleotide contains two pyrimidine tracts between the 5' splice site and the 
branchpoint. It was demonstrated that these two tracts are needed for maximal binding of 
U1 and U2 snRNPs to the splice sites. U2AF and SRp54 are able to bind to the tracts, and 
facilitate intron bridging.
Table 2: The family of pre-mRNA splicing factors containing an RS domain
Class I: SR-proteins (SRp's) References
Human
SRp20 Zahler et. (1992) [222]
SF2/ASF (SRp30a) Ge et al. (1991) [63] Krainer et al. (1991) [103]
SC35 (SRp30b) Fu and Maniatis (1992) [56]
SRp30c Screaton et al (1995) [168]
9G8 (SRp30d) Cavaloc et al. (1994) [25]
SRp40 Screaton et al. (1995) [168]
SRp46 Soret et al. (1998) [174]
SRp55 Screaton et al. (1995) [168]
p54 Chaudhary et al. (1991) [30]
SRp75 Zahler et al. (1993) [224]
Other species
X16 (mouse) = SRp20 Ayane et al. (1991) [4]
RBP1 (drosophila) = SRp20 Kim et al. (1992) [97]
SR-1 (plant) = SF2/ASF Lazar et al. (1995) [112]
RP264 (Chicken) = SC35 Vellard et al. (1992) [205]
HRS (rat) = SRp40 Daimond et al. (1993) [44]
B52 (drosophila) = SRp55 Champlin et al. (1991) [28]
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Kinases w ith RS domains 
Human
Clk-1 (Clk-2 and Clk-3)
Other species
mClk-1/Sty (mouse) = Clk-1
References
Theissen et al. (1986) [195] 
Zamore et al. (1992) [226] 
Zhang et al. (1992) [227] 
Dauwalder et al (1996) [40]
Beil et al. (1997) [7]
Denhez and Lafyatis (1994) [43] 
Blencowe et al. (1995) [18] 
Blencowe et al. (1995) [18] 
Zhang and Wu (1998) [229] 
Tronchere et al. (1997) [200] 
Ono et al. (1994) [148]
Mancebo et al (1990) [121] 
Etzerodt et al. (1988) [51]
Boggs et al. (1987) [21]
Tmrein et al (1988) [2]
Goralski et al. (1989) [66]
Chou etal. (1987) [31]
Denhez and Lafyatis (1994) [43] 
Gee et al. (1997) [64]
Company etal. (1991) [34]
Johnson and Smith (1991) [90] 
Hanes et al. (1994) [74]
Ben-David et al. (1991) [10] 
Howell et al. (1991) [84]
Legend: The table summarises members o f the fam ily  o f SR-proteins, SR-related proteins and 
SR-protein related kinases in humans and other species.
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SRp75
SRp75 is the largest SR-protein, it contains two RRM domains and a very long RS domain of 
315 amino acids [224]. It is abundantly expressed in various cell lines (HeLa) and tissues 
[222]. As yet no distinct functions of SRp75 are known.
STRUCTURE OF THE SR-PROTEIN DOMAINS
SR-proteins have a modular structure consisting of one or two amino-terminal RNA-bin- 
ding domains (RBDs) or RNA recognition motifs (RRMs) and one carboxyl-terminal Arginine 
(R)-Serine (RS) rich domain. The RRM domains are essential for activity and define the 
RNA binding specificity. The RS domain functions primarily as protein-protein recognition 
units but also demonstrate regulatory functions. The RRM domain is a characteristic RNA 
binding domain. It is a region of around 80 amino acids and contains two highly conserved 
submotifs essential for RNA splicing, the octamer RNP-1 and the hexamer RNP-2, located 
about 30 amino acids apart. The second central RRM domain (atypical), not present in all 
SR-proteins, contains less conserved RNP-1 and RNP-2 sub motifs although its tertiary 
structure is thought to be similar to that of the canonical RRM. The RRM is organised into 
four antiparallel 6-sheets and two a-helices which are arranged in the order 61-a1-62-63- 
a2-64. The RNP-1 and RNP-2 are juxtaposed on the centrally positioned antiparallel 63 and 
61 strands, respectively [14] (RNP domains were recently reviewed by [204]). In some SR- 
proteins the RRM domains are separated from the RS domain via a glycine hinge. The RS 
domain is rich in Arginine (R) and Serine (S) residues often present as RS or SR repeats 
which makes this a highly positively charged domain. Its length varies between individual 
SR-proteins. Finally, it should be mentioned that phosphorylation of the RS domain is im­
portant for its proper functioning.
SR-PROTEIN RELATED POLYPEPTIDES
RS domains are also present in several SR-related factors,which are listed in table 2. Among 
these factors are the Drosophila splicing regulators Tra [21], Tra-2 [2,66] and SWAP, 
Suppressor-of-white-apricot [31]. These proteins act as modulating regulators. Tra and Tra- 
2 are involved in the sex determination pathway of Drosophila and have been described 
earlier (pages 8-10). Tra-2a and Tra-26 are two human homologues of Tra-2 [7,40]. Both 
are alternatively spliced and Tra-2a is able to functionally replace the Drosophila Tra-2 protein, 
indicating similar m olecular functions for both  proteins [40]. Cloning of the mouse 
(mmSWAP) and hum an (hsSWAP) homologues of SWAP has revealed that these proteins 
share one RS domain and two repeated SURP modules [43]. The factors auto-regulate splicing 
of their own pre-mRNA, like the Drosophila protein, and regulate among others, the 
alternative splicing of the fibronectin IIICS region and CD45 exon 4 [165].
The U1 snRNP-associated 70 kDa protein contains a RS domain which is present in the 70K
64
General Introduction: Alternative pre-mRNA splicing •
protein [51,121,153,176,195]. U1 snRNP interacts with SR-proteins via its RS domain and it 
is important for 5' to 3' bridging of the intron (or exon) sequence during spliceosome assembly 
(see below for further details).
U2AF65 is an essential splicing factor with three RRM domains and one N-terminal RS 
domain [226] and is related to Prp2 from S. pombe and dU2AF50 from Drosophila [93,152]. 
U2AF65 binds to the 3' splice site as a heterodimer with U2AF35. This 35 kDa subunit contains 
one small RS domain and plays an im portant role in protein-protein interactions with SR- 
proteins [215,227]. Urp, a U2AF35 related protein, is another essential splicing factor which 
interacts with U2AF65 via an U2AF35-homologous region (the U2AF65-binding domain). 
It interacts with true SR-proteins through their RS domain and may position, like U2AF35, 
these factors in the spliceosome [200].
Another SRp-related protein, Sip (SC35 interacting protein), was initially identified by its 
interaction with SC35. However, Sip also interacts with U170K, U2AF65 and several SR- 
proteins. It contains a RS domain, a region with low homology to the SURP module found 
in SWAP and a CTD-binding domain, which interacts with the carboxyl-terminal domain 
(CTD) of RNA polymerase II. Sip is an essential splicing factor with a role in splicing distinct 
from that known for other SR-proteins [229].
Recently, a large nuclear matrix protein was shown to contain multiple RS repeats. This 
protein, SRm160 (SR-related matrix protein of 160 kDa) and the related SRm300 protein are 
co-activators of splicing. It is known that these matrix proteins form a complex with the 
splicing machinery via interactions with the more common SR-proteins, whereby the 
interaction of SRm160/300 is U1 snRNP dependent and is stabilised by U2 snRNP [18,19].
THE ROLE OF hnRNP PROTEINS IN SPLICE SITE SELECTION
Heterogeneous nuclear riboproteins (hnRNPs) are large protein complexes associated with 
newly transcribed mRNAs (pre-mRNAs or hnRNAs). They remain associated with the pre- 
mRNA u n til processing is com plete and th e ir  presence is also ev iden t du ring  
nucleo cytoplasmic transport. During this association, hnRNPs can affect interaction of the 
pre-mRNA with spliceosomal components. They form a large family of proteins with di­
verse structural features including RNA binding and auxiliary domains, designated hnRNP- 
A1 through hnRNP-U. The hnRNPs A1, A2, B1, B2, C1 and C2 are the most abundant and 
best characterised members of this family (reviewed by [204]).
hnRNP-A1 regulates alternative splicing by antagonising SR-proteins. It counteracts the 
activity of SF2/ASF, which usually promotes the use of proximal 5' splice sites, by favouring 
the use of the most distal 5' splice sites [22,124]. Other members of the hnRNP-A/B family, 
hnRNP-A1B, A2 and B1 show also variable antagonistic activities [125]. hnRNP-A1 consists 
of two closely related tandem RNA recognition or binding motifs (RRMs) followed by a 
glycine rich domain. Deletion of this last domain abrogates alternative splicing activity and
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decreases RNA binding and annealing. Two conserved Phe residues in the RNP submotifs of 
the RRM domains are essential for modulating alternative splicing but not for RNA binding 
or annealing [125]. Duplication, deletion or swapping of the RRM domains showed that 
each domain plays a distinct role and their position is important [126]. The duplicated RRM 
domain structure is essential for functional integrity, as is the presence of RRM2.
The concentration dependent influence on splice site selection of SR-proteins and their 
antagonising counterparts, the hnRNP A/B family members, suggest that changing the relative 
levels may be a natural mechanism for regulation of alternative splicing in vivo. This model 
is supported by the fact that protein levels of SF2/ASF and hnRNP-A1 vary naturally over a 
very wide range, as demonstrated for rat tissues and in immortal and transformed cell lines 
[73].
Again, as a recurrent theme, the hnRNP-A1 pre-mRNA is alternatively spliced itself raising 
A1 and A1b mRNAs. These mRNAs encode proteins differing in their ability to modulate 5' 
splice site selection. Regulation of hnRNP-A1 alternative splicing occurs through a highly 
conserved intronic element (CE1) which promotes exon skipping. This element contains 
the sequence UAGAGA, a potential hnRNP-A1 binding site, suggesting that hnRNP-A1 may 
regulate alternative splicing of its own pre-mRNA [27]. Recently it has been demonstrated 
that hnRNP-A1 can repress splicing by its recruitment to exonic splicing silencers (ESS) 
[42]. This repression requires the glycine rich domain, which is necessary for protein-protein 
interactions. In- and exclusion of exons with both an ESS and ESE can thus in principle be 
controlled by changing the relative levels hnRNP-A1 and SR-proteins. An example of an 
exon that is subject to this type of regulation is the EDA/ED1 (or EIIIA) alternative exon of 
human fibronectin.
MECHANISMS OF SR-PROTEIN ACTION AND THEIR ROLE IN CONSTITUTIVE 
AND ALTERNATIVE SPLICING
Initially, it was demonstrated that all individual SR-proteins can complement splicing deficient 
S100 extracts to allow splicing of a variety of pre-mRNAs. This suggests that SR-proteins 
have redundant functions in vitro [25,56,63,100,103,127,222]. Although no differences in 
SR-protein action was observed in in-vitro assays for constitutive splicing several differences 
were observed in their ability to regulate alternative splicing. It was noted that this type of 
factors can affect the usage of competing 5' or 3' splice sites in a specific and concentration 
dependent manner in vitro [58,168,223], in transient transfection assays [22,208] and in 
vivo [209]. These data suggest that SR-proteins have different substrate specificities and 
differential activities in the regulation of the kinetics of alternative splicing.
Constitutive pre-mRNA splicing
It is now generally accepted that SR-proteins are essential splicing factors and act at early
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steps in splicing [53]. The first step in spliceosome assembly is the recruitment of UlsnRNP 
to the 5' splice site. SR-proteins promote and stabilise this binding. SF2/ASF interacts with 
the U1-70K protein to form a stable complex, a prerequisite is that SF2-ASF binds first to 
the pre-mRNA [49,99,178,225]. This interaction requires protein-protein which takes place 
via the RS-domains and is mediated by the U1-70K protein. Excess amounts of SR-proteins 
can even bypass the requirement for UlsnRNP [39,191]. Next, SR-proteins remain associated 
beyond the commitment complex with the spliceosomal complex [20]. They play a role in 
the association of the U4/U6-U5 tri-snRNP with the prespliceosome [161] and also function 
in stimulating the interaction between U2-U6snRNP at the 3' splice site [192]. Finally, SR- 
proteins aid in the correct pairing of the 5' and 3' splice sites by interacting simultaneously 
with U1snRNP and U2AF35 [215]. In addition, the SR-protein SC35 was shown to mediate 
the interaction between U1snRNP and U2 snRNP particles at the 3' splice site [57]. These 
activities at the 5' and 3' splice sites are all referred to “as general functions” of SR-proteins, 
with a role in constitutive splicing.
The precise mode of binding of SR-proteins on the pre-mRNA remains unclear as these 
proteins cannot bind directly to the splice sites which, are recognised by U1snRNP and U2AF. 
One possibility is that they do bind to exonic sequences, implicating that constitutively spliced 
exons also contain enhancers sequences specific for SR-proteins. Such a feature initially was 
thought to function exclusively in alternatively spliced pre-mRNAs. The second possibility 
is that they bind to intronic sequences thereby recruiting U1snRNP or U2AF to the adjacent 
splice sites. Support for the first model was recently given by the finding that, SR-protein 
binding sites are present within constitutively spliced exons and these sites can indeed function 
as splicing enhancers by recruiting SR-proteins [166]. The second possibility was studied by 
analysing the neccessity for exonic sequences for the splicing reactions. It turned out that 
only 1 nt of exon sequence is in fact necessary for RNA substrates to undergo the first step of 
the splicing reaction, cleavage at the 5' splice site and lariat formation, and that for this step 
to occur SR-proteins are required which posses a functional RNA binding domain [79]. These 
results provide evidence that SR-proteins have both exon-dependent and independent 
functions during (constitutively) pre-mRNA splicing.
Alternative pre-mRNA splicing
One feature of alternatively spliced pre-mRNAs is the presence of weak splice acceptor and 
donor sites allowing the action of regulatory mechanisms. SR-proteins are able to influence 
splice site selection and one im portant way to do so is by binding splicing enhancer or silencer 
sequences (see next section). In this manner they are able to enhance splice site recognition 
at the 5' and 3' splice sites by promoting and stabilising complex formation of the components 
of the basic splicing machinery. The precise effect of SR-proteins on 5' splice site selection
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(recruitment of U1snRNP) is depending on the nature of the SR-protein and the type of 
RNA analysed. A specific SR-protein can select the proximal or distal 5' splice sites in a 
concentration dependent manner (see reviews [26,53,122]). At the 3' splice site SR-proteins 
facilitate binding of U2AF65 to the often weak polypyrimidine track of 3' splice site. This 
process is often enhancer dependent whereby U2AF35 mediates the reaction between the SR- 
protein bound to the enhancer sequence and U2AF65 [199,215].
•  Chapter 2
SR-protein recognition of splicing enhancers
Most splicing enhancers are positioned in exons and are purine rich. However, besides purine- 
rich enhancers also A/C rich and other (non-purine-rich, non-A/C rich) enhancers [38] as 
well as silencer elements which inhibit recognition of the particular exon [137] have been 
identified. In all cases members of the family of SR-proteins have been found to bind to 
these sequence elements. Here, the SR-proteins bind either directly to the RNA sequence or 
are recruited to the splicing complex via other RNA-binding factors [154,178,179,184,220]. 
For example, SRp55 can bind specifically to the purine rich splicing enhancer present in 
exon 5 of avian cardiac troponin T. This 30 nucleotide enhancer contains two purine rich 
motifs which both co-operate in SRp55 binding. To form a stable complex two SRp55 proteins 
are required whereby SRp55 binding is guided by the primary sequence and RNA secondary 
structural elements in the enhancer m otif [139].
Selective enrichment from pools of random RNA sequences (SELEX, Systematic Enrichment 
of Ligands by Exponential enrichment) has been employed to identify RNA sequences which 
specifically interact with distinct SR-proteins 630, 628, 674}. The sequences selected by this 
strategy are listed in table 3. Most of them are purine rich and show similarity with the 
GAR-repeat motif, which is found in the majority of enhancer sequences. For example, the















Cavaloc et al. (1999) [24] 
Cavaloc et al. (1999) [25]
Tacke and Manley (1995) [189] 
Tacke and Manley (1995) [189] 
Tacke et al. (1997) [188]
Legends:
Indicated are the nucleotide sequences specific fo r  SR-proteins as selected by the SELEX strategy. 
R = G or A, S = C or G, Y  = C or T.
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consensus sequence bound by SF2/ASF, RGAAGAAC, resembles this motif. However, not all 
selected sequences are purine-rich and some motifs that are recognised have their own unique 
character. The binding specificity of SF2/ASF involves the co-operation of both its RRM 
domains but SC35 is not able to associate to the same enhancer. Three copies of this SF2ASF 
m otif can act as an splicing enhancer and SF2ASF can activated splicing of exons containing 
three copies of this m o tif [189]. Selection of the enhancer sequence for SRp40 is 
phosphorylation dependent and three copies function as a splicing enhancer like was 
demonstrated for SF2/ASF. SRp40 is the only SR-protein able to activate this splicing enhancer 
and the only SR-protein associated with this enhancer [188]
Besides the SELEX strategy, other methods have also been used to identify SR-protein specific 
enhancer sequences. One approach is based on the functional selection of SR-protein specific 
enhancers [115,167] by the insertion of random sequences downstream of an enhancer dep­
endent exon. In this manner enhancer sequences were identified which were specific for 
SRp20 (CTCT/GTCY), SC35 (TGCNGYY), 9G8 (GGACGACGAG and TGCGGTCT) and 
SF2/ASF (GGACAA).
Interaction of specific SR-proteins with intronic enhancers has also been reported. Without 
exception, these elements which can be purine rich or pyrimidine rich are located downstream 
of the alternatively spliced exon [47,61,115]. One example of such an arrangement can be 
found in the chicken b-tropomyosine pre-mRNA. Here, exon 6A and 6B are mutually exclusive 
and a pyrimidine rich intronic enhancer downstream of exon 6A is essential for exon 6A 5' 
splice site recognition. The pyrimidine rich sequence in this enhancer can be replaced by a 
purine rich sequence (GAR) without losing its function. SF2/ASF specifically binds to the 
enhancer and promotes exon 6A splicing whereas SC35 inhibits splicing of exon 6A. This 
suggests that regulation of tissue specific splice site choices of S-tropomyosine exon 6A are 
dependent on the ratio of the splicing factors SF2/ASF and SC35 [61]. Another interesting 
example concerns the tissue specific recognition of exon 4, an embedded 3' terminal exon, 
of the calcitonin/CGRP gene. Here again, the intronic enhancer is located downstream of 
exon 4 and contains both 3' (pyrimidine track) and 5' splice site consensus elements. SRp20 
recognizes the enhancer element and promotes exon 4 inclusion whereby SRp20 binds to 
the pyrimidine track elements in the enhancer [115].
Based on the domain swapping and enhancer mutagenesis studies it is now considered pro­
ven that (1) RS domains can activate splicing independently and that individual RS domains 
can functionally replace each other [29,67,68], (2) strength of enhancing activity relates to 
the number of RS tetra-peptides within each domain and (3) enhancer function depends on 
the distance from the 3’ splice site and the actual number of SR-proteins that can be bound 
[67].
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Splicing repressor molecules
Recently, two SR-protein associated molecules were identified which posses splicing inhibiting 
properties [109,149]. P32 was originally identified as a SF2/ASF associated protein [103] but 
now it is known that it can bind to other SR-proteins like SRp30c as well. It inhibits the 
function of SF2/ASF but not of SRp30c, by preventing a stable interaction of SF2/ASF with 
the RNA through inhibition of the phosphorylation of SF2/ASF [149]. Another protein, 
RSF1 (repressor splicing factor 1), is isolated from Drosophila and comprises a RRM domain 
and a domain rich in glycines (G), arginines (R) and serines (S) (GRS domain). This protein 
inhibits splicing of several reporter RNAs by interaction of its GRS domain with the RS 
domain in SF2/ASF, thereby preventing binding of U1snRNP to the RNA. In addition, 
overexpression of RSF1 rescues the defects caused by overexpression of B52 (SRp55) in flies
[109]. We may conclude that these two proteins may be members of a new family of splicing 
regulatory proteins that selectively antagonise the promoting effect of SR-proteins on splice 
site selection.
REGULATION OF SR-PROTEIN FUNCTION
To add a further level of complexity it should be stressed that SR-proteins function itself is 
subjected to complex regulation by a complex set of mechanisms, including transcriptional 
regu la tion , p o s t- tran sc rip tio n a l m R N A -processing, p ro te in  m od ifica tion  (i.e. 
phosphorylation) and routing regulation. Together with the cis-acting effects of enhancer 
sequences (discussed previously) these mechanisms regulate splice site selection, and ac­
count for subtle differences in splice site efficiency and cell type specific effects in mRNA 
splicing.
Transcriptional regulation or differential SR-protein expression patterns
SR-proteins are cell- or tissue- type specifically expressed and the expression pattern can 
change during the cell cycle (SRp20) or by activation with serum (SRP20), or specific 
hormones like insuline (SRp40) or PHA (SRp30c) [4,56,73,92,168,205,223]. Previously it 
was mentioned that SR-proteins affect alternative splice site choices in a dose dependent 
manner indicating that relative levels of SR-proteins are im portant for splice site decisions 
[22]. Together with the fact that hnRNP A/B proteins can antagonise the splicing effects of 
SR-proteins it is thus conceivable that one way of regulating alternative splicing is by varying 
the expression levels of individual SR-proteins.
Alternative splicing of SR-proteins
Another way of regulating SR-protein levels is by alternative splicing of the pre-mRNA of 
SR-proteins. This, in most cases, gives rise to protein isoforms that lack their RS domain and 
is d em onstra ted  for SRp20, 9G8, SF2/ASF, SC35/RP264, SRp40/HRS and SRp55
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[44,63,91,151,168,185]. The existence of these alternatively spliced isoforms as stable proteins 
in vivo has not been demonstrated yet and the precise role of these isoforms is also not clear. 
However, in vitro data indicate that SR-proteins lacking their RS domain are inactive in S100 
splicing extracts and in promoting 5' splice site switching as was demonstrated for ASF2 and 
ASF3, the alternatively spliced isoforms of SF2/ASF [230]. SRp20 is the only SR-protein for 
which it is demonstrated that both isoforms with and without RS domain, are transcribed as 
proteins upon transfection and that SRp20 auto-regulates this alternative splicing process. 
Overexpression of SRp20 results in inclusion of exon 4 which leads to protein isoforms wit­
hout RS domain [92]. Regulation by alternative splicing, which is a phylogenetically conserved 
phenomenon, may in this way play a role in regulation of the level of functionally distinct 
(active-inactive) SR-proteins.
Regulation by phosphorylation and dephosphorylation
SR-proteins are extensively phosphorylated in vivo on serine residues in their RS domain 
[33,163] and phosphorylation and dephosphorylation phenomena are thought to regulate 
both constitutive and alternative splicing. Phosphorylation of SR-proteins is required for 
spliceosome assembly as illustrated by the fact that addition of PP1, a serine/threonine 
phosphatase, to nuclear extracts inh ib its spliceosom e assembly [132]. M oreover, 
phosphorylation is necessary for progression of the A-complex to the B-complex during 
spliceosome form ation [161]. On the o ther hand, phosphatase activity (perhaps on 
functionally distinct serine or threonine residues) is required for both catalytic steps as 
addition of phosphatase inhibitors specific for PP1 and PP2A, block these steps of the splicing 
reaction in HeLa nuclear extracts [131,193]. The use of thiophosphorylated U1-70K and 
SF2/ASF, to prevent dephosphorylation, was shown to have the same effect [23,194]. The 
effects that phosphorylation can have on individual factors has been particularly well studied 
for SF2/ASF. Xiao and M anley [216,217] and Cao and colleagues [23] proved that 
phosphorylation of SF2/ASF stimulates its interaction with U1-70K and U1snRNP, but blocks 
its binding to SRp40 and/or Tra2. Association with U2AF35 is not effected by phosphorylation.
Several kinases which phosphorylate SR-proteins have been identified. Among them are the 
snR N P-associated kinase [214], SRPK-1, -2 (SR pro te in  specific kinase 1 and 2) 
[70,71,108,207], Clk/Sty-1, -2, -3 [33], topoisomerase I [162] and cdc2 kinase [147]. The 
Clk/Sty and SRPK kinases are specifically involved in phosphorylation of SR-proteins and 
have therefore a direct effect on alternative pre-mRNA splicing. These kinases share 32% 
identity in their catalytic domains and both contain a signature amino acid sequence referred 
to as the LAMMER motif [33]. The Clk/Sty kinases also contain a N-terminal RS domain 
which is im portant for the interaction with the SR-proteins. They are localised, like the 
SRPK kinases, in the nucleus and overexpression results in redistribution of the splicing
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factors in the nucleus. SRPK1 displays a higher substrate specificity compared to Clk/Sty 
which suggest that they may have distinct functions in splicing [33]. Furthermore, differential 
expression patterns of SRPK1 and 2 are found [207] indicating that these kinases are involved 
in tissue specific regulation of splicing processes. Taken together, it seems that cells express 
multiple SR-protein specific kinases with different substrate specificity’s. Expression is 
regulated cell- or tissue type specifically to regulate alternative pre-mRNA splicing via the 
signal transduction pathways.
Besides kinases also SR-protein specific phosphatase play an important role (see also next 
section). Recently, the type 2 2C Ser/Thr phosphatase PP2Cg was identified as a specific pre- 
mRNA splicing factor [138]. PP2Cg localises to the nucleus, is physically associated with the 
spliceosome throughout the splicing reaction and is required for efficient formation of the 
A-complex during the early stages of spliceosome assembly.
COMPARTMENTALISATION OF SR-PROTEINS
Subnuclear localisation and shuttling of SR-proteins
Eukaryotic gene expression requires the co-ordinated execution of multiple nuclear processes 
like transcription, pre-mRNA splicing, polyadenylation and transport of the processed RNA 
out of the nucleus. All processes take place in highly organised compartments in the nucleus 
which, are tightly connected to each other. Transcription and splicing are coupled processes 
and a large body of evidence indicates that splicing occurs co-transcriptionally [6,13]. 
Biochemical support for this model is found in the fact that the CTD domain of the large 
subunit of RNA polymerase II and pre-mRNA splicing factors are physically interacting 
[128,136,221]. Morphological evidence also indicates the coupling of these processes as 
demonstrated by the presence of spliceosomes on the nascent transcript [6,13,98].
In the mammalian nucleus, splicing factors are enriched in 20-50 nuclear domains, the nuclear 
speckles, in addition to their diffuse distribution throughout the nucleus (see review [175]). 
In some cases, snRNP proteins are also located in round nuclear structures, the coiled bodies
[110]. Speckles consist of two distinct structures, the granules (20-25 nm in diameter) that 
are clustered in the interchromatine space (IGCs: interchromatine granule clusters) and the 
fibrils (5 nm in diameter) called perichromatin fibrils (PFs) which often extend from the 
periphery of IGCs. Transcription occurs predominantly in the PFs and is largely excluded 
form the IGCs. Only a m inority of splicing factors is found within the active sites of 
transcription [88,210]. Therefore, it was proposed that the IGCs are the storage and re­
assembly sites for the splicing factors and that these factors are recruited from IGCs to sites 
of transcription (PFs) [89,134]. This recruitment process ensures sufficient supply of splicing 
factors to active sites of transcription [85,89,145].
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The role SR-proteins in this recruitment process has been studied intensively. As mentioned 
before SR-proteins function is dependent on phosphorylation of the RS domain. It appears 
that phosphorylation of the RS dom ain is also required for recru itm ent to sites of 
transcription. Deletion of the RS domain of SF2/ASF, or the lack of phosphorylation on 
serine residues blocks the dissociation of SR-proteins from speckles and prevents their 
migration to active sites of transcription [133]. Moreover, overexpression of SR-protein 
specific kinases (SRPKs or Clks) results in redistribution of splicing factors from speckles to 
a diffuse nuclear pattern [33,70,207]. Phosphatase activity (PP1) can prevent accumulation 
of splicing factors in speckles upon  inh ibition  of transcrip tion . This indicates that 
dephosphorylation facilitates association with the speckles [135]. Finally, deletion of either 
o f the RRM dom ains of SF2/ASF results in its dissociation from the speckles upon 
transcriptional activation. In this case the protein adapts to a diffuse nuclear distribution 
indicating that in the absence of an RRM domain the SR-protein fails to associate with the 
target RNA [133].
Thus, phosphorylation enables the SR-proteins to dissociate form the storage sites (IGCs) 
and become incorporated in the spliceosome. After completion of the splicing reaction (in 
PFs), dephosphorylation releases the SR-proteins from the spliceosome allowing them to 
return to the IGCs.
CONCLUDING REMARKS
As stated in the introduction our understanding of the process of alternative pre-mRNA 
splicing has increased enormously but is still far from complete. Numerous splicing factors 
have been identified by biochemical and molecular approaches, however, referring to the 
size and complexity of the spliceosome, many more remain to be discovered and characterised. 
Also the mechanistic aspects of splicing need to be understood in a more detailed fashion. 
Only then we can begin to think about dynamic aspects of this fascinating process.
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ABSTRACT
We have designed a new cell surface expression plasmid to study the 
structural and membrane-topological requirements for functioning of 
different isoforms of CD45, a leucocyte specific member of the protein 
tyrosine phosphatase (PTPase) family of proteins. Use of this vector in 
cell transfection experiments enabled us to produce multiple CD45 
isoforms (ABC, B, and Null), with their extracellular segment intact and 
the entire membrane spanning and intracellular C-terminal domain 
replaced by a G PI-m em brane-anchor and VSV-tag. O ur strategy 
facilitated the identification and analysis of chimeric proteins and 
selection of producing cell clones from low transfection efficiency 
experiments, and could be of general use for study of proteins with an 
export peptide-signal. We demonstrate here that simple expression of 
GPI-anchored CD45 isoforms on transfected Cos-1 cells does not 
facilitate binding to CD22+ lymphoid cells. This suggests that not only 
the mere presence of CD45 extracellular domains but also their assembly 
into higher order structures at the cell surface, is necessary in order to 
engage in the recognition and/or signaling processes normally used by 
B- and T-cells.
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INTRODUCTION
C- term inal anchoring to the m em brane via a glycosyl-phosphatidyl-inositol (GPI) 
modification confers several functional properties upon cell surface proteins. These properties 
may relate to their role in cell signaling cascades, the conditioning of their sorting and mobility, 
or their reinsertion and intermembrane trafficking-behavior [7,21]. Generally, GPI-anchored 
proteins are diffusely distributed at the cell membrane, but after cross-linking they are 
localized in membrane invaginations known as caveolae. When present in caveolae, GPI- 
anchored proteins may become involved in potocytosis and signaling phenomena [13,14]. 
These effects of GPI-modifications have been exploited in studies with vectors which produce 
synthetic type I integral m em brane proteins or secreted proteins, in which the entire 
transmembrane (TM) and cytoplasmic regions have been replaced by an anchoring signal 
[3,6,18]. This facilitates the study of functional epitopes of these proteins via random  
mutagenesis and expression in eukaryotic cells [18]. Moreover, purified GPI-anchored 
proteins can serve as address- or targeting-tags for liposomes [4] or can be used to “decorate” 
cells, via spontaneous uptake from the medium and incorporation into the cell surface 
membranes in vitro [15].
We have decided to use GPI-anchoring for our study of structure-function relationship of 
different domains in the extracellular segment of CD45 isoforms. CD45, or LCA (leucocyte 
common antigen), is a member of the large family of transmembrane tyrosine phosphatases, 
which is expressed on all hematopoietic cells [17,22,23]. Due to alternative splicing of exon 
4, 5 and 6 in the extracellular domain different isoforms of CD45 can be produced [23]. The 
precise role of this domain shuffling in the extracellular portion of this molecule is still ill 
understood. It is also not well known whether CD45’s role in signaling processes requires its 
partitioning into specific higher order membrane structures, or any kind of lateral association 
with membrane bound partner proteins.
MATERIALS and METHODS
Construction of the GPI-anchoring expression vector (pSG8DAF)
The GPI-anchor encoding DNA fragment was generated as a 227 bp RT-PCR product from 
HeLa RNA and cloned in the filled in BglII site of the eukaryotic expression vector pSG8 (a 
modified version of pSG5 [5]), forming pSG8DAF. For PCR amplification of the DAF segment 
the follow ing p rim ers were used: a 25-m er sense p rim er (5 '- 
TTCAACCCCAAATAAAGGAAGTGGA-3') corresponding to nucleotide residues 1093-1115 
and a 23-mer antisense primer (5'-CCTAAATGAAGAGCACAATTGCA-3') corresponding 
to nucleotide residues 1416-1438 of the human DAF sequence [2]. Two PCR fragments are 
generated, a 227 bp and 345 bp fragment, the smallest fragment is the spliced form containing 
the GPI-anchor attachment signal. In order to facilitate the identification of CD45/DAF-
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GPI fusion products an 11 amino acid long Vesicular Stomatitis Virus Glycoprotein-tag (VSV- 
tag) was included that can be recognized by the monoclonal antibody P5D4 [8,9]. To this 
end a synthetic double stranded VSV-tag sequence, 5'-GG AGA TCT TAT ACA GAC ATA 
GAG ATG AAC CGA CTT GGA AAG GGA TCC CCC-3', was digested with BglII and BamHI 
and cloned in the unique (restored) BglII site of pSG8DAF.
RT-PCR cloning of cDNA fragments encoding CD45 isoforms ABC, B and 
Null
CD45 cDNA isoforms were generated by RT-PCR. To this end, purified tonsillar RNA (2 mg) 
was reverse transcribed for 1 h at 42°C in a reaction mixture of 30 ml containing 0.5 mM 
dNTPs (Pharmacia), 60U RNasin (Promega) in 50 mM Tris-HCl pH 8.3, 40 mM KCl, 6 mM 
MgCl2 and 1 mM DTT with 200U Superscript Reverse Transcriptase (RNase H-, Gibco BRL) 
using 2.5 ng of LCA 9 primer (exon 9, antisense, 5'-GTA ATC CAC AGT GAT GTT TGC-3', 
21 mer). Subsequently, cDNA segments were amplified by PCR using the LCA 2 (exon 2, 5'- 
att gga tcc GCT GAC TTC CAG ATA TGA CC-3', 29 mer) sense primer and the LCA 7.2 
(exon 7, 5'-gac aga tcT TGT TGT GGT TGA AAT GAC-3', 27 mer) antisense primer. 0.1 vol. 
of RT-mixture was amplified in a mix containing 30 pmol of sense and antisense primers, 
125 mM dNTPs and 1U Taq DNA polymerase in 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 
mM MgCl2 and 0.01% gelatin. Samples were overlaid with mineral oil and amplified using 
the following protocol: 1 min. at 94°C, 1 min. at 58°C and 1 min. at 72°C, for 30 cycles. 0.1 
volumes of PCR product was analyzed on 2% agarose. PCR products of different lengths 
(151 bp-637 bp), were purified with the Qiagen spin isolation kit (Qiagen), digested with 
BglII and BamHI and introduced into the vector in the correct orientation.
Cell culture and transfections
Cos-1 cells were cultured in Dulbecco’s MEM (DMEM, Gibco BRL) medium supplemented 
with 10% Fetal Calf Serum (FCS, Gibco BRL). For transfection, cells were grown to 
subconfluency, trypsinized, washed in Phosphate Buffered Saline (PBS) and resuspended at 
5 x 106 cells per ml in electroporation medium (PBS). 5 mg of DNA was mixed with 400 ml of 
Cos-1 cell suspension, kept on ice for 5 min., and the DNA was introduced in the Cos-1 cells 
by electroporation at 125 mF and 300 mV using a Gene Pulser (Bio-Rad) apparatus. After 
electroporation cells were kept on ice for 5 min. and subsequently transferred to culture 
medium in 9 cm dishes or one 6-well plate and grown for 48-72 h.
RT-PCR analysis of transfectants
Total RNA was isolated 48-72 h after transfection of the Cos-1 cells according to the RNAzolTM 
B method (Campro Scientific). Cells were washed twice in cold PBS and lysed in 4 ml RNazol 
solution (per 9 cm dish). RNA was extracted by adding 0.1 vol. of chloroform and precipitated
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with isopropanol. 1-3 mg RNA was reversed transcribed with the DAF antisense primer and 
the cDNA was amplified with the primers LCA2 and LCA7.1 (exon 7, 5'-cc gag atc TTC AGA 
GGC ATT AAG GTA GGC-3'). PCR products were analysed on a 2% agarose gel.
A: Human Decay Accelerating Factor (DAF)
DAF1-------------------------------------------------------------------------------------DAF2 
1093 1115 1416 1438 
--------------------- ►  1326 M  
TAG
309 319
TTPN K G SG TTSG TTRLLSGH TC  FTLTGLLGTLVTM GLLT 
cleavage an d  G P I-anchor a ttach m en t
N ucleo tide
sequence
A m ino  acid 
sequence
B: pSG8VSVDAF vector
T7 p ro m o to r  EcoRI EcoRV H in d lII  C lal 
------- ►
GAATTGTAATACGACTCACTATAGGGC GAATTC GATATC AAGCTT ATCGAT ACC 
GTCGAC CTCGAG GGG GGGCCC GATCC AGATCT TAT ACA GAC
SalI/AccI X hoI D raII/A paI BglII
Figure 1
Schematic diagram of the development of the eukaryotic GPI-anchoring expression vector 
pSG8VSVDAF.
A 227 bp DAF-PCR fragment (the spliced form o f DAF) with the GPI-anchor attachment site was cloned 
in the filled in BglII site of the pSG8 vector, a modified version o f the pSG5 vector (A). The positions for 
the primers used for amplification as well as the encoded C-terminal amino acids of DAF are shown. 
Nucleotide and amino acid position are as given in ref [18]. This BglII site (restored at the 5' site o f the 
DAF fragment) was used for insertion o f the double stranded VSV-tag sequence (BglII/BamHI digested). 
The final expression plasmid (B) contains a multiple cloning sequence (ten restriction sites) in which 
cDNAs or PCR products can be cloned containing their own start initiation codon. The underlined sequence 
(TAT-ACA-GAC) shows the correct reading frame for the first three amino acids o f the VSV-sequence.
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Western blot analysis, Immunohistochemistry and PI-PLC treatment
Cos-1 cells were harvested after transfection and washed in cold PBS. Cells were lysed for 1 h 
on ice in 1% NP-40 in 100 mM Na2HPO4 with protease inhibitors (40 mg/ml PMSF, 
Boehringer Mannheim; 10 mg/ml Leupeptide, Gibco; 10 mg/ml Aprotinine, Gibco and 10 mg/ 
ml Pepstatine, Gibco). Nuclear debris was removed by centrifugation and the lysate was 
mixed with sample buffer (2% SDS, 60 mM Tris-HCl, pH  6.8, 10% glycerol, 5% 2- 
mercaptoethanol and 0.001% bromphenol blue). Cell lysates were subjected to 10% SDS 
polyacrylamide gel electrophoresis and subsequently transferred to nitrocellulose membranes. 
Non-specific binding sites were blocked overnight by 5% non-fat dry milk in TBST (10 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20). Blots were incubated for 2 h with the 
PD7/26 (CD45RB, Dakopatts) or UCHL-1 (CD45RO) antibody. As secondary antibody RAM­
PO (Dakopatts) was used and peroxidase reactivity was revealed with Chemiluminescence 
reagents (Pierce) according to the manufacturers instruction. Blots were visualized by 
exposure to autoradiography films (Kodak X-OMAT-S1).
For the immunofluorescence assay transfected Cos-1 cells were grown on multispot slides 
and analyzed 48-72 h after transfection. CD45 expression of chimeric proteins was determined 
in fixed cells (1 min. methanol, -20°C) and membrane staining was assayed on non-fixed 
cells at 4°C. The CD45 exon specific antibodies 2H4 (CD45RA), PD7/26 (CD45RB), RP1/12 
(CD45RC), UCHL-1 (CD45RO) and the aVSV antibody P5D4 (Sigma) were used. Cells were 
stained with RAM-FITC (Dakopatts).
For PI-PLC digestion, transfected Cos-1 cells were grown on multispot slides for 24 h and 
labeled (unfixed) with the anti-VSV antibody followed by RAM-FITC labeling. PI-PLC 
digestion was performed in culture medium with 1U/ml PI-PLC (Boehringer, Germany) at 
37°C for 1 h.
Dynabead selection of CD45 transfected cells
Selection of positively transfected cell with the magnetic bead selection procedure was applied 
in order to enrich for expressing cells in both transient and stable transformation experiments. 
Transienlty transfected Cos-1 cells were harvested with 20 mM EDTA in PBS at 37°C 16 h 
after transfection. A single cell suspension was incubated with PD7/26 or P5D4 in PBS with 
1% FCS for 2 h. Cells were washed with PBS and selected with Sheep-anti-Mouse IgG 
Dynabeads M450 (Dynal A.S.). After several wash steps positively selected cells were 
transferred to 6 wells plates with coverslips and cells were grown for another 24 h. CD45 
expression was analyzed by immunofluorescence.
To make stably transfected 3T3 cell lines (mouse fibroblasts) a CD45 reporter construct and 
a pMC1-neo cassette for G418 resistance [24] were cotransfected. Circa 500 G418-resistant 
clones were randomly collected and the pooled cells were incubated with the CD45-exon-5 
specific antibody PD7/26. Positive cells were subsequently isolated by incubation with Sheep-
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Figure 2
Cloning of Tonsillar CD45-RT-PCR products in the pSG8VSVDAF vector and the RNA/protein 
expression pattern in transiently transfected Cos-1 cells.
(A) RT-PCR on human tonsillar RNA. Tonsillar RNA was reverse transcribed with the LCA9 primer 
and the cDNA was amplified by PCR with the LCA2 and LCA7.2 primers. (A) A t least four different 
isoforms varying between 154 bp (smallest isoform) and 637 bp (largest isoform) are obtained. These 
PCR products were cloned, after digestion with BamHI/BglII, in the BglII site o f the pSG8VSVDAF 
vector.
(B) RT-PCR pattern o f transfected Cos-1 cells. Cos-1 cells were transfected with different plasmids 
(pSG8LCA-0-VSVDAF, pSG8LCA-B-VSVDAF, pSG8LCA-ABC-VSVDAF) and 24h after transfection 
RNA was isolated and reverse transcribed with the DAF2 antisense primer. PCR was performed with the 
primers LCA2 and LCA7.1. Lane 1: pSG8LCA-0-VSVDAF, 155 bp. Lane 2: pSG8LCA-ABC-VSVDAF, 
637 bp. Lane 3: pSG8LCA-B-VSVDAF, 295 bp. Lane 4: mock transfected Cos-1 cells. Lane 5: positive 
control (CD45 mimic), 738 bp. The RT-PCR products o f the different transfected constructs corresponded 
with the expected length o f the PCR products o f the different isoforms.
(C) Protein expression pattern o f transfected Cos-1 cells. Western blots were analysed with the UCHL-1 
antibody (LCA-0 specific; left panel) and the PD7/26 antibody (exon 5 specific; right panel). Lane 1: 
pSG8LCA-0-VSVDAF, a 35 kD chimeric protein was stained with UCHL1 antibody. Lane 2: pSG8LCA- 
ABC-VSVDAF, a 90 kD protein stained with exon-5-specific antibody, PD7/26. Lane 3: pSG8LCA-B- 
VSVDAF, a 45 kD protein reactive with PD7/26.
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anti-mouse-IgG Dynabeads M-450 followed by vigorous washing according to manufacturers 
procedures. Positive cells were plated in a Costar 6 wells plate and, upon confluency, re­
plated in 9 cm dishes. After repeated cell cloning stable transfected cell lines were isolated.
Adhesion assay of CD45 transfected cell with PBLs or hematopoietic cell lines
The adhesion assay with CD45 transfected cell lines were perform ed accordingly to 
Stamenkovic et al. [20]. Briefly, 48 h after transfection with the CD45ABC/B/Nun constructs 
respectively, the Cos-1 cells were overlaid with 2x106 lymphoid cells per well, in DMEM 
medium (with and without 300 U/ml heparin) and incubated at either 4°C or 37°C for 1 h. 
Non-adhering cells were removed by gentle rinsing with PBS. Left cells were fixed in 1% 
paraformaldehyde for 10 minutes, washed, and CD45 isoform-expressing Cos-1 cells were 
subsequently identified by staining with UCHL-1 (CD45Nu11) or PD7/26 (CD45ABC/B) 
antibodies. Adhering (clusters of) cells (>3 cells per Cos-1 cell) were identified with phase 
contrast illumination and immunofluorescence microscopy. The num ber of cell clusters 
adhering to CD45 negative and CD45 positive Cos-1 cells was evaluated for each well in a 6 
well plate. Lymphoid cells to overlay transfected cells were Ficoll-Paque isolated human PBL’s, 
the B-cell lines Ros and Raji and the cell lines Jurkat (T-ALL) and K562 (erythroid cell line). 
All these cells were tested by immunofluorescence analysis for CD22 cell surface expression 
with the antibody CD22PE (4KB128-IgG1, Dakopatts) before use.
RESULTS and DISCUSSION
Expression of the GPI-anchoring expression vector (pSG8DAF)
Here we describe the construction of a specific GPI-anchoring vector and its use for the 
expression of truncated and tagged CD45 isoforms, which lack the intracellular phosphatase 
domains and part of the extracellular domain, in various cell types. The overall design of the 
expression vector, designated pSG8VSVDAF is shown in Figure 1B. Essential sequences at 
the junctions of different domains are given in the legend of Figure 1B. The GPI-anchor 
segment, encodes the carboxyl-terminal 39 amino acids of the hum an decay accelerating 
factor (DAF) [2,16] with the cleavage site for GPI-anchor attachment (Figure 1A).
Cloning and expression of GPI-anchored CD45 isoforms ABC, B and Null
In order to assess the expected ability of the vector plasmid to produce and anchor VSV- 
labeled CD45 fusion proteins at the cell membrane, we cloned different CD45-cDNA isoforms 
as inserts into the unique BglII site and studied their expression in transiently transfected 
Cos-1 cells. cDNA’s encoding different CD45 isoforms were prepared by using RT-PCR 
amplification of hum an tonsillar RNA (Fig. 2A). Clones containing the largest isoform 
CD45ABC (637 bp, exon 4, 5 and 6), the CD45B isoform (295 bp, exon 5) and the smallest
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Table 1: Immunofluorescence analysis of the expression pattern of Cos-1 cells transfected 
with the three different isoform related constructs.
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A n tib o d y P5D4 2H4 PD7/26 RP1/12 UCHL1
C o n stru c t VSV RA RB RC RO
CD45ABC + + + + -
CD45B + - + - -
CD45Null + - - - +
Legend:
All transfectants (non-fixed cells) were stained positively with the a-VSV-tag antibody P5D4. Staining 
with the CD45 exon specific antibodies was isoform related. CD45ABC transfectants stained with the RA, 
RB and RC restricted antibodies, the CD45B isoform transfectants stained with the RB antibody and 
Cos-1-1 cells transfected with the smallest isoform stained with the exon3-7 junction specific antibody 
UCHL-1.
isoform CD45Nul1 (155 bp, no exon 4, 5 or 6) were studied further.
All three clones were transiently transfected by electroporation in Cos-1 cells and the 
expression was assayed by (1) RT-PCR analysis, (2) W estern B lo tting  and (3) 
immunofluorescence. The results are illustrated in Figure 2 and 3. RT-PCR analysis showed 
that the three different cDNA constructs generated products of 637 bp (CD45ABC), 295 bp 
(CD45B) and 154 bp (CD45NuJl) (Fig. 2B), resulting, at protein level, in 90 kD, 45 kD and 35 
kD proteins (Fig. 2C) respectively. Immunofluorescence analysis (IFA) was carried out on 
both methanol-fixed and non-fixed cells using the aVSV-tag-specific antibody (P5D4) as 
well as CD45 exon-specific antibodies. All clones produced CD45-DAF fusion proteins, which 
were equally well detectable with both antibodies against the CD45 body as well as the aVSV 
tag, in the cytoplasm (Fig.3A) as well as on the cell surface (Fig. 3B) of transfected Cos-1 
cells. Semiquantitative validation of the immunofluorescence pictures (summarised in Table 
1) shows that CD45 and VSV specific epitopes were exposed equally well on cell-surface 
bound CD45ABC, CD45B and CD45NuJl isoforms. This demonstrates that the VSV epitope is 
readily accessible, and that there is no overt steric hindrance for antibody recognition, despite 
its close proximity to the GPI anchor and/or laterally oriented membrane proteins. As 
anticipated the staining patterns of the antisera 2H4, PD7/26, RP1/12 and UCHL-1 was 
isoform specific. Similar results (not illustrated here) were obtained in transfected CHO-, 
NIH3T3 and Swiss-3T3 cells, except that transfection efficiency and expression level were 
ra th e r low com pared to Cos-1 cells. The data o f RT-PCR, W estern b lo ttin g  and 
immunofluorescence analysis (Figure 2 and 3) are thus corresponding with each other.
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PI-PLC treatment of transfected cells
To assess that the membrane expression of CD45-DAF fusion isoforms was indeed due to 
correct anchoring via the GPI moiety transfected Cos-1 cells were coated (unfixed) with a- 
VSV primary antibody and RAM-FITC secondary antibodies and subsequently treated with 
phosphatidyl-inositol-specific phospholipase (PI-PLC). As illustrated by the comparison of 
figures 3C and D this led to an almost complete loss of the bright speckled staining pattern 
on the cell membrane on all transfected cells (approximately 50% of total cells in this 
experiment). Subsequently, the sensitivity towards PI-PLC was confirmed for all constructs, 
showing that all CD45-DAF fusion proteins were similarly bound to GPI rich rafts in the 
Cos-1 cell membrane, independently from their extracellular structure.
Magnetic bead selective enrichment of transiently or permanently transfected 
cells using VSV-tag specific antibodies or CD45 exon specific antibodies
After dem onstrating correct membrane expression of our CD45 chimeric-proteins, we 
decided to apply the magnetic Dynabeads technique to select and enrich pSG8LCA(VSV)DAF 
transfected cell lines of other origins. In pilot experiments, using CD45 exon-specific 
antibodies or VSV-tag specific antibodies we could achieve enrichment up to 80% for VSV- 
tag positive Cos-1 cells, starting with only 10-40% positive cells, in a typical transient 
transfection experiment. Next, we used this strategy to establish permanently transfected 
lines from NIH-3T3 cells. Therefore, these cells were transfected by co-electroporation of 
pSEC-S-LCA1-7 and DNA from a G418-selectable pMC1-Neo [24] resistance cassette in a 
10 to 1 ratio. In this experiment we did not use the CD45 isoform related (i.e. cDNA-based) 
construct but instead a genomic spliceable CD45 reporter construct (pSEC-S-LCA1-7), 
designed to study alternative CD45 splicing (described elsewhere). A large fraction of G418 
resistant clones was analyzed for CD45 expression with the PD7/26 (CD45RB) and UCHL- 
1 (CD45RO) antibody. However, in over hundred clones tested, no positive cell clones were 
identified. Therefore we decided to proceed with the magnetic bead selection procedure to 
isolate and clone CD45 positive cell clones. Approximately 500 G418-resistant colonies were 
randomly collected, pooled and selected after binding to CD45 exon 5-specific antibody 
PD7/26 and sheep-anti-mouse-IgG Dynabeads. Upon selection and further propagation, 
over 90% of the derivatives of the bound cells showed a low but definitive positive CD45 
(isoform B) expression. These experiments demonstrate that membrane expression of CD45 
isoforms renders cell lines accessible for specific antibody-magnetic bead selection. Low levels 
of expression are sufficient to guarantee the fidelity of the procedure and pre-selection by 
co-electroporation with the G418-resistance cassette and selecting G418 resistant clones is 
not further required.
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Figure 3
Immunofluorescence analysis of transfected Cos-1 cells.
Cos-1 cells transfected with the pSG8LCA-ABC-VSVDAF vector and stained with the aVSV antibody 
are shown. (A): Unfixed cells show a speckle-type granular membrane staining on the cell surface 
confirming the GPI-anchoring. (B): Methanol-fixed cells show a strong, diffuse cytoplasmic staining. 
Immunofluorescence analysis with CD45 exon-specific antibodies (2H4 for exon 4; PD7/26 for exon 5; 
RP1/12 for exon 6) showed identical results. Transfections with other CD45 constructs showed similar 
expression patterns as illustrated here. (C): Granular membrane fluorescence on unfixed Cos-1 cells 
transfected with pSG8LCA-ABC-VSVDAF is observed after staining with the aVSV antibody P5D4. 
Cells, coated with mAb and immunofluorescent conjugate were incubated for 1 h at 37o C in medium  
without PI-PLC (as control for D). (D): Dramatic reduction o f the membrane fluorescence after 1 h 
treatment of the cells with PI-PLC 1U/ml at 37° C.
GPI-anchored extracellular CD45 domains do not engage in ligand binding
In order to investigate whether the truncated GPI-linked CD45 isoforms expressed on the 
cell surface of transfected Cos-1 cells still had the ability to bind ligands on lymphoid cells, 
we subjected these cells to adherence tests, using human cell types of various origin. As one
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of the few CD45 ligands that has been positively identified is the membrane glycoprotein 
CD22 [20], we concentrated on cell types with and without this protein as a surface marker. 
By using the antibody CD22PE (4KB128-IgG1, Dako) we could demonstrate that human 
PBL’s contained a low number (< 5%) of CD22-membrane-positive cells (CD22m+). B-cell 
lines Ros and Raji, expressed CD22 at a high level in all cells. In contrast, Jurkat (T-ALL) and 
K562 (erythroid cell line) were negative for CD22. Remarkably, none of these CD22m+ (nor 
the CD22m-) cell-lines showed any adherence to Cos-1 cells transfected with any of the 
CD45 constructs, despite the fact that our adhesion experiments were carried out under 
identical conditions as those reported by Stamenkovic et al. [20]. Peripheral blood 
lymphocytes (106/well), however, formed significant numbers of clusters, up to 3600 per 
well, with a mean cluster size in the range of 20-40 cells, under conditions that transfected 
Cos-1 cells were 20% confluent. All three CD45 reporter constructs (ABC, B and Null) showed 
similar non-specific at random adherence for PBL’s, not different from CD45 negative Cos- 
1 cells. So, no specific binding of CD22m+ cells to CD45ABC> B or Nu11 transfected Cos-1 cells was 
observed. How can we reconcile our findings if compared to those of Stamenkovic et al. 
[20]. It is important to note that these authors used the converse system in which CD22 
ligand was transfected in Cos-1 cells and binding to CD45 was proven with lymphocytes 
that expressed the endogenous CD45NuJl isotype in its normal cellular context. In this test, 
the observed cellular interaction was blocked by UCHL-1, an antibody that recognizes the 
supposed interaction epitope at the sequence specified by the exon 3-7 boundary [20]. Since 
our truncated CD45NuJl isoforms are recognized by UCHL-1 it is not likely that additional 
missing extracellular domains (i.e. the exon 8-transmembrane portion) or shielding-to- 
binding is responsible for the failure of adherence. Rather, we consider it more likely that the 
mere presence of CD45 extracellular domains alone is not sufficient to create stable binding 
to CD22 ligand exposing cells. In lymphoid cells CD45 molecules are associated in larger, 
CD4-TCR containing, complexes [1,12]. It has been shown that the lack of catalytic 
phosphatase domains and the transmembrane region (TM) proper does not prevent this 
association [12]. Therefore, we surmise that the simple reason for missing adherence behavior 
in our test is due to the fact that our Cos-1 cells do not express any of the associative molecules 
required for optimal CD22-CD45 interaction. It is also possible that CD45 domains expressed 
from our vector do not undergo the proper post-translational glycosylation, perhaps because 
they follow a different route during m aturation in the Golgi-complex and subsequent 
transition to the cell membrane. This view is in line with the observation that CD22 recognises 
multiple (sialylated) glycoprotein ligands, i.e. CD45Nu11 on T-cells, CD45RA and CD75 on B- 
cells [10,11,20] and forms also rosettes with erythrocytes and monocytes [19]. Thus it seems 
as if the cellular interactions are critically dependent on the context in which the extracellular 
CD45 domains are presented, whereas the role of CD22 is much less dependent on cell type 
or partner proteins.
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Our now developed expression system will enable us to study this phenomenon in more 
detail by cotransfection with possible association-partner-molecules (CD4/CD8/TCR/MHC) 
and/or by using cell types with different protein modification and protein routing patterns. 
Undoubtedly, this will contribute to our knowledge of structure-function relationship(s) 
for the extracellular domains in CD45 isoforms.
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ABSTRACT
The Leucocyte Common Antigen (LCA or CD45) consists of various 
isoforms generated by alternative splicing of variable exons 4, 5 and 6 
(or A, B and C). To follow splicing behaviour in different cell types we 
developed a hum an CD45 mini-gene and analysed its expression in 
transfected cell lines and transgenic mouse tissues. In Cos-1, HeLa and 
3T3 cells we found distinct expression patterns which could only be 
modulated slightly by protein-synthesis inhibitors but not by variation 
in culture conditions like pH, serum concentration and cell density, or 
by stimulation with phorbolester (TPA). In all non-lymphoid transgenic 
tissues the default splicing pattern (CD45R0) was found, while the 
expression profile in lymphoid cells, where all eight isoforms are pre­
sent, mimics that of the endogenous mouse LCA gene products. Next, 
to examine the factors involved in alternative exon use we analysed the 
expression pattern of members of the family of SR-proteins, well known 
splicing regulators with arginine/serine rich (R/S) domains. Cell lines 
expressed variable levels of SRp75, SRp30 and SRp20 and constant 
amounts of SRp40. Mouse tissues expressed large amounts of SRp75, 
SRp55 and SRp40, additional expression of SRp30’s and SRp20 was 
restricted to lym phoid tissues. Therefore, SRp30 and SRp20 may 
contribute to forming the appropriate cellular conditions for alternative 
use of CD45 exons 4-6 in the hematopoietic compartment.
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INTRODUCTION
CD45 (or LCA: Leucocyte Common Antigen) represents a subfamily of receptor-type protein 
tyrosine phosphatases (RPTPases) expressed as high molecular weight transm em brane 
glycoproteins on the surface of essentially all leucocytes. In humans CD45 is comprised of at 
least five isoforms ranging in molecular weight between 180 kDa and 220 kDa [36,37]. All 
CD45 isoforms are encoded by a single gene and are generated by alternative splicing of 
three variable exons 4, 5 and 6 (or A, B and C, respectively). The alternative splicing of CD45 
is thought to be controlled by cis-acting sequence elements located within exons 4 and 6 
[34,38] and by negative-regulatory trans-acting splicing factors [28] in a cell-type, and 
metabolic and proliferative state-dependent manner. All B cells from most species express 
the high molecular weight isoform (CD45ABC) in which all exons are retained. T cells express 
a number of different isoforms, with splice modes being tightly regulated during both T-cell 
development in the thymus as well as during an immune response in the periphery [1,3,20]. 
In the lowest molecular weight isoform (CD45Nu11), being the main isoform in developing 
thymocytes, the splicing machinery excises exons 4-6 [20]. Virginal T cells predominantly 
express exon 4 containing isoforms including the largest isoform, CD45ABC (220 kDa). In 
contrast, T cell activation causes down regulation of CD45ABC expression leading to the 
formation of 175-180 kDa CD45Nu11 and 190 kDa CD45B isoforms [1-3].
During T cell activation, concomitant with the changes in the expression pattern of CD45 
isoforms, complex changes occur in the mRNA levels of several SR proteins [30]. SR-proteins 
are regulatory splicing factors that contain one or two N-terminal RNA recognition motifs 
and an arginine/serine-rich (R/S) domain [9,43]. Individual members of the SR-protein 
family are involved in the regulation of splice site selection, either in a constitutive mode or 
as specific factors for particular pre-mRNAs [6,9]. The relative amount of each SR-protein 
varies in a tissue specific manner, which may be a determining factor in producing tissue 
specific patterns of alternative splicing of distinct pre-mRNAs [44]. Moreover, the 
overexpression of individual SR-proteins can affect alternative splice site choices, suggesting 
a mechanism whereby alternative splicing is controlled by the relative abundance’s of 
individual SR-proteins [4,30].
Here we report on the development and use of a spliceable CD45 reporter construct (pSEC- 
S-LCA1-7) which allows us to study cell type specific expression patterns of the CD45 
transmembrane receptor molecule in a broad range of cell types under different culture 
conditions in-vitro, and in tissues of transgenic mice in-vivo. The body of the reporter 
construct consists of a spliceable CD45 mini-gene, spanning the genomic segment containing 
exons 1-7. The truncated gene segment, driven by the constitutive active early SV40 promoter, 
is fused to a segment coding for a GPI membrane anchor from Decay Accelerating Factor 
(DAF) to display CD45 products at the cell surface and facilitate their typing. Our data indicate 
that the splice mode of CD45 mini-gene transcripts depends predominantly on cell type
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rather than culture conditions or presence of growth modulatory agents. In contrast to 
expectation, the hum an CD45 mini-gene when expressed in the lymphoid compartment of 
transgenic mice displayed all eight isoforms; i.e. is used in the “mouse mode” instead of the 
“hum an mode”. By studying expression levels of members of the SR-protein family in various 
cell lines and mouse tissues we identified potential candidates in lymphoid tissues that may 
be involved in splice site regulation of our CD45 minigene construct.
MATERIALS and METHODS
Construction of the CD45 reporter plasmid (Figure 1)
The pSEC plasmid (Surface Expression Construct) [35] was used as vector for introducing 
the CD45 mini-gene composed of exons 1-7 with alternative exons 4, 5 and 6. Various cDNA 
and genomic cloning segments were derived from two lambda CD45 genomic DNA clones, 
LCA-204 (Icharon 4a, 13 kb [14]) and LCA-407 (lEMBL 3, 18.8 kb, [14]) and from the 
complete CD45ABC cDNA plasmid, pSP6.DL.LCA6 [33], kindly provided by Dr. M. Streuli 
(Dana Farber Cancer Institute, Boston, USA).
The cloning strategy was divided into three major steps. First, a 1.8 kb HindIII fragment of 
LCA-204 was cloned in the pBluescript II KS+ vector (Stratagene) and used as template to 
generate a 600 bp PCR fragment comprising the intron 6-exon 7 sequence (primers used 
were the T3 and the LCA7a2 oligomers). After end trimming by digestion with HindIII and 
BglII the PCR fragment was cloned in the pSEC vector forming plasmid pSEC-204(exon-7). 
Exon 7 of CD45 was hereby fused in frame to the DAF sequence. As the intron size between 
exon 2 and exon 3 (> 50 kb) precluded cloning we decided to fuse the cDNA fragment of 
exon 1-2-3 (with signal peptide and start codon in exon 2) to the large genomic fragment of 
exon 3-7 via homologous recombination. To this end the 12.5 kb HindIII genomic fragment 
of LCA-407 containing exons 3, 4, 5 and 6 was cloned in the HindIII site of pBluescriptII 
KS+. Then, the intron sequence in front of exon 3 (2.4 kb) was trimmed to 0.7 kb by EcoRV 
digestion and the resulting plasmid, pBlue-407(exon 3-6)EcoRV, was closed by ligation. Next, 
the CD45 exon 1-2-3 cDNA fragment was obtained by PCR using a sense primer (SP6) in 
the promoter region of the vector and an antisense primer in exon 3 of CD45 (LCA3a). 
Plasmid pSP6.DL.LCA6 (CD45ABC cDNA) was used as template DNA for the PCR reaction. 
The resulting PCR fragment of 300 bp was cloned in the blunted NotI site of pBlue-407(exon 
3-6)EcoRV with the exon 3 sequence of the cDNA facing in tandem the exon 3 sequence of 
the genomic fragment, and with a unique EcoRV site in between. Opening of the construct 
with EcoRV digestion and transfection of the linearized DNA into E. Coli host cells enabled 
the homologous overlapping exon 3 segments to recombine, resulting in loss of the duplicated 
segment and causing fusion of the plasmid ends into one continuous exon 3 sequence. The 
entire insert containing exons 1-2 as cDNA and 3-6 as genomic sequence was then excised as
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Figure 1
Schematic diagram of the CD45 reporter construct.
(A) The pSEC expression vector [35] with GPI-anchor signal (DAF sequence) was used as a recipient 
vector for a CD45 mini-gene (cloned as H indlll-Bglll fragment). The mini-gene was composed of exon 
1-3 cDNA and the complete CD45 genomic sequence from exon 3 up to exon 7. The open reading frame 
at the exon-7 - DAF junction is: TCA ACC ACA ACA Aga tct tCA  ACC CC (CD45 exon 7 sequence in 
bold, DAF sequence in italic and the connecting Bglll site in small characters). Numbered open boxes are 
CD45 exons; connecting lines are intron sequences. The start/initiation codon, ATG, is located in exon 2 
and the stop codon, TAG, is located in the DAF sequence. (B) Diagram showing the position o f the 
oligonucleotides used for (RT)-PCR experiments and Southern blot hybridisation. Sense (->) and anti­
sense (<-) primers for DAF and CD45 are positioned at the appropriate locations above the minigene 
sequence. In most assays cDNA products were formed by use o f the LCA7a2 and DAF2 oligonucleotides 
as primers for reverse transcription, and exon 2 and 7 specific (LCA2 (forward) and LCA7a1 (reverse)) 
oligonucleotides as (nested) amplification primers. Exon lengths (bp) and exon lengths obtained using 
specific oligonucleotide pairs are indicated below the figure. (C) Schematic diagram o f the eight possible 
alternatively spliced CD45 transcripts and their corresponding glycoproteins (MW) in endogenous and 
transfected cells and the predicted sizes o f the variable exon containing transcripts after PCR with the 
oligonucleotides LCA2 and LCA7a1. The diagram set-up is taken from Thomas [36].
a 10.5 kb HindIII fragment and inserted in the correct orientation into the HindIII site of 
the pSEC-204(exon-7) vector. Finally, a SalI site present in a residual linker sequence adjacent 
to exon 1 was deleted, leaving one SalI site in front of the SV40 promoter and one SalI site at 
the end of the SV40-poly A addition sequence. Opening at these sites allowed us to transfect 
the spliceable CD45 reporter, pSEC-S-LCA1-7, as a 13 kb linear DNA segment.
A non-spliceable control construct was also generated. A cDNA fragment from the largest 
isoform of CD45 (exon 4-5-6) was amplified by PCR using the sense (SP6) and antisense 
(LCA7A2) primers and pSP6.DL.LCA6 as template DNA. The resulting 850 bp PCR frag­
ment was cloned as a HindIII-BglII fragment in the pSEC vector, forming plasmid pSEC-N- 
LCA456. In a derivative plasmid a short sequence specifying a Vesicular Stomatitis Virus 
(VSV) reporter-tag was inserted in the BglII site between exon-7 and the DAF sequence, 
forming pSEC-N-LCA456VSV. All cloning junctions in the spliceable and non-spliceable 
construct were verified by sequence analysis.
Oligonucleotides
The following oligonucleotides (Pharmacia Biotech) were used as PCR primers or as probes 
for Southern hybridisation (capitals in the oligonucleotides indicate specific sequences; small 
characters are non-specific nucleotides, including restriction sites):
T3: 18 mer, 5' ATTAACCCTCACTAAAGG 3'
SP6: 19 mer, 5' GATTTAGGTGACACTATAG 3'
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LCA2: exon 2, (+) 29 mer,
LCA3a: exon 3, (-) 15 mer,
LCA4: exon 4, (+) 20 mer,
LCA5: exon 5, (+) 20 mer,
LCA6a: exon 6, (-) 20 mer,
LCA7a1: exon 7, (-) 29 mer,
LCA7a2: exon 7, (-) 27 mer,
LCA9a: exon 9, (-) 21 mer,
DAF1: (+) 25 mer,
5' attggatccGCTGACTTCCAGATATGACC 3' 
5' GGG GGA AGG TGT TGG 3'
5' ACC CAA GTA TCC CCG GAC TC 3' 
5' AAC CCT ACC CCA GGC AGC AA 3' 
5' CT GGC TGT ACT CCT CTC TCC 3'
5' ccgagatc TTC AGA GGC ATT AAG GTA GGC 3' 
5' gacagatcT TGT TGT GGT TGA AAT GAC 3'
5' GTA ATC CAC AGT GAT GTT TGC 3'
5' ttCAACCCCAAATAAAGGAAGTGGA 3'
5' CCTAAATGAAGAGCACAATTGCA 3'DAF2: (-) 23 mer,
Cell lines and culture conditions
The human cell lines Raji (Burkitt lymphoma), Jurkat (T-ALL), Hut-78 (T-ALL) and K562 
(erythroleukemia) were obtained from the American Type Culture Collection (ATCC, 
Rockville, Maryland, U.S.A.). Ros (Burkitt lymphoma) and KM3 (pre-B cell) were gifts from 
Dr. Cortenbach (CLB, Amsterdam, NL). All cell lines were grown in RPMI-1640 based cul­
ture medium (Gibco BRL, Paisley, UK) supplemented with 10% FCS (Foetal Calf Serum, 
Gibco BRL). H um an lym phocytes were prepared from  hum an tonsils obtained by 
tonsillectomy. Cos-1, HeLa cells and Swiss-3T3 (C7C2) mouse fibroblasts were cultured in 
Dulbecco’s MEM (DMEM, Gibco BRL) medium supplemented with 10% FCS or 10% Bovine 
Calf Serum (BCS, Gibco, BRL), respectively.
DNA transfections
For analysis of CD45 splicing 2.0 x 106 Cos-1 cells (60% confluency) were resuspended in 
PBS, mixed with 5-10 |ig DNA and electroporated at 125 |iF and 300 mV using a Gene Pulser 
(Bio-Rad) apparatus. HeLa cells were transfected using lipofectine (Gibco BRL), according 
to the manufacturer’s procedures. After transfection cells were transferred to culture me­
dium and grown for 48-72 h.
Swiss-3T3 fibroblasts were grown to 40% confluency, trypsinized, washed and resuspended 
at 6.5 x 106 cells per ml. 20 |ig pSEC-S-LCA1-7 DNA linearized with PvuI and 2 |ig pMC1 
Neo [39] vector DNA linearized with BglII were mixed with 400 |i1 of cell suspension and 
electroporated at 960 |iF and 280V (Bio-Rad Gene Pulser). Cells were selected for DNA uptake 
and stable transfection 24 h later in 700 |ig/m1 G418 (Gibco BRL) and allowed to grow for 7 
days before individual colonies were isolated.
Wild type E14 ES cells were collected and mixed with 20 |ig of SalI linearized pSEC-S-LCA1- 
7 DNA and 2 |ig of BglII linearized pMC1 Neo DNA, electroporated at 500 |iF and 250 mV 
and plated onto irradiated SNLH9 feeder cells [40]. Selection was applied 24 h later using 
300 |ig/m1 G418. Individual G418 resistant ES clones were picked after 7-9 days and typed
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for the number of genomic integration sites and for having the correct karyotype.
Southern blot analysis of transfected Swiss-3T3 cells and ES cells
Genomic DNA from individual Swiss-3T3 or ES cell clones was digested with XbaI and 
analysed by Southern blot analysis according to standard procedures [32]. The ±13 kb SalI 
fragment of the pSEC-S-LCA1-7 vector was labelled with [a -32P]-dCTP and used as probe 
after prehybridisation with 100 |ig sonicated hum an DNA for 4h at 650 in 0.5 M sodium 
phosphate buffer pH 7.4 containing 7% SDS and 1 mM EDTA to block repetitive sequences 
(pre-association). Blots were then hybridised o/n at 650 C, washed with a final stringency of 
0.2x SSC/0.3% SDS and exposed to Kodak-X-Omat S1 films using intensifying screens for 
2-7 days.
In vitro differentiation of ES cells and generation of chimeric mice
For in vitro differentiation ES cells were grown to subconfluency in 0.1% gelatine-coated 
culture flasks in DMEM supplemented with Leukaemia Inhibiting Factor (LIF, 1000 U/L), 
treated with 0.25% trypsine in PBS to obtain small cell clumps, replated in sterile bacterial 
dishes in DMEM with 10% FCS, and cultured for 10-15 days to form embryoid bodies (EBs). 
After 10 days, pulsation of small patches of differentiated myocardiocytes within the EBs 
was visible. ES cells and EBs were monitored by both hematoxylin-eosin (HE) staining and 
immunocytochemically for expression of the cytoskeletal proteins desmin and vimentin, 
markers of myogenic and mesenchymal differentiation, respectively.
To generate transgenic mice, ES cell clones with appropriately integrated pSEC-S-LCA1-7 
DNA were injected into recipient C57Bl/6 blastocysts and implanted into pseudopregnant 
(C57B1/6 X CBA/Ca)F1 foster mothers as described by Steeghs et al. [32]. CD45 isoform 
analysis was restricted to highly chimeric mice (75%-95%) as scored by agouti coat colour.
Modulation of CD45 expression by TPA, pH, actinomycin-D and 
cycloheximide treatment
Stably transfected Swiss-3T3 cell clone EC2 was grown in 6-well plates to subconfluency 
(40%) and incubated for 12-72 h with 10-7M TPA (12-O-tetradecanoy1phorbo1-13-acetate, 
Sigma), prepared from 100x stock in DMSO (Merck, Darmstad). Cells cultured in presence 
of 1% DMSO were included in control experiments. The effect of pH of the culture medium 
was analysed by culturing the cells for 48-72 h in media at pH 6.6, pH 7.0 or pH 7.6, in closed 
culture flasks. The desired pH was kept constant by changing the medium every 7 h. To 
determine the half-life time of the CD45 RNAs cells were grown in presence of 5 |ig/m1 
Actinomycin-D (AD, Sigma) for 0, 3, 7, 24 and 28 h. RNA was isolated and hybridised with 
DAF specific probe. To prepare the probe a standard PCR reaction of 25 cycles was performed 
with the DAF1 and DAF2 primers in the presence of [a -32P]dCTP (Amersham). After
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hybridisation blots were exposed to Kodak-X-Omat S1 films. To asses effects of a block in 
protein synthesis EC2 cells were cultured with 20 |ig/m1 Cycloheximide (CHM, Sigma) for 0, 
24 and 48 h respectively and RNA was used for RT-PCR analysis.
Monoclonal antibodies and Immunofluorescence assay (IFA)
To identify the different isoforms of hum an CD45 we used (monoclonal) antibodies. 4B2 as 
general marker for CD45 (ATCC), 2H4 specific for CD45 exon 4 (a gift from Dr. M. Streuli) 
PD7/26 specific for CD45 exon 5 (Dakopatts, Copenhagen, Denmark), RP1/12 specific for 
CD45 exon 6 (a gift from Dr. M.O de Landazuri, Servicio de Immunologia, Madrid, Spain 
[45]) and UCHL-1 specific for CD45RO [31](a gift from Prof. P. Beverley, Edward Jenner 
Institute, Berkshire, UK). For monitoring cytoskeletal proteins, we used OVTL12-5 mAb for 
anti-human keratin 5, 7, 14 and 19 [24], K5 polyclonal antibody for desmin, and RV202 
mAb for vimentin. P5D4 mAb (Sigma) was used to detect VSV-tagged (Vesicular Stomatitis 
Virus glycoprotein) proteins in transfected cells [19]. Transfected cells were grown on cover­
slips or m ultispot slides for 48-72 h. Total expression of CD45-chimeric protein was 
determined in fixed (1 min methanol, -200C) cells, while membrane expression was assayed 
by incubating non-fixed cells with primary antibodies for 45 minutes at 00 C. Cells were 
stained with RAM-FITC (Dakopatts).
Western blot analysis
CD45 proteins containing cell extracts were made by lysing cells in 1% NP-40 in 100 mM 
Na2HPO4 containing 40 |ig/m1 PMSF (Boehringer Mannheim) and 5 |ig/m1 Leupeptide, 10 
|ig/m1 Aprotinin and 10 |ig/m1 Pepstatin (Gibco BRL). Proteins in Cos-1 and Swiss-3T3 cell 
lysates were separated on 12% SDS-polyacrylamide gels using standard procedures and 
transferred to nitrocellulose membranes (Schleicher-Schuell, Germany). Non-specific bin­
ding sites were blocked for 2 h in 5% non-fat dry milk and 2% normal rabbit serum in TBST 
(10 mM Tris-HCl, pH8.0, 150 mM NaCl, 0,05% Tween-20). Blots were incubated with PD7/ 
26 (CD45RB; 1:500) or UCHL-1 (CD45RO; culture supernatant 1:10) to detect CD45 
(chimeric) proteins.
SR-proteins were extracted by lysis of cells in 5% SDS, 50 mM Tris-HCl, pH 6,8 and 20 mM 
EDTA buffer and sonication of samples. Proteins were separated on 12% SDS-polyacrylamide 
gels and transferred to nitrocellulose. Immunoblots were blocked and incubated overnight 
with mAb 104 supernatant (1:5) [27] in 1% non-fat dry milk in TBST or with affinity purified 
polyclonal antibody anti-9G8 (N-terminal, 1:1000; kindly provided by Dr. J. Stevenin, IGBMC, 
Illkirch, France) in 1% non-fat dry milk in TBST with 2% goat serum.
As secondary antibody RAM-PO (Dakopatts) was used. The peroxidase activity was revealed 
by using BM Chemiluminescence Western Blotting reagents (Boehringer M annheim , 
Germany) and exposure to Kodak X-OMAT-S1 films.
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RNA Isolation and RT-PCR analysis
Total RNA was isolated by lysis in RNAzolTMB solution (guanidinium thiocyanate/phenol; 
Campro Scientific) according to the m anufacturers protocol. RNA concentration was 
determined by measuring the absorption at 260 nm. Prior to isolation, murine PBLs were 
isolated after centrifugation on a ficoll gradient (Histopaque 1083, Sigma) according to 
standard procedures.
For cDNA synthesis 2 |ig of total RNA was reverse transcribed for 1 h at 420 C in a reaction 
mixture of 30 ml containing 0.5 mM dNTPs (Pharmacia), 60 U RNAsin (Promega) in 50 
mM Tris-HCl pH 8.3, 40 mM KCl, 6 mM MgCl2 and 1 mM DTT using 100 U Superscript 
Reverse Transcriptase (RNase H-, Gibco BRL) and 2.5 ng (0.4 pmol) specific primer (DAF2 
or LCA9a). Next, 3 ml of the RT reaction mixture was added to a PCR mix containing 100 ng 
sense and antisense primer, 125 |iM dNTPs and 1U of Taq DNA polymerase in 10 mM Tris- 
HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2 and 0.01% gelatine in a total volume of 100 ml. 
Samples were amplified for 30 cycles (1 min at 940 C, 1 min at 580 C and 1 min at 720 C) on a 
Perkin Elmer Thermal cycler. PCR products were separated by electrophoresis in a 2% (w/v) 
agarose gel and visualised by ethidium bromide staining.
Southern blot analysis of RT-PCR products
For Southern blot analysis agarose gels with DNA fragments were denaturated in 0.4M NaOH 
and transferred to BioTrace HP nylon membranes (Gelman Sciences). Blots were probed 
with [g-32P]-ATP 5’-end labelled oligonucleotides (LCA3a, LCA4, LCA5 and LCA6a). After 
o/n hybridisation at 370 C in 5x SSPE/0.3% SDS (0.75 M NaCl, 0.04 M NaH2PO4 and 4 mM 
EDTA pH 8.0), blots were washed to a final stringency of 0.2x SSPE/0.3% SDS at 420 C and 
exposed to Kodak X-Omat S1 film.
RESULTS
CD45 mini-gene reporter construct
To investigate the splicing behaviour of the three alternative exons 4, 5 and 6 in human 
CD45 pre-mRNA in different cellular environments we developed the constitutively expressed 
splice-reporter plasmid pSEC-S-LCA1-7 shown in Fig. 1A. This vector contained (i) the CD45 
exon 1-2 cDNA region comprising the translational start codon and signal peptide sequence,
(ii) the genomic segment comprising exons 3 to 7 with the optional exons 4, 5 and 6, and
(iii) a fragment from the DAF (Decay Accelerating Factor) gene which specifies a stretch of 
thirty nine C-terminal amino acids, including the cleavage and GPI-attachment site, to ensure 
membrane anchoring of the N-terminal domain of CD45. In our rationale for the design, 
we planned to leave intact all possible gene segments that might have ds-acting effects on 
splice site recognition necessary for removal of introns 3, 4, 5 and 6. We deliberately had to
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Figure 2
RT-PCR products of CD45-mRNAs from endogenously expressing leukaemic cells and transfected 
cell lines.
CD45 isoform expression pattern was analysed by RT-PCR using the LCA2 and LCA7a1 primers for 
amplification (Fig. 1B and 1C). PCR products were resolved on a 2% agarose gel and visualised by 
ethidium bromide staining. The size (bp) o f the PCR products and the corresponding isoform types are 
indicated. (A) Expression pattern o f endogenous CD45-mRNA in Raji, Jurkat and K562 cells. (B) 
Expression pattern o f Cos-1, HeLa and Swiss-3T3 (C7C2) cells transfected with the pSEC-S-LCA1-7 
vector. (C) Expression pattern o f embryonic stem (ES) cell clone, E14-74, and differentiating embryoid 
bodies (EB) stably transfected with the pSEC-S-LCA1-7 construct. EBs were analysed after 10-12 days o f 
in-vitro growth and differentiation, ES cells were kept for the same period in culture.
remove the intron between exons 2 and 3, however, because of its size (> 50 kb) being too 
large for cloning in plasmid-based vector systems. Also, for equally obvious reasons, we 
truncated the gene after exon 7.
CD45 splicing patterns in endogenous and CD45-transfected cell lines
Next, the reporter construct was used to compare the spectrum of pSEC-S-LCA1-7 mRNA 
isoforms in transfected non-expressor cells like Cos-1, HeLa and Swiss-3T3 (C7C2) to that 
of endogenous CD45 mRNAs in lymphocytes and leukaemic cells. The RT-PCR strategy 
used is schematised in Fig. 1B, an overview of the anticipated cDNA products is given in Fig. 
1C and the identity of the RT-PCR products found in all samples analysed is summarised in 
Table 1.
Most B-cell lines (Raji, ROS and KM3, Table 1) expressed two isoforms, a strong CD45ABC 
band, and a CD45BC band (Raji, Fig. 2A) which was less prominent and varied between cell 
lines. In the Jurkat T cell line (Fig. 2A) three major mRNA isoforms were identified (CD45BQ 
B and Nu11), as well as traces of CD45ABC and AB which were only detectable after Southern 
hybridisation. The HUT-78 T-cell line expressed a distinct set of isoforms (CD45ABQ BC and B
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but not CD45Nul1; Table 1). The erythroid/megakaryocytic cell line, K562 predominantly 
expressed CD45Nu11, a minor amount of CD45B and traces of CD45ABC’ AB and BC (Fig. 2A). Finally, 
in tonsils all known human isoforms, CD45ABC> AB BC B and Nu11, were detected (Table 1). It is of 
note that CD45A C and AC were not found in cells from human origin.
Transiently transfected Cos-1 cells produced five mRNA variants (CD45ABC> BC AB B and Nul1, Fig. 
2B), of which the weakly expressed AB isoform required identification by Southern 
hybridisation. The isoform distribution pattern remained largely constant over the time 
span between 18-72 h post transfection (not shown). The splice mode appeared also 
insensitive to variations in either serum concentration (1, 5 or 20 vol. %) during cultivation, 
or the cell density (1x105 to 5x10 6 cells/ml) during electroporation and plating. In HeLa 









Stability of CD45 mRNA splicing in permanently transfected Swiss-3T3 cell lines.
Stably transfected Swiss-3T3 cell clones containing the pSEC-S-LCA1-7 mini-gene were subjected to 
treatment with (TPA), different pH  culture conditions and inhibitors o f protein synthesis (CHM). RT- 
PCR analysis was carried out with primers LCA2-LCA7a1. (A) Southern blot hybridisation with an 
exon 3 labelled oligonucleotide on RT-PCR products o f 10 stably transfected cell lines. The cell clones 
show only variability in the level o f exon B expression. Isoform types are indicated on the right, band sizes 
are given on the left. (B) All panels show Southern blots o f RT-PCR products probed with an exon-3 
labelled oligo. Left panel: EC2 transfectants after culturing for 72 h in media with pH  6.6, pH  7.0 and pH  
7.6. Essential no ratio shifts in CD45Null/CD45B expression is seen. Middle panel: EC2 cells treated with 
and without TPA. Exon B expression increased slightly after culturing in presence of 10-7 M  TPA in 1% 
DMSO, and in 1% DMSO alone. Right panel: EC2 cells subjected to cycloheximide (CHM, 20 mg/ml) 
treatment for 0, 24 and 48 h. Minor shifts are observed in expression levels o f isoforms B/BC/ABC.
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for isoforms CD45BC> B> and Nul1. Permanently transfected Swiss-3T3 fibroblasts expressed mainly 
CD45B and Nul1 isoforms (Fig. 2B). In a panel of different Swiss-3T3 clones, variation in splicing 
patterns remained restricted to the expression level of the B isoform (Fig. 3A). The robustness 
of this distribution pattern was tested in a representative cell line EC2, but appeared hardly 
affected by different pH (Fig. 3B, left panel) or changes in serum conditions (not shown) 
maintained during a 72 h culture period. This is in line with our observations in Cos-1 cells. 
Treating the EC2 cells with the phorbolester TPA or DMSO (Fig. 3B, middle panel) modulated 
the level of the B-isoform only slightly but did not force the cells into a “splice mode” other 
than the CD45B and Nul1 isoforms. Therefore, we investigated whether more drastic events like 
a complete block of protein synthesis with CHM (20 |ig/ml) for 48 h would perhaps evoke a 
further disbalance in the concentration of splicing factors and CD45 pre-mRNAs and result 
in a more evident shift in the isoform spectrum. As shown in Fig. 3B (right panel) the EC2 
cell line indeed responded by shifting to larger isoforms (more exons included), but again 
effects were only marginal. This confirmed that simply affecting the cell’s overall synthetic 
program does not induce a significant shift in splicing behaviour.
Finally, in order to exclude that presence of long-lived reporter CD45-mRNA products might 
mask the production of small amounts of any new isoforms during the test period we 
estimated its half-life. Upon treatment of the cells with actinomycin D the reporter RNA 
concentration dropped to 50% level in 3-5 h (not shown). We may therefore conclude that 
there are no caveats in our experimental approach and that monitoring CD45 isoform patterns 
over a period of 72 h should be a sufficiently long time span to demonstrate any changes in 
splice pattern, if present.
Immunolocalization and Western blot analysis of CD45 reporter proteins
Our CD45 minigene was designed to enable facile study of the splicing behaviour at the 
protein level by immunofluorescence (even on living cells) and Western blotting. When 
transfected Cos-1 cells were stained with exon specific monoclonal antibodies (RA, RB and
Figure 4
Immunolocalization of CD45-chimericproteins in Cos-1 cells and Swiss-3T3 fibroblasts transfected 
with the pSEC-S-LCA1-7 reporter construct.
(A) Methanol-fixed transfected Cos-1 cells, stained with the PD7/26 (CD45RB) antibody and RAM- 
FITC conjugate showed a diffuse cytoplasmic staining o f CD45RB-proteins superimposed with strong 
fluorescent coarse intra-cytoplasmic granules. (B) In non-fixed transfected Cos-1 cells a fine granular 
fluorescence was found exclusively on the cell surface. (C) Methanol-fixed Swiss-3T3 transfectants stained 
with the UCHL-1 antibody (CD45R0) displayed a fine granular intra-cytoplasmic and cell membrane 
staining. (D) In non-fixed Swiss-3T3 transfectants a fine granular pattern on the cell surface was found. 
The anti-keratin antibody OVTL 12-5, used as control for the cell surface labelling procedure, revealed a 
strong filament labelling in methanol-fixed Cos-1 cells (E), and no labelling in non-fixed Cos-1 cells (F).
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RC) and the UCHL-1 antibody (RO, exon 3-7) all cells showed identical immunofluorescence 
staining patterns, i.e. a diffuse cytoplasmic fluorescence superimposed with strongly stained 
granules in fixed Cos-1 cells (Fig. 4A), and a speckled fine-granular fluorescence at the cell 
surface of non-fixed Cos-1 cells (Fig. 4B). Similar staining, but with lesser fluorescence 
intensity, was found for Swiss 3T3 transfectants (Fig. 4C and D). These cells could not be
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stained with RA- and RC-specific antibodies, in keeping with the mRNA typing results. Anti­
keratin antibodies (OV-TL12/5) served as an experimental negative control (Fig. 4F) for 
non-fixed cells, and as positive control for fixed cells (Fig. 4E). As a control, we transfected 
the non-spliceable CD45ABC-cDNA construct with a membrane-juxtal VSV-tag (pSEC-N- 
LCA-456VSV) into Cos-1 cells. The anti-VSV-tag antibodies as well as all CD45-exon specific 
antibodies (except for RO) revealed a strong granular location of CD45 proteins throughout 
the cytosol as well as at the cell surface. This pattern was identical to that obtained with the 
spliceable construct. We may conclude that anchoring of chimeric CD45 products in the 
membrane occurs correctly and follows upon translation and glycosylation of CD45 products 
as anticipated.
Based on these findings we felt confident to use Western blot analysis to further substantiate 
our data on the processing of CD45 protein isoforms. In transfected Cos-1 cells, in agreement 
with the RT-PCR findings, three different exon B containing proteins of 85, 65 and 41 kDa
Figure 5
Western Blot analysis of CD45 (chimeric) proteins in Cos-1 and Swiss-3T3 cells transfected with 
pSEC-S-LCA1-7.
Protein lysates o f transfected cells were subjected to electrophoresis on 12% SDS-PAGE-gels and 
subsequently transferred to nitro-cellulose. Western blots were incubated with CD45 exon specific 
monoclonal antibodies PD7/26 (CD45RB) and UCHL-1 (CD45R0) and bound antibodies were visualised 
by chemiluminescence. Protein size markers (in kDa) are indicated on the left o f each panel. (A) In Cos- 
1 cells transiently transfected with the pSEC-S-LCA1-7 construct three protein products of 85, 65 and 41 
kDa were detectable with PD7/26. Cos-1 cells transfected with the non-spliceable control constructpSEC- 
N-LCA456VSV expressed the 85 kDa CD45ABC isoform only. (B) Swiss-3T3 cell line EC2 permanently 
transfected with the pSEC-S-LCA1-7 construct expressed two protein products: an exon B containing 41 
kDa band upon staining with PD7/26 and a 33 kDa band after staining with UCHL-1.
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were identified (Fig. 5A) representing the CD45ABC> BC and B isoforms. The smallest CD45Ndl was 
found as a 33 kDa protein as identified with antibody UCHL-1 (data not shown). Analysis of 
products originating from the pSEC-N-LCA456VSV control construct with the PD7/26 anti­
body confirmed that the CD45ABC isoform was indeed expressed as an 85 kDa band (Fig. 5A). 
As anticipated from the RT-PCR analysis, the EC2 cell line expressed the 41 kDa CD45B and 
the 33 kDa CD45Ndl isoform (Fig. 5B).
It should be stressed that the actual size of protein products determined from the migration 
on “Western-gels” appeared conspicuously larger than the size calculated on basis of the 
amino acid sequences. This discrepancy is likely due to complex O-type glycosylation of the 
exon 3-7 domain in the truncated CD45 protein products in Cos-1 and Swiss-3T3 fibroblasts 
[22,37].
CD45 mRNA products in transfected mouse embryonic stem cells and 
transgenic mice in vivo
After establishing the CD45 specific splicing patterns in transfected non-expressor cell lines, 
we turned to the use of ES cells with constitutive CD45 expression to examine the CD45 
splicing process under conditions of progressive differentiation, in-vivo and ex-vivo. ES cells 
permanently transfected with the CD45 minigene revealed two CD45 isoforms (B and Null) 
when kept in the undifferentiated state. When induced to differentiate into embryoid bodies 
(EBs) during 12 days in-vitro differentiation, still no changes in the CD45 expression profile 
was seen except for a shift of CD45B to weaker levels (Fig 2C). During the 12-day differentiation 
period a multitude of different cell types including muscle cells and hematopoietic (stem) 
cells in blood islands had formed.
Therefore, to answer the question whether the specific assembly of splicing machinery 
involved in use of CD45 exons 4-6 occurs only in highly specialised cell types and requires 
terminal differentiation, we generated chimeric transgenic mice from our pSEC-S-LCA1-7 
positive ES cells. Only animals with a 75-95% contribution of “transgenic cells” were 
examined. Throughout all non-lymphoid tissues (muscle, lung, heart, pancreas) the default 
splicing pattern with the CD45Nul1 and very weakly the CD45B isoform was observed (Fig. 6A, 
mouse derived from ES cell clone E14-74). Lymphoid tissue, in contrast, displayed a distinct 
mRNA profile (Fig. 6B, Table 1). While the thymus expressed almost exclusively the smal­
lest, CD45NuU isoform, spleen profiles were much more complex, showing 5 isoforms. Again 
CD45Nu11 and CD45B were the predominant isoforms, but we now also observed expression 
of CD45BC> A and C (Fig. 6B). Interestingly, bone marrow (BM) and PBLs expressed all (possible) 
eight isoforms, with again CD45Null and CD45B being the most abundant. Our data illustrate 
that the product profile of our ‘human’ CD45 construct in the chimeric-transgenic tissue in 
fact closely resembles that of the endogenous mouse gene. Wild type mouse controls were 
negative in all assays.
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Probe: E xon 3 Exon 4 Exon5 E xon 6
Figure 6
RT-PCR and Southern blot analysis of pSEC-S-LCA1-7 products expressed in tissues of chimeric 
mice.
Chimeric mice were generated from pSEC-S-LCA1-7 transfected ES cells. Tissues o f highly chimeric 
mice (75-95%) were processed for RT-PCR analysis with the primer combination LCA2-LCA7a1. The 
PCR products were subjected to Southern blot hybridisation with CD45 exon specific probes (exon 3, 4, 5 
and 6). Samples o f one representative mouse (E14-74 derived; 95% chimeric) are shown. (A) Analysis of 
CD45 isoforms expression in different chimeric mouse tissues (exon 3 probe). Note the absence o f CD45 
expression in the control Wild Type (W T) spleen. (B) Analysis o f CD45 isoforms products in hematopoietic 
tissue with specific probes for exon 3, 4, 5 and 6. BM: bone marrow; PBL: peripheral blood leukocytes. 
The identity o f different isoform signals is given on the right, size o f bands (bp) is indicated on the left.
From the above results we conclude that all lymphoid tissues like bone marrow, PBLs, spleen 
and thymus, are rather unique in that they provide the conditions, that promotes alternative 
use of exons 4, 5 and 6 in CD45 mRNAs.
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SR-protein expression patterns in cell lines and mouse tissues
Since alternative splicing is thought to be determined by the composition and abundance of 
SR-proteins, we investigated the expression profile of these SR-proteins in cell lines and 
mouse tissues using initially the broad-spectrum monoclonal antibody 104. This antibody 
is specific for a conserved phospho-epitope found in all SR-proteins [27]. As shown in Fig. 
7A hematopoietic and transfected cell lines expressed a broad range of the 104 defined SR- 
proteins, with some fluctuation in the SRp75 and the SRp20 expression levels as well as in 
the number of 30kDa SR-proteins, between 3 and 5 bands. SRp55 expression was very low or 
even absent in most cell lines, whereas it was present in variable levels in all mouse tissues 
(Fig. 7A and B). Mouse tissues expressed SRp75, SRp55 and SRp40 proteins both in lymphoid 
and non-lymphoid tissues (Fig. 7B) and presence or absence of these proteins (SRp75/55/ 
40) could not be correlated to any specific CD45 splice mode. Interestingly, the SRp20 and 
SRp30’s were well expressed in lymphoid mouse tissues but were absent or expressed at low 
levels in non-lymphoid mouse tissues, thus accounting for the most notable difference in 
SR-protein profile between lymphoid and non-lymphoid tissues.
The expression profile of SRp30’s in lymphoid and non-lymphoid tissues was confirmed by 
analysing the distribution of the 9G8 SR-protein, a representative of the SRp30 group of 
proteins, using an affinity purified polyclonal antibody directed against the first 12 residues 
of the 9G8 protein (N-term inal Ab) (Y. Cavaloc, R. Gattoni and J. Stevenin, personal 
communication). This analysis confirmed that the 9G8 SR-protein (a 30-32 kDa polypeptide) 
was indeed strongly expressed in cell lines and lymphoid tissues but was essentially absent in 
non-lymphoid tissue (data not shown).
DISCUSSION
To follow the effects of trans-acting conditions that govern the alternative production of 
CD45’s extra-cellular segments we designed a (human) mini-gene reporter construct that 
enables us to monitor the product profile simultaneously at the protein and mRNA level, in 
different cell types in vitro and in vivo.  The rationale behind its design is based on practical 
considerations concerning the organisation and the shear size of the genomic CD45 DNA 
segments, and on pre-existing knowledge regarding the location of cis-acting splice signals 
that affect the alternative splicing of CD45 pre-mRNA. We omitted intron 1 and 2 sequences 
in the 5’ part of the construct and the segment downstream of exon 7, to obtain a DNA 
segment with a clonable format, and because no elements that affect splicing have ever been 
identified in these regions [34,38]. Motifs for binding of splice factors in the CD45 sequence 
have been localised within both exons 4 (segments of 3 bp, 52 bp and 11 bp, and position 77, 
respectively) and 6 (segment of 122 bp). It is of note that several groups have reported on the 
use of CD45 minigenes, for different research aims. The constructs designed by Saito’s group 
were meant for the identification of cis-sequences and therefore truncated human CD45
117
•  Chapter 4
Figure 7
Western blot analysis of the SR-protein expression pattern in cell lines and mouse tissues.
Cell and tissue samples were lysed in SDS-containing lysis buffer, sonicated and subjected to 12% SDS- 
PAGE gel electrophoresis. After transfer to nitro-cellulose, blots were incubated with mAb 104 and bound 
antibodies were visualised by chemiluminescence. Cell lines and mouse tissues analysed for SR-protein 
expression are indicated above each panel. Protein size markers are indicated on the left o f each panel 
and the appropriate position o f each SR-protein is indicated on the right. (A) and (B) Immunoblots 
probed with the mAb 104. BM: bone marrow; PBL: peripheral blood lymphocytes.
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minigenes expressing only one of the variable exons were required [34,38] in their studies. 
Boyse’s group reported on a mouse genomic clone expressing exon 3-7, however, they did 
not compare expression at the RNA and protein levels throughout all tissues [29].
We first verified our approaches by recapitulating previous data on the endogenous CD45 
expression profiles in different types of (human) lymphoid and leukaemic cells. The diversity 
of splice forms (collectively summarised in Table 1) can be most easily explained as being 
related to differences in cell type and differentiation-activation status of the cells examined. 
CD45 isoform profiles in Raji, ROS and KM3 resemble the patterns usually seen in B-cells. 
Naive unprimed T-cells are known to be CD45RAhigh/CD45RNulllow expressors [1,8], whereas 
in primed memory T-cells exons A, B and C are spliced out to form the CD45Ndl isoform. 
Thus, Jurkat cells could resemble activated T-cells, while HUT78 resemble naive resting T- 
cells in this respect. The erythroid cell line K562 expressed CD45Ndl as the main isoform and 
CD45B as a minor component. This profile fits to the default pattern in CD34+ bone marrow 
stem cells for which it was shown that they remain CD45Nu11 and B positive upon erythroid 
differentiation [7].
Transient and stable transfection of the CD45 mini-gene into several non-hematopoietic/ 
non-expressor cell lines yielded expression patterns in which, together, the isoforms known 
for hum an CD45 are represented. These data confirm that our CD45 mini-gene indeed 
contains all essential elements needed for alternative splicing.
In contrast to expectation, the CD45 isoform profile in our transfected Cos-1 cells did not 
overlap with the default pattern (CD45Nul1 and B), expected on findings in 3T3 and HeLa cells 
[34], but included all five hum an isoforms (CD45ABC> AB> BC> B> and Nul1), with a relative high 
contribution of CD45BC and ABC. These observations can be most easily explained by assuming 
that the extraordinary high production of pre-CD45 mRNA in Cos-1 cells causes titration 
(i.e. shortage) of splicing factors that normally would assist in exon 4-6 removal. By inhibiting 
the protein synthesis with cycloheximide (CHM) in the stable transfectant 3T3-EC2 a similar 
effect, with a slight shift towards the production of larger isoforms, was obtained. It is of 
note however, that Streuli et al., in a comparable experiment with thymocytes [28], observed 
a much more dramatic shift from CD45Nul1 isoforms to CD45ABC isoforms. Hence, it may be 
the balance in splice factor composition and the effect of cell type thereon, more than the 
simple ratio between the number of binding factors and target sites in pre-mRNAs, that 
determines the outcome of alternative splicing. Obviously, in non-hematopoietic cells in 
culture the balance between the concentrations of pre-mRNAs and splicing modulatory 
factors is quite robust in nature. This would also explain why our attempts to influence 
splice site choices by modulating culture conditions or by adding stimulatory agents like 
TPA failed (only slight alterations in the level of CD45B could be induced), or had rather 
marginal effects as in the case of CHM treatment of Cos-1 cells. Can a more delicate balance 
in splicing behaviour like in T-cells be found elsewhere, in non-lymphoid tissues that do
119
•  Chapter 4
normally not express CD45, during growth or maturation? To answer this question we turned 
to the use of ES cells, differentiating embryoid bodies (EBs) and tissues in transgenic chimeric 
mice. Again, in all tissues analysed with the exception of lymphoid cells, production of the 
CD45Nu11 isoform together with a low level of CD45B was the default pattern. This indicates 
that the conditions that favour skipping of exon 4-6 are ubiquitous, and already present 
during the earliest phases of differentiation and throughout development in all non-lymphoid 
cell types. Strikingly, the factors involved in CD45 splicing in lymphoid tissues seem to act 
promiscuously, in that they can recognise the human-type sequences in pSEC-S-LCA1-7 
derived transcripts. In bone marrow and PBLs of the transgenic chimeras we observed not 
less than eight different pSEC-S-LCA1-7-derived mRNA isoforms, more than reported for 
the hum an CD45 gene, but similar to the distribution of endogenous mouse isoforms. In 
the thymus we observed mainly the CD45Nu11 isoform. This does not correspond entirely 
with observations that claim the existence of a small population of immature double negative 
(CD4/CD8) thymocytes (less than 5%) expressing high molecular weight isoforms of CD45 
[11,25,41,45]. It is conceivable, however, that low amounts of thymocytes with high MW 
isoforms of CD45 are overwhelmed by double positive (CD4+8+) thymocytes expressing 
CD45Nu11 isoforms in our situation. We thus may have overlooked exon A, B and/or C bearing 
isoforms because we did not apply special cell selection criteria (see [25]) or sensitive Southern 
blot assays to demonstrate minute quantities of these proteins. The spleen as a collection of 
(im)mature Th1/Th2 cells, B cells, monocytes and hematopoietic (stem-) cells expressed 
five CD45 isoforms, of which CD45Nu11 and B were most abundant and CD45A> C and BC were minor 
components. Surprisingly, we did not observe the CD45ABC isoform, although generally 10­
15% of the spleen is composed of B-cells, which express predominantly CD45ABC [15,26,37]. 
To understand this observation it is important to stress that the overall levels of CD45 mRNA 
levels expression were rather low in our transgenic model. Furthermore, the contribution of 
naive T-cells to ABC isoforms in the spleen is neglectable, as CD45ABC T-lymphocytes 
selectively accumulate in lymph nodes but not in the spleen [17]. Another possible factor 
may be that the relevant segments in human, pSEC-S-LCA1-7, RNA have less avidity for the 
appropriate splicing factors than the segments in the endogenous mouse CD45 RNA. Finally, 
we can also not exclude that expression of GPI-anchored and truncated CD45 isoforms 
interferes with the final stages of cell activation and differentiation proper in our model. 
The question whether we may expect mRNA from our reporter construct to precisely mimic 
the behaviour of endogenous CD45 mRNAs in lymphoid tissues cannot be elucidated until 
all binding elements in hum an and mouse CD45 pre-mRNAs have been delineated and 
splicing factors involved have been characterised. For example, only exonic sequences are 
im portant in hum an exon 6 splicing whereas in mouse also intronic sequences flanking 
exon 6 are important [29,38]. Hence, species specific differences in cis-acting mRNA elements 
could explain why our hum an construct does not precisely mimic the mouse pattern
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quantitatively, while qualitatively it overlaps with the endogenous situation by generating 
all eight isoforms.
Alternative use of exons 4-6 in CD45 is thought to be regulated by trans-acting splicing 
factors [28]. Members belonging to the SR-family of RNA-binding proteins, which participate 
in spliceosome assembly and block or promote splice site selection, are among the best 
candidates to be involved in the process. In fact, the cell-type dependent composition of SR- 
protein mixtures probably creates a universal basis for tissue specific regulation of splice 
patterns [4,12,30,44]. Therefore, we tried to identify possible candidate factors by correlating 
the SR-protein constitution of cell lines and tissues to the mode of CD45 splicing, firstly by 
using the broad spectrum mAb 104, that binds to a phosphorylated epitope conserved in all 
SR-proteins [27,44], on Western blots. By far the best correlation between factor presence 
and inclusion of exon 4-6 sequences in our CD45 minigene products was found for SRp30 
and SRp20, which were well expressed in cell lines and lymphoid mouse tissues but not or 
hardly in non-lymphoid organs. A similar distribution of SRp30 was found in organs of calf 
[44]. The SRp30 proteins include SF2/ASF (SRp30a), SC35 (SRp30b), SRp30c and 9G8 
[5,10,13,18,30]. By using a 9G8-specific polyclonal antibody we could indeed confirm that 
9G8 was among the SRp30 candidates that are specifically expressed in tissues of lymphoid 
origin.
Can we thus use the finding of absence and presence of members of the SRp20 and SRp30 
subfamily in somatic mouse tissues for a straightforward speculation about their role in 
CD45 splicing? Unfortunately, this appears not to be the case as in cell lines in vitro there 
was no clear-cut correlation between the level of members of the SR-protein family and 
CD45 splicing mode. For example, SRp30 proteins were expressed at prominent levels in 
almost all cell types, and also SRp20 was present in 3T3 and HeLa cells. Strikingly, SRp55 
expression was virtually absent in all cell lines, which is in sharp contrast to the situation in 
mouse organs (see [43]). Moreover, the fact that comparable SR-protein profiles were found 
in cell lines like Raji, Jurkat and K562, with distinct CD45 isoform profiles indicates that 
there must be other regulatory principles involved than just the SR-protein presence. Future 
work, therefore, should also take into account the degree of phosphorylation of SR-proteins, 
their localisation (i.e. distribution in nuclear compartments) and the level of production of 
isoform variants with skipped RS-domains [16,21,23,42]. The use of transfectable cell lines 
with low SRp30/SRp20 expression and the CD45 minigene construct or cotransfection 
experiments with SR-protein cDNA constructs and the CD45 minigene should help us further 
in unravelling the mechanism(s) that govern the alternative use of exons 4-6 of CD45.
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CD45 isoform expression*
Cell type ABC AB BC AC A B C Null
Human lymphoid cells
Tonsils ++++ + +++ - - +++ - +++
Raji ++++ - + - - - - -
ROS +++ - ++ - - - - -
KM3 ++++ - + - - - - -
Jurkat +/- +/- ++ - - ++++ - +++
Hut78 ++ - ++++ - - +++ - +/-
K562 +/- +/- +/- - - + - ++++
Transfected cell lines
Cos-1 +++ +/- ++++ - - +++ - +++
HeLa - - ++ - - ++++ - +++
3T3 - - + - - +++ - ++++
ES - - - - - +++ - ++++




- - - +/- - ++++
Thymus - - - - - - - ++++
Spleen - - +/- - + ++++ + ++++
Bone Marrow + + ++ + + +++ + ++++
PBLs ++ + + + ++ +++ + ++++
* Expression levels of the various isoforms were inferred by RT-PCR analysis, Southern blot hybridisation 
and immunofluorescence staining and scaled in a semi-quantitive manner, indicated by + and -.
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ABSTRACT
CD45 is a transmembrane glycoprotein possessing tyrosine phosphatase 
activity, which is involved in cell signalling. CD45 is expressed on the 
surface of most leukocytes (reviewed by Thomas [54], Trowbridge and 
Thomas [55]), and can be alternatively spliced by the inclusion or 
skipping of three variable exons (4, 5 and 6 or A, B and C) to produce up 
to eight isoforms. In T cells the splicing pattern of CD45 isoforms chan­
ges after activation, naive cells express isoforms which include exon A 
(CD45RA), whilst activated cells lose expression of all the alternatively 
spliced exons to form the null isoform (CD45RO).
Little is known about the specific factors controlling the switch in CD45 
splicing which occurs on activation. In this paper we examined the 
influence of the SR family of splicing factors, which, like CD45, are 
expressed in tissue specific patterns, and have been shown to modulate 
the alternative splicing of a variety of transcripts. We show that specific 
SR proteins have antagonistic effects on CD45 splicing leading either to 
exon inclusion or skipping. Furthermore, we were able to demonstrate 
specific changes in the SR protein expression pattern during T-cell 
activation.
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INTRODUCTION
Intron removal is an essential step during eukaryotic gene expression. This process requires 
recogn ition  o f the 5' and 3' splice sites by the spliceosom e: a m u ltico m p o n en t 
ribonucleoprotein complex. The m ajor com ponents of the spliceosome are the small 
ribonucleoprotein particles (snRNPs) U1, U2 and U4/U6 and the non-snRNP proteins 
including the family of SR proteins (reviewed by Green [20], Krämer [28]). This family of 
closely related, highly conserved proteins is characterised by the presence of one or two N- 
terminal RNA recognition motifs (RRMs) and a C-terminal domain rich in arginines and 
serines (RS domain). SR proteins function at multiple steps of the splicing reaction and have 
been shown to modulate the splicing of a variety of transcripts both in-vitro and in-vivo 
[7,19,27,32].
CD45 is a transmembrane glycoprotein expressed on leukocytes {reviewed by Thomas, [54]; 
Trowbridge and Thomas, [55]). Alternative splicing of three variable exons (4, 5 and 6 or A, 
B and C) allows the production of 8 possible isoforms. In rodent cells all of these isoforms 
have been isolated [2,41,42], whilst in humans only 5 have been identified [37,49]. The splicing 
is cell-type specific and activation dependent, B-cells express mainly the high molecular 
weight isoform (ABC), whilst T-cells express a panel of different isoform ranging form the 
smallest isoform (Null), found also on thymocytes, to the largest isoform (ABC). T-cell 
activation leads to a programmed shift from high to the low molecular weight isoforms, i.e. 
exon inclusion to exon skipping. It is this change in cell surface phenotype, which is used to 
differentiate naive from memory T-cells [1].
In this study we sought to identify factors involved in the regulation of alternative splicing of 
CD45. Members of the SR protein family were analysed for their influence on splice site 
selection by cotransfection experiments with a CD45 minigene in Cos-1 cells in-vitro [53]. 
Furthermore, we analysed the SR-protein profile in T-cells, before and after stimulation.
MATERIALS and METHODS
DNA Cloning
The CD45 minigene pSEC-S-LCA1-7 was constructed in the pSEC expression plasmid [52] 
and contains (i) the 5' CD45 structural gene region (exon 1 and 2) comprising the ATG 
codon and the signal peptide, (ii) the genomic CD45 sequence of exon 3 to exon 7 with the 
alternative exons 4, 5 and 6, (iii) the Decay Accelerating Factor (DAF) GPI-anchor attachment 
signal to ensure membrane expression of the expressed proteins (Figure 1A).
SR protein cDNAs were cloned in the vector pCGT7 which carries an N-terminal tag from 
the bacteriophage T7 gene [5,61]. SR protein products can therefore be recognised by the 
T7-tag monoclonal antibody (Novagen, Inc., Madison, USA). SRp75 was cloned into the 
parental vector pCG, which lacks the T7 tag.
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The SR protein chimeras and deletion mutants are listed in figure 8. RRM or RS domain 
swaps or deletions were all constructed by pfu-PCR amplification of the desired fragments 
with specifically designed primers and subcloning of the fragments in the pCGT7 expression 
vector. [Nomenclature of the constructs is illustrated for SF2/ASF (30aRRM1-30aRRM2- 
30aRS) and SC35 (30bRRM1-30bRS). E.g. substitution of the RS domain of SF2/ASF by the 
RS domain of SC35 is called 30aRRM1-30aRRM2-30bRS, deletion of a domain e.g. RS domain 
of SC35 is indicated by A or delta, 30bRRM1- A30bRS.] To generate the SRp20-SC35 chimera’s 
PCR products of SRp20-RRM (amino acid 1-88), SRp20-RS (amino acid 88-164), SC35- 
RRM (amino acid 1-115) and SC35-RS (amino acid 116-221) were subcloned in pCGT7 in 
the indicated combinations. The SF2-ASF-SRp40 chimeras and SF2/ASF deletion mutants 
were described in Caceres et al. [5,6].
In vivo analysis of alternative CD45 splicing
Cos-1 cells were cultured in Dulbecco modified eagle medium  (DMEM, Gibco BRL) 
supplemented with 10% foetal calf serum (FCS, Gibco BRL) in 6-well plates. At a cell density 
of 30-40% cells were (co)transfected with 1 mg of minigene DNA and the indicated amount 
of SR protein construct using lipofectin reagents according to the manufacturer (Gibco, BRL). 
Transfected cells were harvested 48-72 h after transfection and RNA was isolated with the 
RNAzol B (Cinna Biotec Laboratories) method and analysed by RT-PCR. First-strand 
specifically primed (DAF reverse primer: 5' CCTAAATGAAGAGCACAATTGCA 3') cDNA 
synthesised with Superscript Reverse Transcriptase (Gibco, BRL) from 200 ng of RNA was 
am plified  for 22 cycles using a 5' end labelled  forw ard p rim er (LCA2: 5' 
ATTGGATCCGCTGACTTCCAGATATGACC 3') and a non-labelled reverse primer (LCA7: 
5' CCGAGATCTTCAGAGGCATTAAGGTAGGC 3'). PCR products were run  on a 6% 
denaturing polyacrylam ide gel and detection and quan tita tion  were carried out by 
autoradiography and Phosphor Image analysis (Kodak X-OMAT S1, Biorad Molecular 
Analyst) respectively.
RNA from PHA stimulated RO+ and RA+ T-cells was reversed transcribed with the LCA9 
primer (5’ GTAATCCACAGTGATGTTTGC 3’) and amplified using LCA2 and LCA7 primers. 
PCR products were run on a 2% agarose gel.
For immunofluorescence analysis Cos-1 cells were seeded on coverslips in 6-well plates and 
transfected with the CD45 minigene. Cells were stained 48h after transfection at 4°C with 
the CD45 exon B specific antibody PD7/26 (Dakopatts, Copenhagen, Denmark).
SR proteins and Immunoblotting
To analyse SR protein products (SR proteins, chimeric constructs and deletion mutants) 
expressed by the pCGT7 vector, transfected Cos-1 cells were lysed in 5% SDS in 50 mM Tris- 
HCl, pH 6.8 and 20 mM EDTA, sonicated and resolved by 12% SDS-PAGE. Proteins were
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electroblotted and probed with the T7 tag antibody (Novagen) or the 104 mAb [38].
For SR protein detection in lymphocytes human T-cells were isolated from fresh buffy coats 
and separated into CD45RA+ and CD45RO+ populations by selection with the UCHL1 
(CD45RO) and the SN130 (CD45RA) antibodies. Both populations were stimulated with
CD45 Minigene












PCR products CD45 expression
LCA2 - LCA7 Human Mouse
637 bp  + +
493 bp  + +
496 bp  - +
439 bp  + +
352 bp  - +
295 bp  + +
298 bp  - +
154 bp  + +
5 6 7
132
Regulation of CD45 alternative splicing by SR-proteins •
phytohaemagglutin (PHA-P) for 0, 12, 36, 72 and 144 h and analysed at indicated time points 
for CD45RA/RO expression by flow cytometry to observe changes in RA/RO expression. 
Subsequently, equal amount of cells were lysed in 5% SDS lysis buffer and sonicated for 2 
times 20 sec. Proteins were resolved on 12% SDS-PAGE, electroblotted and probed with the 
104 mAb.
Cell separation and stimulation of CD45RA+ and CD45RO+ T-cells
PBMC were isolated from buffy coats (NE London Blood Transfusion Service) by Ficoll- 
Paque density-gradient centrifugation (Pharm acia, St Albans, UK). M onocytes and 
macrophages were removed by adherence to plastic for 1 h at 37°C, these were saved and 
used as antigen presenting cells after mitomycin C treatment where required. CD45RA+ and 
CD45RO+ T-cells were then negatively selected. Non-adherent cells were incubated at 4°C 
for 30 min. with a cocktail of mAbs, BU12 (anti-CD19, gift from N. Ling), OKM1 (anti- 
CD11b, ATCC), and R10 (anti-glycophorin, a gift from P. Edwards) together with SN130 
(anti-CD45RA, Imperial Cancer Research Fund) for removal of CD45RA+ T-cells, or UCHL1 
(anti-CD45RO, Imperial Cancer Research Fund) for removal of CD45RO+ T-cells. After 
washing, the cells were incubated with sheep anti mouse IgG-coated magnetic beads at 4°C 
for 20 min. (Dynal, Bromborough, UK), labelled cells were then removed with a Dynal magnet. 
After 5 rounds of magnetic beads separation purity was greater than 98% by FACS analysis. 
For stimulation 2x106 CD45RA+ or CD45RO+ T-cells were incubated in 24 well, flat bottom 
tissue culture plates (Becton Dickinson) together with 5% mitomycin C-treated adherent 
cells and 1 mg/ml of PHA-P (Sigma) for 0, 12, 36, 72 and 144 hours. Cells were analysed by 
flow cytometry at the time points indicated for alterations in CD45RA and CD45RO 
expression.
RESULTS and DISCUSSION
Alternative splicing of CD45 occurs by inclusion or skipping of three alternative exons 4, 5 
and 6 (or A, B and C) and results in a maximum of eight different isoforms of which five are 
expressed in hum an hematopoietic cells (Fig. 1B). Cis-acting sequences and trans-acting
Figure 1
CD45 alternative splicing.
(A) Diagrammatic representation of the CD45 minigene. Transcription is driven by the SV40 promoter, 
introns are shown as lines, numbered boxes are CD45 exons. DAF: Decay Accelerating Factor GPI 
attachment site. The position o f the oligonucleotide primers LCA2 and LCA7 used for PCR are shown as 
arrows above exons 2 and 7 respectively.
(B) Diagram o f the eight possible alternatively spliced CD45 transcripts and the predicted sizes of the 
PCR products after amplification with the LCA2 and LCA7primers. The CD45 isoform expression pattern 
in human and mouse is taken from Thomas [54].
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Figure 2
Alternative splicing o f the CD45 minigene in Cos-1 cells.
(A) Immunofluorescence analysis of non-fixed transfected Cos-1 cells stained with the CD45RB anti­
body (PD7/26).
(B) Isoform expression pattern of the CD45 minigene after transient transfection in Cos-1 cells. The left 
panel shows radioactive labelled RT-PCR products run on a denaturing gel. CD45 isoforms are indicated 
on the left and isoform size (bp) on the right. M=CD45 marker (637 bp, 295 bp and 154 bp). 
Phosphorimage quantitation of the CD45 isoform expression (n=3).
factors have been postulated to influence the alternative splicing pattern of CD45. Linker 
scanning analysis revealed that in exon A three segments (position 8-10, 40-91 and 127-137, 
total length 198 bp) and in exon C one large segment (position 16-137, total length 144 bp) 
were essential for tissue specific alternative splicing [50,56]. Fusions between T and B cells 
retain the T cell phenotype producing the null isoform which led to the suggestion that exon 
inclusion is the default pattern whilst skipping is regulated by dominant trans-acting factors 
in T cells [40].
We studied the splicing of CD45 with a recently designed CD45 minigene (pSEC-S-LCA1-7, 
Fig. 1A), which can be analysed at both the RNA and protein level [53]. The minigene is 
driven by the SV40 promotor and contains exons 1-7 of CD45. A cDNA fragment of exon 1 
and 2 is fused to a genomic fragment of exon 3-7. Exon 7 is then fused to the GPI anchor 
sequence of Decay Accelerating Factor, which allows the truncated CD45 sequences to be
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expressed at the cell surface. Cos-1 cells transfected with the CD45 minigene and stained 
with a CD45 exon specific antibody showed a granular membrane staining pattern (Fig. 2A). 
We have previously demonstrated that regulation of alternative splicing of this CD45 minigene 
is restricted to lymphoid cells. All non-lymphoid transgenic cells and transfected cell lines 
such as Cos-1, HeLa and 3T3 showed a specific and stable pattern of splicing to form either 
the CD45 Null or B isoforms.
SR proteins display antagonistic effects on the alternative splicing of CD45
The focus of this paper was to examine the role of SR proteins in CD45 alternative splicing. 
SR proteins are essential for constitutive splicing [9,16,24,26,45,64] and alternative splicing
[7,18,19,27,45,58,65]. The family is highly conserved between diverse species and have been 
shown to be essential for cell survival [59,60]. SR proteins function at multiple steps during 
the splicing reaction. In early steps they facilitate U1 snRNP binding to the 5’ splice site 
[13,25]. Furthermore, they stabilise complex assembly at the 3’ splice site by assisting the 
binding of U2AF [51] and by forming bridges to connect 5’ and 3’ splice sites [17,48,62]. 
Substrate specific effects of individual SR proteins have been demonstrated in constitutive 
as well as alternative splicing [14,19,24,27,35,65]. SR proteins are expressed in tissue specific
b p  M  
6 3 7 A B C
Null
1 2  3 4  5 6  7  8 
Figure 3
Role o f SR proteins in regulation o f CD45 alternative splicing.
Cos-1 cells were cotransfected with the CD45 minigene and the indicated SR protein constructs. Lane 1, 
CD45 marker (637 bp, 295 bp and 154 bp), lane 2, control transfection with the CD45 minigene only; 
lane 3, control cotransfection with thepCGT7 lacking an insert; lanes 4-11 cotransfection with the indicated 
SR proteins.
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patterns [14,45,64,65] and can be regulated by phosphorylation [63]. The effects of the SR 
proteins SF2/ASF can be antagonised by the heterogeneous ribonucloproteins A1 and A2B1 
[33,34]. In addition, a further level of control of SR protein function may be subserved by 
nucleo-cytoplasmic shuttling [5,6]. The SR proteins are thus candidates to control CD45 
splicing.
In Cos-1 cells, the CD45 minigene is processed to give a mixture of isoforms (Fig. 2B) of 
which the smallest is the most abundant (CD45 Null, which skips the alternative exons). 
The ability of SR proteins to modulate CD45 splicing was assessed by cotransfecting individual 
SR cDNAs with the CD45 minigene (Fig. 3). Three groups of SR proteins with different 
specificities were identified. In the first group, SF2/ASF, SC35, SRp30c, SRp40 and SRp75, 
overexpression resulted in exclusion of all alternative exons and formation of the smallest 
CD45 Null isoform (Fig. 3, lane 6-9,11). The second group, SRp20 and 9G8, showed the 
opposite (Fig. 3, lane 4-5), with elevated expression of the largest, ABC, isoform and a decrease 
in expression of the smallest, CD45 Null, isoform. SRp20 and 9G8 both have a single 
(canonical) RRM and the homology between the two proteins in this domain is high (79%) 
when compared to the canonical RRM of the other SR proteins (35-45%) [9]. Finally, SRp55 
showed no effect on the alternative splicing of CD45 (Fig. 3, lane 10).
The effects of the antagonistic SR proteins SRp30c and SRp40 (exon skipping) versus SRp20 
and 9G8 (exon inclusion) were examined in more detail using incremental amounts of the 
SR construct co-transfected with 1mg of the CD45 target (Fig. 4A and B). The shift to exon 
inclusion induced by SRp20 was almost complete with only small amounts of isoforms BC 
and B still detectable. The effect of 9G8 was less dramatic, the ABC band increased to almost 
20% of the total sum, but the smallest isoform did not decrease and kept steady at 50%. 
Interestingly 9G8 promoted the appearance of the AB isoform, which is hardly detectable in 
the other transfections. Overexpression of SRp30c and SRp40 resulted in a dramatic switch 
to the smallest isoform skipping exons A, B and C.
These experiments were repeated several times in both Cos-1 and HeLa cells, small differences 
in the levels of CD45 isoform expression in the control lanes were seen, but changes induced 
by SR co-transfection were reproducible in all cases. SR protein expression (except SRp75)
Figure 4
Antagonistic effects o f SR proteins SRp20 and 9G8 versus SRp30c and SRp40 on the alternative 
splicing o f CD45.
(A) Increasing amounts (0.1-5 mg) o f SRp20, 9G8, SRp30c and SRp40 were cotransfected with a constant 
amount o f the CD45 minigene. Results were analysed by RT-PCR and radioactive products resolved on 
denaturing polyacrylamide gels.
(B) Isoforms were quantitated by phosphor image analysis and the amounts are shown as a percentage of 
the sum. The histogram is extracted from the cotransfection experiments using 3 mg o f the tested SR 
proteins shown in (A).
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was analysed and confirmed by western blotting using the T7 epitope tag. Localisation to 
nuclear speckles was also verified by immunofluorescence analysis (data not shown). 
Regulation of CD45 splicing by SRp20 and 9G8 causing exon inclusion could be explained 
by the presence of exonic (or intronic) enhancer sequences in the CD45 pre-mRNA. Several 
independent studies identified a SRp20 binding sequence with enhancer activity, all sharing 
the degenerate sequence CUC(U/G)UC(C/T) [12,30,31,44]. In addition, application of the 
so-called SELEX strategy yielded SRp20 specific sequences with the consensus CA/UA/UC 
[8]. The CUC(U/G)UC(C/T) sequence is also found in exon 4 of the SRp20 gene, the splicing 
of which is autoregulated by SRp20 itself [22]. In this study it was suggested that recognition 
and splicing of exons with weak splice acceptor sites is a general function of SRp20. A perfect 
match to the SRp20 consensus sequence is not found in the exonic sequences of CD45 
however, the sequence CACCACUGCAUUCUCACCC (nucleotide 59-77 in exon 4) is 
reminiscent of all the identified SRp20 enhancer sequences. In another study the Drosophila 
Melanogaster homologue of SRp20, RBP1 was shown to activate weak polypyrimidine tracts 
[21]. The splice donor and acceptor sequences of the alternative CD45 exons match well to 
the consensus, however the polypyrimidine tracts preceding exons 4, 6 and to a lesser extent 
exon 5 are suboptimal indicating a possible role for SR protein regulation. The homology 
score of the Y-track upstream (10 nucleotides) of the NYAG consensus sequence of the 3’splice 
site is 60% for exon 4, 90% for exon 5 and 80% for exon 6 which illustrates the poor 
conservation.
All tracks contain the sequence TGAT, which is also found in the SRp20 enhancer sequence 
of the CT/CGRP gene where it is essential for regulated alternative splicing of exon 4 [30]. 
The TGAT sequence is present in the intron upstream of the 3’ splice site of exon 4 (nucleotide 
minus 46-49), exon 5 (nucleotide minus 19-22 and 27-30) and exon 6 (nucleotide minus 18­
21) and is conserved between human and mouse CD45 [54].
Overexpression of 9G8 promotes CD45 AB and ABC splicing. This shift is not as complete as 
Figure 5
Role o f modular domains o f SRp20, SC35 and SF2/ASF in CD45 splicing.
(A) RS domain deletion mutants and domain swap constructs o f SRp20 and SC35 were cotransfected 
with the CD45 minigene and analysed by RT-PCR. Lane M, CD45 marker and lane (-), control 
transfection with the CD45 minigene only.
(B) The indicated deletion mutants o f SF2/ASF and the construct 30b1030aRS were cotransfected with the 
CD45 minigene and analysed by RT-PCR. Single transfection with the CD45 minigene is shown in (-). 
CD45 isoforms are indicated on the right, isoform size (bp) is indicated on the left.
(C) and (D) CD45 isoform expression patterns shown in (respectively, A  and B) were quantitated using 
Phosphor Image (Biorad molecular analyst) analysis and reflected in a histogram. Relative amounts of 
CD45 isoforms are shown as a percentage o f the sum. Isoforms are indicated on the right o f the figure and 
also by grey colour, cotransfected constructs are indicated below the figure and isoform expression level 
(%) is indicated on the left.
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the switch induced by SRp20, as the CD45 Null, B and BC splicing are still detectable. 
Appearance of the AB isoform, together with the ABC isoform, indicates that 9G8 is 
specifically involved in exon A splicing. No other SR protein was able to promote CD45 AB 
splicing. Recently, two very divergent 9G8 splicing enhancers have been described [44]. One
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shows strong homology with the 9G8 consensus sequence AGAC(G/U)ACGAY isolated by 
the SELEX approach [8] while the other is pyrimidine rich and shows some sequence 
homology with the Drosophila double sex (dsx) splicing enhancer (UCUUCAAUCAAACA) 
which can bind 9G8 specifically [31]. SELEX, using a mutated form of 9G8 lacking the zinc- 
knuckle region, yields a pyrimidine rich sequence (C(A/U)(A/U)C) which resembles the 
SRp20 SELEX winner sequence [8,44]. Sequences closely resembling the 9G8 consensus are 
found in CD45 exon 4 but not in exon 5 and 6 (e.g. CD45 exon 4: 306GACTGACTACA316, 
nucleotide numbers are from the CD45ABC cDNA) which may explain the ability of 9G8 to 
promote the use of CD45 isoforms containing exon 4.
CD45 exon exclusion is promoted by SF2/ASF, SC35, SRp30c, 40 and 75. It has recently been 
shown using a CD45 minigene containing only alternative exon 4 that overexpression of 
hsSWAP, SF2/ASF, SC35, SRp40 and SRp75 all promoted exclusion of exon 4 in agreement 
with our findings [29,43]. Lemaire and colleagues also demonstrated that regulation of 
CD45 exon 4 splicing is dependent on exon 4 itself and not affected by the presence of the 3’ 
constitutive exon, exon 7. Information for exon exclusion must therefore be present in the 
exonic (or intronic) sequences of the alternative CD45 exons. Elements that repress splice 
sites have been identified in other systems [3,4,10,11,23,36,46,47]. In Drosophila binding of 
Sxll to the 3’splice site interferes with U2AF binding [57]. In addition, a splicing silencer 
(IIIA) present in the adenovirus late region L1 mRNA was demonstrated to bind SR-proteins, 
which prevented recruitment of U2snRNP to the spliceosome. This silencer binds a number 
of SR-proteins but is most efficiently bound by SF2/ASF-SC35 [23]. However enhancer/ 
silencer elements specific for the SR proteins causing CD45 exon exclusion have not been 
identified and will be the subject of our future studies.
Role of structural domains of SR proteins in splice site selection of the CD45 
pre-mRNA
As detailed above SR-proteins consist of two or three modular domains i.e. the RS domain 
and either one or two N -term inal RRM’s. All SR proteins share the canonical RRM
Figure 6
Role o f modular domains o f SRp40 and SF2/ASF on the alternative splicing o f CD45.
(A) Alteration in the splicing pattern o f the CD45 minigene after cotransfection with the SRp40 deletion 
m utant and the SRp40-SF2/ASF swap constructs. RT-PCR analysis o f the cotransfection experiments 
with the indicated constructs is shown. Control transfection with the CD45 minigene only is shown in 
(-). CD45 isoforms are indicated on the right, isoform size (bp) is indicated on the left o f the figure.
(B) Histogram o f CD45 isoform expression pattern after cotransfection with the SRp40 deletion mutant 
and the SRp40/SRp30a swap constructs. CD45 isoforms are indicated on the right, constructs used for 
cotransfection are indicated below the figure and percentage o f isoform expression as a fraction o f the 
total is indicated on the left o f the figure.
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characterised by the conserved RNP-1 and RNP-2 submotifs. In addition, a subset of SR 
proteins also have a central atypical RRM which lacks the conserved residues in the RNP 
submotifs [15,32]. To determine which of these domains is responsible for the switch in 
CD45 splicing noted above we examined the function of a series of domain deletion and 
domain swap constructs containing fragments of SRp20, SF2/ASF, SC35 and SRp40. In each 
case the expression and integrity of these constructs was tested by western blotting using the 
T7-tag antibody (data not shown).
To evaluate whether the RRM or RS domain of SRp20 was responsible for the change in 
CD45 alternative splicing we constructed an RS domain deletion m utant (20 delta RS) and 
substituted the RRM of SRp20 with the corresponding domain of SC35 (30b:-20RS, Fig. 5A 
and C). Deletion of the RS domain of SRp20 promoted skipping of all alternative exons (Fig. 
5A, lane 5). When the RRM of SRp20 was exchanged for the RRM of SC35 (30b1-20RS) exon 
skipping was also seen giving a similar pattern to wild type SC35 (Fig. 5A, lane 4 and 7), 
implying a role of the RRM of SRp20 in the formation of the ABC isoform.
Domain swap chimeras between SF2/ASF and SRp40 are shown in figure 6. Both the wild 
type proteins promote exon skipping, as do many of the mutants except those in which 
RRM2 of SRp40 is fused to RRM1 of SF2/ASF (Fig.6 lanes 6 and 7). RRM2 of SF2/ASF seems 
to play a specific role in splice site selection, when it is deleted the splicing of SF2/ASF 
resembles SRp20 with a switch to exon inclusion and production of higher molecular weight 
isoforms (Fig. 5B and D lane 8). This is seen not only with the deletion of RRM2 in wild type 
SF2/ASF but also in the chimera between the RS domain of SF2/ASF and the RRM of SC35 
(Fig. 5B lanes 5 and 8). Deletion of the RS domains of SF2 and SC35 has little effect on 
function, like the wild type proteins, promoting exon skipping. (Fig. 5B lane 6 and Fig. 5A 
lane 6).
The results of the experiments using chimeric SR proteins are tabulated in Fig. 8. In summary, 
these data demonstrate that the atypical RRM of SF2/ASF determines the specificity for 
CD45 mRNA splicing. All constructs that include this domain promote exon skipping while 
all constructs lacking this domain promoted exon inclusion and behave like SRp20. The 
results resemble those with adenovirus E1A where wild type SF2/ASF favours the selection 
of the most proximal 13S site whilst the m utant lacking RRM2 switches splicing to the 12S 
site which is also promoted by SRp20 [5].
Changes in SR protein expression following the switch in CD45 splicing
Upon stimulation naive T-cells switch from CD45RA+ (exon inclusion) to CD45RO+ (exon 
skipping), whereas m ature m em ory CD45RO+ cells remain RO+. Resting T-cells were 
separated into RO+ and RA+ populations and activated by culture in the presence of 
phytohaemagglutinin (PHA). After 6 days 99% of the RA+ T-cells had lost expression of the 
exon A epitope and become RO+. RT-PCR revealed that at the RNA level the CD45 ABC, AB
142
Regulation of CD45 alternative splicing by SR-proteins •
A
C D 4 5 R A  cells 





C D 4 5  R O  cells 
12 36 72 M
637 bp
B CD45 RO cells CD45RA cells
k D a








Dynamic protein expression levels o f SR proteins in stimulated CD45RA and CD45R0 T-cells.
CD45RO and RA selected T-cells, stimulated with PHA for the indicated times, were analysed by (A) 
RT-PCR or (B) Western blot analysis using the SR protein specific mAb 104. Position o f the SR proteins 
are indicated on the right o f each panel.
and BC isoforms were down regulated between 36-72 hours and by 72 hours there was a 
predominant expression of the CD45 Null and B isoforms. The CD45RO+ T-cell population 
expressed mainly the CD45 Null and B isoform and remained CD45 Null and B positive 
upon stimulation (Fig. 7A).
MAb 104, which recognises a phospho-epitope expressed by all SR proteins [38,39], was 
used to assess SR protein expression in RA+ and RO+ cells over the time course of stimulation 
(Fig. 7B). Expression of SR proteins is low in resting cells and by 36-72h, when cells were 
proliferating well, SR protein levels were increased. Beside this total increase of SR protein 
expression several changes occur specifically in CD45RA+ stimulated T-cells. SRp75 induction 
is greater, and occurs later in RA+ versus RO+ stimulated cells. Furthermore, in RA+ stimulated 
T-cells a band appears in the 30-kDa cluster of SR proteins. This 30-kDa SR-protein increased 
markedly after 72 h of stimulation and judging by its size it may represent SRp30c, the smallest
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CD45 splicing
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Figure 8
Summary o f the role o f the SR proteins and their modular domains on the alternative splicing o f 
CD45 in vivo.
The SR protein constructs, deletion mutants and domain swap constructs used in this work are shown 
schematically. Promotion o f CD45 ABC or Null splicing after overexpression o f each construct is indicated 
by (+ + +  or ++). No effect is indicated by (-) and a single (+) indicates no promotion o f ABC or Null 
splicing but formation of intermediates. Overexpression o f 9G8 promotes AB splicing in addition to ABC.
SR-protein in the 30-kDa group, however direct identification is not possible, as a specific 
mAb is not available. We have previously shown induction of SRp30c at the RNA level 
following T-cell activation. Also apparent from these blots are differences in the ratios of 
some of the 30-kDa SR-proteins. For instance the third band possibly representing SC35 is 
induced more in RA stimulated cells whilst the fourth band possibly 9G8 is not upregulated 
in the RA stimulated cells. SRp55 and SRp20 were hardly detectable in these T-cell populations. 
The expression level, phosphorylation, cellular location and specific mix of SR/hnRNP 
proteins are believed to be one component in the regulation of specific splice site choices
[14,45,65]. This model presumes that SR protein expression patterns are tissue specific, 
developmentally regulated and responsiveness to the metabolic state of the cells. We have 
demonstrated complex changes in the expression of SR-proteins upon T-cell activation, which 
occur in parallel w ith changes in the splicing of CD45. Furtherm ore, we have also 
demonstrated that members of the SR protein family can have dramatic and antagonistic 
effects on CD45 splicing by transfection in-vivo. The SR protein family is thus a strong 
candidate for CD45 regulation in-vivo. In future experiments we hope to strengthen these 
observations using T cell transgenic mouse technology and also plan to map the SR specific 
intronic and exonic enhancer/silencer sequences within the CD45 gene.
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Alternative splicing of CD45, 
new players
INTRODUCTION
CD45 or LCA is the “acronym” for a collection of isoprotein products 
from one single large, evolutionary conserved gene. CD45 isoforms are 
members of the large family of receptor PTPases. Their expression is 
governed by the process of alternative splicing and is uniquely confined 
to the hematopoietic cell lineage (see Chapter 1). The CD45 isoform 
profile is dependent on cell type and the stage of differentiation. In turn, 
individual isoforms play an essential role in the Ag-mediated activation 
and developm ent of T- and B-cells via the engagem ent of their 
extracellular domains with unidentified molecules in the environment. 
Low molecular weight isoforms confer higher responsiveness to TCR 
mediated T-cell stimulation than high molecular weight isoforms. The 
switch from high to low molecular weight isoforms in the course of T- 
cell activation thus correlates with the acquisition of the T cells to react 
with an increased response to recall antigen (see Chapter 1). Although 
this clearly illustrates the significance of fine tuning in the regulation of 
alternative CD45 splicing there is still a relative poor understanding of 
the different mechanistic aspects that are involved in this process.
Our data as presented in chapter 4 indicate that the regulatory network 
that determines the CD45 isoform profile has a rather robust character 
in that the splicing behaviour of human transgene products in a mouse 
environment closely mimics that of the endogenous CD45 pre-mRNA. 
The default splicing pattern, exclusion of the alternative exon 4-6 
(CD45Null and CD45B isoforms) is used in T cells, thymocytes,
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monocytes, macrophages and granulocytes. Exon inclusion is uniquely found in B-cells and 
a select set of immature T cells. The exact same expression distribution is seen with the 
CD45 minigene in lymphoid organs of the transgenic mouse model. If CD45 mRNA is 
ectopically expressed in transgenic non-lymphoid organs, the default splicing pattern is also 
used. This would suggest that inclusion of alternative exons in CD45 pre-mRNA requires a 
well balanced machinery which is confined to cells of the lymphoid origin, and that non­
lymphoid cells contain, in this respect, a more standard splicing factor repertoire that 
irrevocably promotes complete exclusion of the exon 4-6 area.
Streuli and colleagues proposed a negative regulatory model of CD45 splicing a decade ago 
[9,12]. This model assumes the presence of a thymocyte or T cell specific negative regulatory 
factor that prevents alternative exon inclusion. B cells do not express this factor and therefore 
retain all variably spliced exons. Moreover, they demonstrated that non-lymphoid cell lines 
also express this negative regulatory factor and promote skipping of all alternative exons. 
Our work presented here indicates (chapter 5) that besides splicing factors promoting exon 
exclusion also splicing factors promoting exon inclusion do exists. Therefore, we like to pro­
pose a new working model for CD45 alternative splicing based on both old and new 
knowledge, which is presented in Figure 3. First, it is conceivable that B cells contain a well 
balanced mixture of factor(s) that promote exon inclusion, as well as factors that promote 
exon skipping. Second, in cells expressing the default pattern the splicing factor(s) mediated 
exon exclusion must dominate other splicing factors probably by higher expression levels or
Figure 1
Cis-acting sequence elements in the CD45 pre-mRNA.
The 5' and 3' splice sites (indicated above the exons) o f all exons involved in CD45 alternative splicing 
are depicted, capitals are exonic nucleotides and small characters are the intronic nucleotides o f the splice 
sites. The consensus C/T nucleotides in the pyrimidine track (Py-track) are underlined. A  conserved 
TGAT (bold) is found in all these tracks. All exon/intron boundaries are homologous with the consensus 
sequences for the 5' and 3' splice sites.
Exons are indicated as boxes and introns as lines, exon 4 and 6 are enlarged as they are the only exons 
which contain cis-acting sequence elements necessary for tissue specific alternative splicing. The black 
boxes depict essential sequences for tissues specific alternative splicing. Below the exons sequence elements 
are indicated which (potentially) are involved in the regulation o f splicing o f these exons. A  Purine-rich 
sequence (bold) element o f 11 or 12 residues respectively is present in exon 4 (position 90-100) and 6 
(position 8-19). Furthermore, two homologous sequences elements are present in exon 4 and 6 (underlined, 
thin black line). The sequence elements 57-67 and 78-89 in exon 4 are homologous with the sequence 
elements 79-89 and 24-35, respectively, in exon 6. Furthermore, putative bindings sites (BS) in exon 4 
and 6 for SRp20 (exon 4 position 58-77 and exon 6 position 70-77 and 89-95) and 9G8 (exon 4 position 
1-10 and 96-104 and exon 6 position 16-24) are indicated by a bold black line. Also putative intronic 
SRp20 binding sites (BS) are indicated by a bold black line in the intronic sequences upstream o f exon 4 
and 6. These elements are discussed further on in the text.
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better binding avidity. From our data we conclude that CD45 alternative splicing is regulated 
by a complex mixture of factors with splicing promoting or repressing activities and that the 
balance of these factors decides whether splicing inclusion or exclusion occurs.
Cis-acting sequence elements involved in CD45 alternative splicing
Cis-acting sequences involved in tissue specific alternative splicing of CD45 have been
EXON 3 5’ 3’ EXON 4
Py-track




g t tg g c
1 10 57 67 77 90 100
GATTGACGAT A C T CAC A CC A CT GCA T T C  TC A  C C C  GCA AGC A CC TT T  G AA A G A  G AA AAT GAC TCA
9G8 BS SRp20 BS Pu-rich 9G8 BS
EXON 4 5’ Py-track
gttggc gggggaagactgatgtaatgatctcactttcctacc ttag
3’ EXON 5
CAG GT CAG gtttgc
3’ EXON 6
Py-track
CAG gtttgc cagacacaagtgacagtgctgatggccciifiigatt 
SRp20 BS
gcag AT CAG g tc tg a
133 1440 6
8 19 24 35 79 89 95
CCA G G A  G A G  A G G  A G T ACA G CC A G C A CC  TT T  CCT C TC  A GC C TT GCA CAC CAC A G C T C T  G CT
P u -r ic h  9G8 BS SRp20 BS SRp20 BS
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identified in (illustrated in Figure 1, black [12,17]) exon 4 and exon 6 but not in exon 5. In 
fact, large parts of these exons (4 and 6) cannot be deleted without affecting alternative 
splicing. Beside these cis-acting sequence elements, at least three conspicuous sequence 
elements can be discerned in the area of the alternatively spliced exons. First, there are two 
purine rich (Pu-rich) elements of 11 and 12 nucleotides present in exon 4 and 6 respectively 
(illustrated in bold in Figure 1). These sequences lay outside the cis-elements essential for 
tissue specific alternative splicing but are conserved between hum an and mouse (Figure 2) 
implicating a functional role. Pu-rich elements are known as binding sites for splicing factors 
like SR-proteins. Second, two homologous regions of 12 nucleotides are shared between 
exon 4 and 6 (Figure 1, sequences are underlined with a thin black line, [12]). These two 
elements lie within the cis-acting domains as defined by Streuli and colleagues [9,12] and it 
is likely that they represent binding sites for trans-acting splicing factors. The third element 
identified is an intronic nanomer sequence found 5' of all alternative exons in human and 
mouse. This element contains a conserved TGAT sequence (Figure 1; indicated in bold in 
the intronic sequences [15]). The importance of this intronic element remains unknown 
however it is speculated that it might facilitate in the regulation of CD45 alternative splicing 
by binding splicing factors thereby enhancing 3' splice site recognition [15].
It is noteworthy that mutation of only one base at position 77 of exon 4 (A) is able to abolish 
splicing of exon 4 [16,18]. The idea is that this mutation abolishes the binding of a splicing 
factor, which is able to promote splicing of exon 4. This mutation is localised in the cis- 
acting sequence elements necessary for tissue specific alternative splicing but not in one of 
the previously discussed elements.
All three potential regulatory sequence elements may bind splicing factors and induce 
(enhancer elements, ESS) or inhibit (suppressor or silencer elements, ESE) splice site 
recognition. Future will learn whether they have indeed a regulatory role in CD45 splicing. 
Mutational analysis, SR-protein binding analysis and domain swapping will be needed for
90 102
ACC TTT GAA AGA GAA AAT GAC TTC TCA 
ATC TCT GAA AGA GGA AAT GGC TCT TCA
9 18
AT GTC CCA GGA GAG AGG AGT ACA GCC 
GT GTG CCA GGG GAG AGG ACT GTA CGG 
Figure 2
Alignment o f the Purine-rich sequence element present in CD45 exon 4 and 6 o f human and mouse.
The exonic nucleotide position of the purine-rich stretch is indicated above the nucleotide sequences. 










SR-proteins involved in CD45 alternative splicing
Our data implicate that CD45 alternative inclusion or exclusion of exons 4-6 can be promoted 
by specific SR-proteins. SRp20 and 9G8 induce exon inclusion upon overexpression and 
SF2/ASF, SC35, SRp30c, 40 and 75 induce exon skipping upon overexpression (chapter 5). 
We would therefore like to hypothesize that the switch from CD45 high molecular to CD45 
low molecular weight isoforms during activation is due to a specific subset of SR-proteins 
which are transcriptionally upregulated or post-translationally activated. The regulation of 
SR-protein action is very complex and involves, among other things, transcriptional control 
m echanism s (expression levels and regu la tion  by alternative splicing) and 
(de)phosphorylation of serine residues in the RS domain. It is beyond the scope of this 
chapter to discuss all possible regulatory principles behind SR-protein action. Based on 
knowledge of potential SR-protein binding site sequences in the CD45 pre-mRNA, we would 
like to propose the model for differential splicing of CD45 which is illustrated in Figure 3.
CD45 alternative exon inclusion
Splicing factors that cause inclusion like SRp20 or 9G8 are able to interact with the CD45 
pre-mRNA and recruit components of the splicing machinery to the splice sites. RNA 
sequences implicated in binding of SRp20 share the homologous sequence CUC(U/G)UC(C/ 
U) [2,7,11]. Putative SRp20 binding elements are found intronic (polypyrimide track region) 
as well as exonic in the CD45 exon 4-6 area. A sequence element in exon 4 is of particular 
interest, as it is m ost hom ologous to the SRp20 enhancer sequence. This sequence, 
CACCACTGCATTCTCACCC (nucleotide 59-77, illustrated in Figure 1, bold black line), 
also contains the C nucleotide of position 77 which is essential for exon 4 splicing [16,18]. In 
exon 6 also two putative SRp20 binding site are present at position 70-77 (CTCAGCC) or 
89-95 (CTCTGCT) which are illustrated in Figure 1 as bold black line.
In the case of an intronic SRp20 enhancer region no perfect match with the binding sequence 
of SRp20 could be demonstrated (the same as for the exonic SRp20 enhancer). The sequences 
that slightly match are for exon 4, 5'-CCTTCTC-3' (which would give a perfect match in the 
3’ -5 ’ orientation) and for exon 6, 5'-CCCTTCT-3' (illustrated in Figure 1 as a bold black 
line). Upstream sequence elements were also found important [3,4,7], not for binding of 
SRp20 but for splicing regulation proper. This was demonstrated for the calcitonin/calcitonin 
gene-re la ted  pep tide  po lyadeny la tion  enhancer. SRp20 b inds to this enhancer 
(CTCCGCTCCTCTTCC) and promotes inclusion of the upstream terminal exon 4. In the 
upstream sequence of the enhancer an essential TGAT sequence could be delineated which 
influences splicing of exon 4 but does not bind SRp20 [7]. Such a TGAT sequence is also 
found in the 3' splice site regions of all CD45 alternative exons and is conserved between
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human and mouse [15]. We therefore believe that this sequence and SRp20 might play an 
important role as is illustrated in the model of Figure 3.
The SR-protein 9G8 seems to have its most prominent role in exon 4 (A) inclusion (chapter 
5). The consensus sequence AGACG/TACGAY, a splicing enhancer, is implicated in binding 
9G8 [1,11]. The most closely match to this sequence is found in exon 4 (GATTGACGAT,
nr |  | Exon with enhancer/suppressor sequencei | Exon without enhancer/suppressor sequence
U1 UlsnRNP SRP (sRp)
SF2/ASF, SC35, 
SRp30c, SRp40,
¿ 6 0 U2AF(65 + 35)
SRp75





nucleotide 1-10). This element may play a role in enhanced recognition of exon 4 by 9G8. In 
addition, two elements overlapping the purine rich elements in both exon 4 and 6 (respectively 
GAAAATGAC, nucleotide 96-104 and GGAGTACAG, nucleotide 16-24, all elements are 
indicated by a bold black line in Figure 1) are matching, however these matches are weak, 
with the 9G8 consensus sequence. This might perhaps indicate that the purine rich elements 
and their closely surroundings in exon 4 and 6 are candidate sequences to bind 9G8. We 
proposed this interaction in our model (Figure 3).
CD45 alternative exon exclusion
Alternative exon exclusion may be promoted by SF2/ASF, SC35, SRp30c, 40 and 75, and 
involves other types of sequences. First, we like to point out that presence of the flanking 
exons 3 and 7 are not essential for exon skipping. SF2/ASF was previously demonstrated to 
promote exclusion of exon 4 in a single exon 4 CD45 minigene [10]. Later it was demonstrated 
that this was depending on the presence of exon 4 and that the flanking exons 3 and 7 could 
be replaced by exon 2 and 8. In addition, exon exclusion was not promoted when exon 9 
replaced exon 4 [6]. These results indicate that the action of SF2/ASF is most likely uniquely 
dependent on the presence of exon 4 and its surrounding intronic sequences. The same 
criteria probably hold for the other exon exclusion inducing SR-proteins.
The SR-proteins that inhibit splicing of exon 4, 5 and 6 probably interact with splicing 
suppressor or silencer element, which prevents the binding of components of the splicing 
machinery (illustrated in Figure 3). Splicing repressor sequences have been demonstrated 
which are exonic or intronic, bind SR-proteins and can also be purine rich like enhancer 
sequences [5,8]. Clearly, there is position and sequence dependence. Not only do mutations 
or positional changes abolish repressor function, it was even demonstrated that when a 
repressor element was placed in another position in the mRNA it could act as an enhancer
Figure 3
A model for CD45 alternative splicing.
A) Splicing factors involved in alternative exon inclusion: CD45ABC
Splicing factors SRp20 binds to or near the poly-pyrimidine track of all alternatively spliced exons thereby 
enhancing binding o f U2AF65 to the 3' splice site. 9G8 binds to enhancer sequences in exon 4 and 6 
thereby recruiting UlsnRNP to the 5' splice site. Both splicing factors are able to enhance splice site 
recognition o f the alternatively spliced exons, which results in exon inclusion and formation o f the 
CD45ABC isoform.
B) Splicing factors involved in alternative exon exclusion: CD45 Null
SR-proteins bind to exonic or intronic suppressor elements, which inhibit spliceosome formation on exon 
4, 5 and 6 and results in direct joining o f exon 3 and 7.
All protein components, including SR-proteins, involved in spliceosome formation are indicated as circles 
or squares, the CD45 exons 3-7 as boxes and splicing events as dotted lines (all components are explained 
in the box below the figure).
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element. The other way around is also true, when an enhancer sequence was placed at the 
position of the repressor it could act as a repressor element [5]. This indicates that suppressor 
and enhancer elements specific for a SR-protein might have identical consensus (binding) 
sequences. However, this has only been demonstrated once [5] and it is not known whether 
this is a general principle.
SF2/ASF, SC35 and SRp40 binding or enhancer sequences have been identified (not for SRp30c 
and SRp75) which are respectively RGAAGAAC [14], TGCNGC/TC/T [11] and TGGGAGC 
RGTY RGCTCGY [13]. The SF2/ASF enhancer is a purine rich element, which resembles 
the purine rich elements present in exon 4 and 6 weakly. This could indicate that the purine 
rich elements act as repressor elements instead of enhancer elements, which was proposed 
previously. There are several possible matches for the SC35 enhancer sequence in exon 5 
(e.g. CGCAGAC and CGCAGAC, position 38-44 and 46-52, respectively) and exon 6 (e.g. 
TGCTGCC, position 92-98) but not in exon 4 (sequences are not indicated in Figure 1). No 
matches were found for the SRp40 protein. In summary, there are several candidate binding 
sequences for SR-proteins. However, the mode of action of these sequence elements, i.e. 
suppression or promoting of exon splicing has not been demonstrated yet for any of these 
putative binding elements.
Concluding remarks
CD45 alternative splicing is regulated by splicing factors promoting exon inclusion and exon 
exclusion. Whether exon inclusion or exclusion will take place depends on the specific balance 
and activity of these factors. In turn  this is dependent on multiple parameters including SR- 
protein expression levels, protein modification like phosphorylation and routing phenomena. 
The precise delineation of the RNA binding elements and definition of the identity of the 
SR-proteins which bind to these sequence will ultimately help us to understand the complex 
regulation of CD45 alternative splicing.
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The Leucocyte Common Antigen (LCA) CD45 is a protein tyrosine 
phosphatase th a t is expressed exclusively in nucleated  cells of 
haemopoietic origin in bone marrow, blood and lymphoid organs. The 
gene for CD45 produces a pre-mRNA that can be processed to distinct 
types of mRNA, which encode different types of proteins (isoforms). 
Although we know quite well how the CD45 phosphatases antagonise 
lymphocyte specific kinases, hereby playing an essential role in keeping 
lymphocytes alert to signalling triggers from their environment, we do 
not know yet the precise functional role of the distinct CD45 isoforms. 
Furthermore we do not know whether each isoform talks with a unique 
molecule on other cells, or with specific neighbouring molecules on its 
own cell. Fundamental, to these questions is the issue how the RNA 
processing m achinery regulates the skipping or inclusion of the 
alternative exons to generate the different CD45 isoforms. This thesis 
gives a general overview of the process of alternative pre-mRNA splicing 
in general and then turns to the use of the CD45 gene as a model to 
study alternative pre-mRNA splicing. First, we focus on the regulation 
of CD45 isoform expression in lymphoid cells, transfected cell lines and 
in lymphoid and non-lym phoid transgenic mice tissues. Then, by 
cotransfecting our CD45 minigene with individual splicing factors we 
study the individual regulatory factors involved in CD45 alternative 
splicing.
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In Chapter I I reviewed the data known on the differential CD45 expression patterns in all 
lymphoid cells and tissues and its function in development and during antigen mediated 
activation in B- and T-cells. CD45 isoforms participate and associate with other membrane 
molecules such as CD4/CD8, TCR, CD3 or BCR (mIgM or mIgD) to form the antigen- 
signalling complexes. Intracellularly, CD45 is linked to “signalling substrates” such as the 
kinase LCK and FYN to transduce the incoming signals.
In Chapter 2 I discussed the recent data from the literature concerning (alternative) pre- 
mRNA splicing and the role of splicing factors like the standard spliceosomal components 
and the SR-proteins and the role of exon or intronic RNA sequences which act as enhancer 
or suppressor elements in the splicing reaction.
In Chapter 3 we report how we designed an eukaryotic expression vector with a GPI-anchor 
attachment site (derived from the Decay Accelerating Factor, DAF). Three CD45 isoforms 
were cloned as cDNAs in this membrane expression vector and transiently expressed in Cos- 
1 cells. The extracellular segment of the CD45 isoforms was intact and a GPI-membrane- 
anchor and VSV-tag replaced the entire membrane spanning and intracellular C-terminal 
domain of the CD45 molecule. We used this expression system in adhesion studies between 
CD45 transfected cells and CD22+ lymphoid cells and demonstrated that no adhesion occurs 
between these cells. This indicates that not only the mere presence of CD45 extracellular 
domains but also their proper assembly into higher order structures at the cell surface, is 
probably necessary to interact with CD22+ cells.
In Chapter 4 we designed, developed and assayed a new hum an CD45 minigene (13 Kb) 
which mimics the large endogenous CD45 gene of 120Kb with respect to its spliceability. We 
analysed its expression behaviour in transfected non-lymphoid cells and transgenic mouse 
tissues, which was compared to the endogenous CD45 isoform expression pattern in lymphoid 
cells. In Cos-1, HeLa and 3T3 cells we found distinct expression patterns, which could only 
be m odulated slightly by protein-synthesis inhibitors bu t not by variation in culture 
conditions or by stimulation with phorbolester (TPA). In all non-lymphoid transgenic mouse 
tissues a constant default CD45 splicing pattern of CD45 Null and B isoforms, was found. 
However, all possible eight CD45 isoforms instead of the 5 isoforms normally found in human 
tissues were expressed in transgenic mouse lymphoid tissues. Therefore, our human construct 
mimics the endogenous mouse LCA gene products in the mouse cellular environment.
The rather inert CD45 expression pattern in cell lines and non lymphoid tissues and the 
dynamic expression pattern in lymphoid tissues triggered us to analyse the SR-protein 
(splicing regulators) content of all cell lines and tissues used for CD45 monitoring. Whereas 
cell lines expressed variable levels of SRp75, SRp30 and SRp20 and constant amounts of
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SRp40, mouse tissues expressed large amounts of SRp75, SRp55 and SRp40. Additional 
expression of SRp30’s and SRp20 was restricted to lymphoid tissues. Therefore SRp30 and 
SRp20 can be considered serious candidates in the CD45 splicing machinery.
In Chapter 5 we analysed more closely the role of SR-proteins in CD45 alternative splicing. 
By cotransfecting the CD45 minigene with SRp’s constructs in variable quantities we were 
able to identify individual SR-proteins that caused either skipping or inclusion of exons, i.e. 
demonstrating antagonistic effects on CD45 alternative splicing. SRp20 and 9G8 promoted 
inclusion of exons, while skipping was favoured by SF2/ASF, SC35, SRp30c, SRp40 and SRp75. 
In addition to intact SR-proteins also domain mutants and domain-swap constructs of the 
SR-proteins were analysed for their effectiveness to influence the splicing pattern of CD45. 
Normally SF2/ASF induces exon skipping. Deletion of the atypical RNA recognition motif 
(RRM2) in SF2/ASF turned exon splicing into exon inclusion. During T-cell activation the 
CD45 isoform pattern shifts from the largest to the smallest isoform. Therefore, we analysed 
the SR-protein profile in T cells during activation and observed remarkable changes. The 
expression of SRp75 and SRp30 proteins (probably SRp30c and 9G8) changes during 
activation. This coincides remarkably with the shift in CD45 isoform expression.
In Chapter 6 we present a new model for CD45 alternative splicing that involves both SR- 
proteins and recently defined binding sites for these SR-proteins, so called SR-protein specific 
enhancer (or silencer) sequences. The role of the SR-proteins inducing exon skipping or 
inclusion and the putative sequences in the CD45 RNA which might be involved in binding 
of these SR-proteins is discussed.
This thesis describes the possible involvement of SR-proteins in CD45 splicing and paves 
the way for further study of the regulatory mechanism involved in alternative splicing. Our 
data may also shed some light on the tissue-specific regulation of CD45 alternative splicing. 
Future experiments should involve the precise demarcation of specific enhancer or silencer 
sequences in the CD45 RNA, the analysis of interaction of specific SR-proteins with these 
sequences and the typing of specific and functional changes in SR-protein profile during T- 
cell activation.
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SAMENVATTING
In dit proefschrift wordt de regulatie beschreven van alternatieve pre-mRNA splicing van 
het molecuul CD45 dat ook wel het ‘Leucocyte Common Antigen’ (LCA) wordt genoemd. 
CD45 beh o o rt to t de familie van proteine tyrosine phosphatases en w ordt als een 
transmembraan eiwit tot expressie gebracht op alle kernhoudende cellen van het im m uun­
systeem. Het gen dat codeert voor het CD45 molecuul produceert verschillende mRNA’s, 
wat leidt tot de productie van verschillende isovormen van het CD45 eiwit. Het proces dat 
ten grondslag ligt aan de productie van verschillende mRNA’s uit één voorloper RNA wordt 
ook wel alternatieve pre-mRNA splicing genoemd. In het geval van CD45 worden drie exonen 
(exon 4, 5 en 6) optioneel toegevoegd of weggelaten wat een maximum van acht verschil­
lende mRNA’s kan opleveren. Er zijn verschillende factoren die dit proces kunnen beïnvloe­
den: de zogenaamde ‘trans-acting’ factoren zijn eiwitten die binden aan korte RNA volgor­
des en op die manier het splicing proces beïnvloeden; de ‘cis-acting’ factoren zijn nucleotide 
volgordes die in het RNA zelf aanwezig zijn en afhankelijk van hun samenstelling bezet kun­
nen worden door de ‘trans-acting’ eiwitten.
De betekenis van de verschillende CD45 isovormen moet gezocht worden in de wijze waarop 
het CD45 molecuul samenspeelt met andere moleculen in de cel. CD45 is direct betrokken 
bij de signaaloverdracht in cellen van het immuunsysteem, en regelt waarschijnlijk de mate 
waarin een immuuncel alert kan reageren op prikkels vanuit de omgeving. Zo is de isovorm 
CD45 Null, waarbij exon 4, 5 en 6 zijn weggelaten of ‘uitgespliced’, meer capabel om de 
prikkelbaarheid van de T-cel te beinvloeden dan de CD45 ABC isovorm waarin genoemde 
exonen wel aanwezig zijn. De precieze rol van de verschillende isovormen van CD45 is ech­
ter nog niet opgehelderd.
In dit proefschrift wordt het CD45 gen gebruikt als model om ‘alternatieve pre-mRNA splicing’ 
te bestuderen. Daartoe hebben we eerst de CD45 isovorm expressie bestudeerd in lymfoide 
cellen, in getransfecteerde cellen en in trangene muizen weefsels (lymfoïd en niet-lymfoïd). 
Vervolgens, hebben we de invloed van regulerende factoren (de zogenaamde ‘trans-acting’ 
splicing factoren) bestudeerd door co-transfecties uit te voeren met het CD45 minigen en 
constructen die coderen voor de individuele splicing factoren.
In hoofdstuk 1 wordt een algemeen overzicht gegeven van het algemene bouwplan van het 
CD45 molecuul. Aandacht wordt besteed aan de isovorm expressie patronen van CD45 in de 
verschillende typen cellen en weefsels van het immuunsysteem. Vervolgens wordt geanaly­
seerd hoe het CD45 isovorm expressie patroon verandert tijdens de ontwikkeling van 




In hoofdstuk 2 wordt een overzicht gegeven van de recente literatuur met betrekking tot 
(alternatieve) pre-mRNA splicing en de rol van verschillende splicing factoren daarin. Met 
name de rol van SR-eiwitten en de zogenaamde ‘enhancer elementen’ wordt besproken.
In hoofdstuk 3 wordt het ontwerp en de constructie beschreven van de eukaryotische ex­
pressie vector pSG8-DAF met GPI-anker afkomstig van de ‘Deacay Accelerating Factor’ (DAF) 
met behulp waarvan de tot expressie gebrachte moleculen via een GPI-anker aan het mem­
braan gebonden worden. Drie isovormen die uitsluitend exonen 1 tot en met 7 van CD45 
bevatten , werden in deze vector gekloneerd en tijdelijk  to t expressie gebracht in 
getransfecteerde Cos cellen. Vervolgens w erden adhesie studies uitgevoerd tussen 
getransfecteerde Cos cellen en CD22 positieve cellen. Wij stelden vast in onze studie dat er 
geen adhesie plaatsvond tussen de Cos cellen en de CD22 positieve celtypen. In een eerdere 
studie was aangetoond dat CD22 getransfecteerde cellen wel in staat zijn te adhereren aan 
lymfoïde cellen via CD45. Het wijst er dus op dat expressie van getrunkeerde isovormen van 
CD45 niet voldoende is voor adhesie maar dat de volledige structuur en cellulaire omgeving 
vereist zijn.
In hoofdstuk 4 wordt het ontwerp en de ontwikkeling beschreven van een nieuw humaan 
CD45 minigen (13 Kb) dat grote gelijkenissen vertoond met het endogene CD45 gen van 
120 Kb. Het minigen bestaat slechts uit de eerste zeven exonen van het CD45 gen maar het 
‘splice gedrag’ is overeenkomstig met het endogene CD45 gen. Het expressie patroon van dit 
CD45 minigen werd bestudeerd in getransfecteerde niet-lymfoïde cellijnen en in trangene 
muizen weefsels. In de cellijnen Cos-1, HeLa en 3T3 werd een specifiek CD45 expressie 
patroon gevonden wat niet of nauwelijks gemodeleerd kon worden door veranderingen aan 
te brengen in de kweekomstandigheden of door stimulatie met phorbolesters (TPA). Tot 
onze verrassing kon in transgene muizen weefsels onderscheid gemaakt worden tussen het 
expressie patroon in lymfoïde en niet-lymfoïde weefsels waarbij in het eerste geval alle acht 
CD45 isovormen konden worden teruggevonden. Deze situatie vertoont sterke gelijkenis 
met het endogene CD45 expressie patroon in muizen weefsels. In niet-lymfoïde weefsels 
echter werden alleen de CD45 Null en B isovormen gevonden wat overeenkomt met het 
‘default’ expressie patroon.
Het verschil in CD45 expressie patroon tussen cellijnen en niet-lymfoïde weefsels enerzijds 
en lymfoïde weefsels anderzijds gaf ons aanleiding om specifiek te kijken of het profiel van 
SR-eiwitten in deze cellijnen en weefsels samenhang vertoonde met het CD45 expressie- 
patroon. De meest opvallende correlatie was zichtbaar in muizenweefsels waar de SR eiwit­
ten SRp30 en SRp20 sterk aanwezig waren in de lymfoïde weefsels en nauwelijks in de niet- 
lymfoïde weefsels. Omdat de patroonverschillen in de overige SR eiwitten minimaal waren 
werd geconcludeerd dat SRp30 en SRp20 eiwitten mogelijk een rol kunnen spelen bij het
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‘splicen’ van CD45.
In hoofdstuk 5 werd de rol van SR eiwitten in detail bestudeerd door middel van transfectie 
studies. Door het CD45 minigen te cotransfecteren met verschillende constructen van SR 
eiwitten kon worden vast gesteld welke SR eiwitten exon-inclusie dan wel -exclusie konden 
veroorzaken. SRp20 en 9G8 bleken exon inclusie te bevorderen terwijl exon exclusie werd 
geïnduceerd door SF2/ASF, SC35, SRp30c, SRp40 en SRp75. Door gebruik te maken van 
zogenaamde domein-mutanten en ‘domain-swap’ constructen kon de rol van de verschil­
lende domeinen aanwezig in SR eiwitten worden bestudeerd. Terwijl het intacte SF2/ASF 
exon exclusie bevorderde bleek dat bij verwijdering van het atypische RNA bindings domein 
(dit is het tweede, centraal gelegen RNA bindings domain) dit effect verandert en juist leidt 
tot exon-inclusie.
Omdat het expressie-patroon van CD45 isovormen veranderingen ondergaat gedurende 
activatie van T-cellen werd, in analogie, daarom ook van dit celtype het SR eiwit patroon 
bestudeerd. Een verandering in expressie werd waargenomen voor SRp75 en SRp30 eiwitten 
gedurende T-cel activatie wat een indicatie kan zijn van een mogelijke betrokkenheid van 
deze eiwitten bij de regulatie van alternatieve splicing van het CD45 molecuul.
In hoofdstuk 6 wordt een nieuw model gepresenteerd om de alternatieve splicing van CD45 
inzichtelijk te maken. Het samenspel tussen de verschillende SR eiwitten die hier mogelijk 
bij betrokken zijn (als trans-elementen) en de (cis-)sequentie elementen in het CD45 pre- 
mRNA, de zogenaamde ‘enhancer of silencer’ elementen, wordt hierin beschreven.
In dit proefschrift hebben we een mogelijke rol van SR eiwitten beschreven in de alterna­
tieve splicing van CD45. Bovendien hebben deze resultaten nieuwe inzichten gegeven in de 
weefsel-specifieke regulatie van CD45 alternatieve splicing. Dit opent nieuwe wegen om het 
mechanisme wat ten grond slag ligt aan dit proces verder te bestuderen. Toekomstig onder­
zoek zou zich daarby met name moeten richten op de precieze lokalisatie van betrokken 
‘enhancer en silencer’ elementen in het CD45 RNA en de interaktie van specifieke SR eiwit­





Het schrijven van een dankwoord aan het einde van het proefschrift geeft een 
gevoel van opluchting dat de klus geklaard is, en brengt opnieuw in herinnering 
hoe je leven als promovendus verlopen is. Je beseft hoeveel nieuwe mensen er 
in je leven terecht zijn gekomen en dat je de klus niet alleen hebt geklaard 
maar dat veel mensen daaraan bijgedragen hebben. Ik wil iedereen daarvoor 
bedanken.
Dat ik als promovendus in de woelige tijd van de afdeling, niet overstag ben 
gegaan, heb ik mede te danken aan de positieve inzet van mijn prom otor en 
copromotor.
Be, je hebt me altijd met creatieve ideeën in de vaart gehouden. Alles werd 
altijd snel gecorrigeerd en je rustte niet voordat ook de laatste letter goed stond. 
Ik waardeer het zeer dat je me de kans hebt gegeven, na wat omzwervingen, 
om de haven binnen te varen.
Lambert, goede, lieve vriend. Zonder jou was het schip misschien in ondiep 
water terecht gekomen. Jij hebt mijn hoofd boven water gehouden, mijn en­
thousiasme voor de immunologie nog verder vergroot, studenten en ook je 
zelf aangedragen als extra mankracht voor mijn onderzoek. Het was fijn varen 
met je.
Ik ben de medewerkers van de afdeling Celbiologie zeer erkentelijk voor de 
collegiale samenwerking en gezellige werksfeer. Lab 69, in al zijn wisselende 
samenstellingen is altijd mijn lab geweest en ik wil iedereen bedanken die daar 
heeft vertoefd voor de goede sfeer en gezelligheid. Verschillende studenten 
hebben bijgedragen aan het onderzoek, zoals Antoinette Brink, Roel Arends, 
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